

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 December 2002 (05.12.2002)

PCT

(10) International Publication Number
WO 02/097074 A2

(51) International Patent Classification⁷: C12N 9/00

(21) International Application Number: PCT/EP02/05874

(22) International Filing Date: 29 May 2002 (29.05.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/294,006 30 May 2001 (30.05.2001) US
60/354,928 11 February 2002 (11.02.2002) US

(71) Applicant (for all designated States except US): BAYER AKTIENGESELLSCHAFT [DE/DE]; 51368 Leverkusen (DE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): ZHU, Zhimin [CN/US]; 45 Hinckley Road, Waban, MA 02468 (US).

(74) Common Representative: BAYER AKTIENGESELLSCHAFT; 51368 Leverkusen (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

Published:

- without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: REGULATION OF HUMAN PROTEIN PHOSPHATASE 2C-LIKE ENZYME

(57) Abstract: Reagents that regulate human protein phosphatase 2C-like enzyme and reagents which bind to human protein phosphatase 2C-like enzyme gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, CNS disorders, COPD, obesity, and diabetes.



WO 02/097074 A2

REGULATION OF HUMAN PROTEIN PHOSPHATASE 2C-LIKE ENZYME

This application incorporates by reference co-pending provisional application Serial No. 60/294,006 filed May 30, 2001.

5

TECHNICAL FIELD OF THE INVENTION

The invention relates to the regulation of human protein phosphatase 2C-like enzyme.

10

BACKGROUND OF THE INVENTION

Protein phosphorylation and dephosphorylation plays a key regulatory role in many cellular processes. There is a need in the art to identify enzymes involved in these processes, which can be regulated to provide therapeutic effects.

15

SUMMARY OF THE INVENTION

It is an object of the invention to provide reagents and methods of regulating a human protein phosphatase 2C-like enzyme. This and other objects of the invention are provided by one or more of the embodiments described below.

20

One embodiment of the invention is a protein phosphatase 2C-like enzyme polypeptide comprising an amino acid sequence selected from the group consisting of:

25

amino acid sequences which are at least about 97% identical to the amino acid sequence shown in SEQ ID NO: 2; and

the amino acid sequence shown in SEQ ID NO: 2.

30

Yet another embodiment of the invention is a method of screening for agents which decrease extracellular matrix degradation. A test compound is contacted with a protein phosphatase 2C-like enzyme polypeptide comprising an amino acid sequence selected from the group consisting of:

5

amino acid sequences which are at least about 97% identical to the amino acid sequence shown in SEQ ID NO: 2; and

the amino acid sequence shown in SEQ ID NO: 2.

10

Binding between the test compound and the protein phosphatase 2C-like enzyme polypeptide is detected. A test compound which binds to the protein phosphatase 2C-like enzyme polypeptide is thereby identified as a potential agent for decreasing extracellular matrix degradation. The agent can work by decreasing the activity of the protein phosphatase 2C-like enzyme.

15

Another embodiment of the invention is a method of screening for agents which decrease extracellular matrix degradation. A test compound is contacted with a polynucleotide encoding a protein phosphatase 2C-like enzyme polypeptide, wherein the polynucleotide comprises a nucleotide sequence selected from the group consisting of:

20

nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO: 1; and

25

the nucleotide sequence shown in SEQ ID NO: 1.

Binding of the test compound to the polynucleotide is detected. A test compound which binds to the polynucleotide is identified as a potential agent for decreasing extracellular matrix degradation. The agent can work by decreasing the amount of the

30

- 3 -

protein phosphatase 2C-like enzyme through interacting with the protein phosphatase 2C-like enzyme mRNA.

5 Another embodiment of the invention is a method of screening for agents which regulate extracellular matrix degradation. A test compound is contacted with a protein phosphatase 2C-like enzyme polypeptide comprising an amino acid sequence selected from the group consisting of:

10 amino acid sequences which are at least about 97% identical to the amino acid sequence shown in SEQ ID NO: 2; and

the amino acid sequence shown in SEQ ID NO: 2.

15 A protein phosphatase 2C-like enzyme activity of the polypeptide is detected. A test compound which increases protein phosphatase 2C-like enzyme activity of the polypeptide relative to protein phosphatase 2C-like enzyme activity in the absence of the test compound is thereby identified as a potential agent for increasing extracellular matrix degradation. A test compound which decreases protein phosphatase 2C-like enzyme activity of the polypeptide relative to protein phosphatase 2C-like enzyme activity in the absence of the test compound is thereby identified as a potential agent for decreasing extracellular matrix degradation.

25 Even another embodiment of the invention is a method of screening for agents which decrease extracellular matrix degradation. A test compound is contacted with a protein phosphatase 2C-like enzyme product of a polynucleotide which comprises a nucleotide sequence selected from the group consisting of:

30 nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO: 1; and

the nucleotide sequence shown in SEQ ID NO: 1.

Binding of the test compound to the protein phosphatase 2C-like enzyme product is detected. A test compound which binds to the protein phosphatase 2C-like enzyme product is thereby identified as a potential agent for decreasing extracellular matrix degradation.

Still another embodiment of the invention is a method of reducing extracellular matrix degradation. A cell is contacted with a reagent which specifically binds to a polynucleotide encoding a protein phosphatase 2C-like enzyme polypeptide or the product encoded by the polynucleotide, wherein the polynucleotide comprises a nucleotide sequence selected from the group consisting of:

nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO: 1; and

the nucleotide sequence shown in SEQ ID NO: 1.

Protein phosphatase 2C-like enzyme activity in the cell is thereby decreased.

The invention thus provides a human protein phosphatase 2C-like enzyme that can be used to identify test compounds that may act, for example, as activators or inhibitors at the enzyme's active site. Human protein phosphatase 2C-like enzyme and fragments thereof also are useful in raising specific antibodies that can block the enzyme and effectively reduce its activity.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 shows the DNA-sequence encoding a protein phosphatase 2C-like enzyme Polypeptide (SEQ ID NO: 1).

Fig. 2 shows the amino acid sequence deduced from the DNA-sequence of Fig.1 (SEQ ID NO: 2).

Fig. 3 shows the amino acid sequence of the protein identified by aageneseq|AAW04327|AAW04327 (SEQ ID NO: 3).

Fig. 4 shows the DNA-sequence encoding a protein phosphatase 2C-like enzyme Polypeptide (SEQ ID NO: 4).

5 Fig. 5 shows the BLASTP - alignment of 533_Protein (SEQ ID NO: 2) against aageneseq|AAW04327|AAW04327.

Rat petrin.

Fig. 6 shows the BLASTP - alignment of 533_Protein (SEQ ID NO: 2) against trembl|AB032983|AB032983_1.

10 Fig. 7 shows the BLASTP - alignment of 533_Protein (SEQ ID NO: 2) against aageneseq_alert|EP1074617.1.

Fig. 8 shows the BLASTP - alignment of 533_Protein (SEQ ID NO: 2) against tremblnew|AJ277743|FSY277743_1.

15 Fig. 9 shows the BLASTP - alignment of 533_Protein (SEQ ID NO: 2) against swissnew|P49598|P2C4_ARATH.

Fig. 10 shows the BLASTP - alignment of 533_Protein (SEQ ID NO: 2) against pdb|1A6Q|1A6Q.

Fig. 11 shows the HMMPFAM - alignment of 533_Protein (SEQ ID NO: 2) against pfam|hmm|PP2C.

20 Fig. 12 shows the HMMPFAM - alignment of 533_Protein (SEQ ID NO: 2) against pfam|hmm|PP2C.

Fig. 13 shows the BLOCK search result.

Fig. 14 shows the BLASTN - alignment of 533_DNA_extended against BAYER_LIB_DNA|cb_379101045220171

25 Fig. 15 shows the Genewise output.

Fig. 16 shows the Relative expression of human protein phosphatase 2C-like enzyme.

30 Fig. 17 shows the Relative expression of human protein phosphatase 2C-like enzyme in human respiratory tissues and cells. Key: HBEC=cultured human bronchial epithelial cells; H441=Clara-like cells; SMC=cultured airway smooth muscle cells; SAE= cultured small airway epithelial cells;

- 6 -

AII=primary cultured alveolar type II cells; PMN=polymorphonuclear leukocytes; Mono=monocytes; Cult. Mono=cultured monocytes (macrophage-like), T cell = freshly isolated CD4⁺/CD8⁺ cells.

5 **DETAILED DESCRIPTION OF THE INVENTION**

The invention relates to an isolated polynucleotide from the group consisting of:

- 10 a) a polynucleotide encoding a protein phosphatase 2C-like enzyme polypeptide comprising an amino acid sequence selected from the group consisting of:

amino acid sequences which are at least about 97% identical to
the amino acid sequence shown in SEQ ID NO: 2;
the amino acid sequence shown in SEQ ID NO: 2;

15

- b) a polynucleotide comprising the sequence of SEQ ID NO: 1;

- c) a polynucleotide which hybridizes under stringent conditions to a polynucleotide specified in (a) and (b) and encodes a protein phosphatase 2C-like enzyme polypeptide;

20

- d) a polynucleotide the sequence of which deviates from the polynucleotide sequences specified in (a) to (c) due to the degeneration of the genetic code and encodes a protein phosphatase 2C-like enzyme polypeptide; and

25

- e) a polynucleotide which represents a fragment, derivative or allelic variation of a polynucleotide sequence specified in (a) to (d) and encodes a protein phosphatase 2C-like enzyme polypeptide.

- 30 Furthermore, it has been discovered by the present applicant that a novel protein phosphatase 2C-like enzyme, particularly a human protein phosphatase 2C-like

enzyme, can be used in therapeutic methods to treat a CNS disorder, COPD, obesity or diabetes. Human protein phosphatase 2C-like enzyme comprises the amino acid sequence shown in SEQ ID NO: 2 (AB032983, SEQ ID NO: 14; FIG. 2). A coding sequence for human protein phosphatase 2C-like enzyme is shown in SEQ ID NO: 1. This sequence is contained within the longer sequence shown in SEQ ID NO: 4, which is located on chromosome 12. Related ESTs (AJ277743, BE916530, BE911677, AU155021, BE572774, AU133840, BF899747, AU120900, AB032983, P49598) are expressed in mammary tumor, ovarian tumor, bone marrow, and embryonic tissue.

Human protein phosphatase 2C-like enzyme is 96% identical over 514 amino acids to aageneseq|AAW04327|AAW04327 (FIG. 1). The protein also is 99% identical over 263 amino acids to aageneseq_alert|EP1074617.1 (FIG. 3), 25% identical over 283 amino acids to tremblnew|AJ277743|FSY277743_1 (FIG. 4), and 24% identical over 317 amino acids to swissnew|P49598|P2C4_ARATH (FIG. 5).

Human protein phosphatase 2C-like enzyme of the invention is expected to be useful for the same purposes as previously identified protein phosphatase 2C enzymes. Human protein phosphatase 2C-like enzyme is believed to be useful in therapeutic methods to treat disorders such as CNS disorders, COPD, obesity, and diabetes. Human protein phosphatase 2C-like enzyme also can be used to screen for human protein phosphatase 2C-like enzyme activators and inhibitors.

Polypeptides

Human protein phosphatase 2C-like enzyme polypeptides according to the invention comprise at least 6, 10, 15, 20, 25, 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, or 514 contiguous amino acids selected from the amino acid sequence shown in SEQ ID NO: 2 or a biologically active variant thereof, as defined below. A protein phosphatase 2C-like enzyme polypeptide of the invention therefore can be a portion of a protein phosphatase 2C-

like enzyme protein, a full-length protein phosphatase 2C-like enzyme protein, or a fusion protein comprising all or a portion of a protein phosphatase 2C-like enzyme protein.

5 Biologically Active Variants

Human protein phosphatase 2C-like enzyme polypeptide variants that are biologically active, *e.g.*, retain a phosphatase 2C activity, also are protein phosphatase 2C-like enzyme polypeptides. Preferably, naturally or non-naturally occurring protein phosphatase 2C-like enzyme polypeptide variants have amino acid sequences which are at least about 97% or 99% identical to the amino acid sequence shown in SEQ ID NO: 2 or a fragment thereof. Percent identity between a putative protein phosphatase 2C-like enzyme polypeptide variant and an amino acid sequence of SEQ ID NO: 2 is determined by conventional methods. See, for example, Altschul *et al.*, *Bull. Math. Bio.* 48:603 (1986), and Henikoff & Henikoff, *Proc. Natl. Acad. Sci. USA* 89:10915 (1992). Briefly, two amino acid sequences are aligned to optimize the alignment scores using a gap opening penalty of 10, a gap extension penalty of 1, and the "BLOSUM62" scoring matrix of Henikoff & Henikoff, 1992.

Those skilled in the art appreciate that there are many established algorithms available to align two amino acid sequences. The "FASTA" similarity search algorithm of Pearson & Lipman is a suitable protein alignment method for examining the level of identity shared by an amino acid sequence disclosed herein and the amino acid sequence of a putative variant. The FASTA algorithm is described by Pearson & Lipman, *Proc. Nat'l Acad. Sci. USA* 85:2444(1988), and by Pearson, *Meth. Enzymol.* 183:63 (1990). Briefly, FASTA first characterizes sequence similarity by identifying regions shared by the query sequence (*e.g.*, SEQ ID NO: 2) and a test sequence that have either the highest density of identities (if the ktup variable is 1) or pairs of identities (if ktup=2), without considering conservative amino acid substitutions, insertions, or deletions. The ten regions with the highest density of identities are then rescored by comparing the similarity of all paired amino acids

using an amino acid substitution matrix, and the ends of the regions are "trimmed" to include only those residues that contribute to the highest score. If there are several regions with scores greater than the "cutoff" value (calculated by a predetermined formula based upon the length of the sequence the ktup value), then the trimmed
5 initial regions are examined to determine whether the regions can be joined to form an approximate alignment with gaps. Finally, the highest scoring regions of the two amino acid sequences are aligned using a modification of the Needleman-Wunsch-Sellers algorithm (Needleman & Wunsch, *J. Mol. Biol.* 48:444 (1970); Sellers, *SIAM J. Appl. Math.* 26:787 (1974)), which allows for amino acid insertions and deletions.
10 Preferred parameters for FASTA analysis are: ktup=1, gap opening penalty=10, gap extension penalty=1, and substitution matrix=BLOSUM62. These parameters can be introduced into a FASTA program by modifying the scoring matrix file ("SMATRIX"), as explained in Appendix 2 of Pearson, *Meth. Enzymol.* 183:63 (1990).

15 FASTA can also be used to determine the sequence identity of nucleic acid molecules using a ratio as disclosed above. For nucleotide sequence comparisons, the ktup value can range between one to six, preferably from three to six, most preferably three, with other parameters set as default.

20 Variations in percent identity can be due, for example, to amino acid substitutions, insertions, or deletions. Amino acid substitutions are defined as one for one amino acid replacements. They are conservative in nature when the substituted amino acid has similar structural and/or chemical properties. Examples of conservative
25 replacements are substitution of a leucine with an isoleucine or valine, an aspartate with a glutamate, or a threonine with a serine.

Amino acid insertions or deletions are changes to or within an amino acid sequence. They typically fall in the range of about 1 to 5 amino acids. Guidance in determining
30 which amino acid residues can be substituted, inserted, or deleted without abolishing biological or immunological activity of a human protein phosphatase 2C-like enzyme

polypeptide can be found using computer programs well known in the art, such as DNASTAR software.

5 The invention additionally, encompasses protein phosphatase 2C-like enzyme polypeptides that are differentially modified during or after translation, *e.g.*, by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications can be carried out by known techniques including, but not limited, to specific chemical cleavage by 10 cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH₄, acetylation, formylation, oxidation, reduction, metabolic synthesis in the presence of tunicamycin, etc.

Additional post-translational modifications encompassed by the invention include, 15 for example, *e.g.*, N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and addition or deletion of an N-terminal methionine residue as a result of prokaryotic host cell expression. The protein phosphatase 2C-like enzyme polypeptides may also 20 be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the protein.

The invention also provides chemically modified derivatives of protein phosphatase 2C-like enzyme polypeptides that may provide additional advantages such as 25 increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (see U.S. Patent No. 4,179,337). The chemical moieties for derivitization can be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol, and the like. The polypeptides can be modified at random 30 or predetermined positions within the molecule and can include one, two, three, or more attached chemical moieties.

Whether an amino acid change results in a biologically active protein phosphatase 2C-like enzyme polypeptide can readily be determined by assaying for phosphatase activity, as described for example, in U.S. Patent 5,853,997.

5

Fusion Proteins

Fusion proteins are useful for generating antibodies against protein phosphatase 2C-like enzyme polypeptide amino acid sequences and for use in various assay systems.

10 For example, fusion proteins can be used to identify proteins that interact with portions of a protein phosphatase 2C-like enzyme polypeptide. Protein affinity chromatography or library-based assays for protein-protein interactions, such as the yeast two-hybrid or phage display systems, can be used for this purpose. Such methods are well known in the art and also can be used as drug screens.

15

A protein phosphatase 2C-like enzyme polypeptide fusion protein comprises two polypeptide segments fused together by means of a peptide bond. The first polypeptide segment comprises at least 6, 10, 15, 20, 25, 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, or 514 contiguous
20 amino acids of SEQ ID NO: 2 or of a biologically active variant, such as those described above. The first polypeptide segment also can comprise full-length protein phosphatase 2C-like enzyme protein.

The second polypeptide segment can be a full-length protein or a protein fragment.
25 Proteins commonly used in fusion protein construction include β -galactosidase, β -glucuronidase, green fluorescent protein (GFP), autofluorescent proteins, including blue fluorescent protein (BFP), glutathione-S-transferase (GST), luciferase, horseradish peroxidase (HRP), and chloramphenicol acetyltransferase (CAT). Additionally, epitope tags are used in fusion protein constructions, including
30 histidine (His) tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags. Other fusion constructions can include maltose

binding protein (MBP), S-tag, Lex a DNA binding domain (DBD) fusions, GAL4 DNA binding domain fusions, and herpes simplex virus (HSV) BP16 protein fusions. A fusion protein also can be engineered to contain a cleavage site located between the protein phosphatase 2C-like enzyme polypeptide-encoding sequence and the heterologous protein sequence, so that the protein phosphatase 2C-like enzyme polypeptide can be cleaved and purified away from the heterologous moiety.

A fusion protein can be synthesized chemically, as is known in the art. Preferably, a fusion protein is produced by covalently linking two polypeptide segments or by standard procedures in the art of molecular biology. Recombinant DNA methods can be used to prepare fusion proteins, for example, by making a DNA construct which comprises coding sequences selected from SEQ ID NO: 1 in proper reading frame with nucleotides encoding the second polypeptide segment and expressing the DNA construct in a host cell, as is known in the art. Many kits for constructing fusion proteins are available from companies such as Promega Corporation (Madison, WI), Stratagene (La Jolla, CA), CLONTECH (Mountain View, CA), Santa Cruz Biotechnology (Santa Cruz, CA), MBL International Corporation (MIC; Watertown, MA), and Quantum Biotechnologies (Montreal, Canada; 1-888-DNA-KITS).

Identification of Species Homologs

Species homologs of human protein phosphatase 2C-like enzyme polypeptide can be obtained using protein phosphatase 2C-like enzyme polypeptide polynucleotides (described below) to make suitable probes or primers for screening cDNA expression libraries from other species, such as mice, monkeys, or yeast, identifying cDNAs which encode homologs of protein phosphatase 2C-like enzyme polypeptide, and expressing the cDNAs as is known in the art.

Polynucleotides

A protein phosphatase 2C-like enzyme polynucleotide can be single- or double-stranded and comprises a coding sequence or the complement of a coding sequence
5 for a protein phosphatase 2C-like enzyme polypeptide. A coding sequence for human protein phosphatase 2C-like enzyme is shown in SEQ ID NO: 1.

Degenerate nucleotide sequences encoding human protein phosphatase 2C-like enzyme polypeptides, as well as homologous nucleotide sequences which are at least
10 about 50, 55, 60, 65, 70, preferably about 75, 90, 96, 98, or 99% identical to the nucleotide sequence shown in SEQ ID NO: 1 or its complement also are protein phosphatase 2C-like enzyme polynucleotides. Percent sequence identity between the sequences of two polynucleotides is determined using computer programs such as
15 ALIGN which employ the FASTA algorithm, using an affine gap search with a gap open penalty of -12 and a gap extension penalty of -2. Complementary DNA (cDNA) molecules, species homologs, and variants of protein phosphatase 2C-like enzyme polynucleotides that encode biologically active protein phosphatase 2C-like enzyme polypeptides also are protein phosphatase 2C-like enzyme polynucleotides. Polynucleotide fragments comprising at least 8, 9, 10, 11, 12, 15, 20, or 25
20 contiguous nucleotides of SEQ ID NO: 1 or its complement also are protein phosphatase 2C-like enzyme polynucleotides. These fragments can be used, for example, as hybridization probes or as antisense oligonucleotides.

Identification of Polynucleotide Variants and Homologs

25 Variants and homologs of the protein phosphatase 2C-like enzyme polynucleotides described above also are protein phosphatase 2C-like enzyme polynucleotides. Typically, homologous protein phosphatase 2C-like enzyme polynucleotide sequences can be identified by hybridization of candidate polynucleotides to known
30 protein phosphatase 2C-like enzyme polynucleotides under stringent conditions, as is known in the art. For example, using the following wash conditions--2X SSC (0.3 M

NaCl, 0.03 M sodium citrate, pH 7.0), 0.1% SDS, room temperature twice, 30 minutes each; then 2X SSC, 0.1% SDS, 50 °C once, 30 minutes; then 2X SSC, room temperature twice, 10 minutes each--homologous sequences can be identified which contain at most about 25-30% basepair mismatches. More preferably, homologous
5 nucleic acid strands contain 15-25% basepair mismatches, even more preferably 5-15% basepair mismatches.

Species homologs of the protein phosphatase 2C-like enzyme polynucleotides disclosed herein also can be identified by making suitable probes or primers and
10 screening cDNA expression libraries from other species, such as mice, monkeys, or yeast. Human variants of protein phosphatase 2C-like enzyme polynucleotides can be identified, for example, by screening human cDNA expression libraries. It is well known that the T_m of a double-stranded DNA decreases by 1-1.5 °C with every 1% decrease in homology (Bonner *et al.*, *J. Mol. Biol.* 81, 123 (1973). Variants of
15 human protein phosphatase 2C-like enzyme polynucleotides or protein phosphatase 2C-like enzyme polynucleotides of other species can therefore be identified by hybridizing a putative homologous protein phosphatase 2C-like enzyme polynucleotide with a polynucleotide having a nucleotide sequence of SEQ ID NO: 1 or the complement thereof to form a test hybrid. The melting temperature of the test
20 hybrid is compared with the melting temperature of a hybrid comprising polynucleotides having perfectly complementary nucleotide sequences, and the number or percent of basepair mismatches within the test hybrid is calculated.

Nucleotide sequences which hybridize to protein phosphatase 2C-like enzyme
25 polynucleotides or their complements following stringent hybridization and/or wash conditions also are protein phosphatase 2C-like enzyme polynucleotides. Stringent wash conditions are well known and understood in the art and are disclosed, for example, in Sambrook *et al.*, MOLECULAR CLONING: A LABORATORY MANUAL, 2d ed., 1989, at pages 9.50-9.51.

Typically, for stringent hybridization conditions a combination of temperature and salt concentration should be chosen that is approximately 12-20 °C below the calculated T_m of the hybrid under study. The T_m of a hybrid between a protein phosphatase 2C-like enzyme polynucleotide having a nucleotide sequence shown in SEQ ID NO: 1 or the complement thereof and a polynucleotide sequence which is at least about 50, preferably about 75, 90, 96, or 98% identical to one of those nucleotide sequences can be calculated, for example, using the equation of Bolton and McCarthy, *Proc. Natl. Acad. Sci. U.S.A.* 48, 1390 (1962):

$$T_m = 81.5\text{ }^{\circ}\text{C} - 16.6(\log_{10}[\text{Na}^+]) + 0.41(\%G + C) - 0.63(\%\text{formamide}) - 600/l,$$

where l = the length of the hybrid in basepairs.

Stringent wash conditions include, for example, 4X SSC at 65 °C, or 50% formamide, 4X SSC at 42 °C, or 0.5X SSC, 0.1% SDS at 65 °C. Highly stringent wash conditions include, for example, 0.2X SSC at 65 °C.

Preparation of Polynucleotides

A protein phosphatase 2C-like enzyme polynucleotide can be isolated free of other cellular components such as membrane components, proteins, and lipids. Polynucleotides can be made by a cell and isolated using standard nucleic acid purification techniques, or synthesized using an amplification technique, such as the polymerase chain reaction (PCR), or by using an automatic synthesizer. Methods for isolating polynucleotides are routine and are known in the art. Any such technique for obtaining a polynucleotide can be used to obtain isolated protein phosphatase 2C-like enzyme polynucleotides. For example, restriction enzymes and probes can be used to isolate polynucleotide fragments, which comprise protein phosphatase 2C-like enzyme nucleotide sequences. Isolated polynucleotides are in preparations that are free or at least 70, 80, or 90% free of other molecules.

Human protein phosphatase 2C-like enzyme cDNA molecules can be made with standard molecular biology techniques, using protein phosphatase 2C-like enzyme mRNA as a template. Human protein phosphatase 2C-like enzyme cDNA molecules can thereafter be replicated using molecular biology techniques known in the art and disclosed in manuals such as Sambrook *et al.* (1989). An amplification technique, such as PCR, can be used to obtain additional copies of polynucleotides of the invention, using either human genomic DNA or cDNA as a template.

Alternatively, synthetic chemistry techniques can be used to synthesize protein phosphatase 2C-like enzyme polynucleotides. The degeneracy of the genetic code allows alternate nucleotide sequences to be synthesized which will encode a protein phosphatase 2C-like enzyme polypeptide having, for example, an amino acid sequence shown in SEQ ID NO: 2 or a biologically active variant thereof.

Extending Polynucleotides

Various PCR-based methods can be used to extend the nucleic acid sequences disclosed herein to detect upstream sequences such as promoters and regulatory elements. For example, restriction-site PCR uses universal primers to retrieve unknown sequence adjacent to a known locus (Sarkar, *PCR Methods Applic.* 2, 318-322, 1993). Genomic DNA is first amplified in the presence of a primer to a linker sequence and a primer specific to the known region. The amplified sequences are then subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.

Inverse PCR also can be used to amplify or extend sequences using divergent primers based on a known region (Triglia *et al.*, *Nucleic Acids Res.* 16, 8186, 1988). Primers can be designed using commercially available software, such as OLIGO 4.06 Primer Analysis software (National Biosciences Inc., Plymouth, Minn.), to be 22-30

nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68-72 °C. The method uses several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.

5

Another method which can be used is capture PCR, which involves PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA (Lagerstrom *et al.*, *PCR Methods Applic. 1*, 111-119, 1991). In this method, multiple restriction enzyme digestions and ligations also can be used to place an engineered double-stranded sequence into an unknown fragment of the DNA molecule before performing PCR.

10

Another method which can be used to retrieve unknown sequences is that of Parker *et al.*, *Nucleic Acids Res. 19*, 3055-3060, 1991). Additionally, PCR, nested primers, and PROMOTERFINDER libraries (CLONTECH, Palo Alto, Calif.) can be used to walk genomic DNA (CLONTECH, Palo Alto, Calif.). This process avoids the need to screen libraries and is useful in finding intron/exon junctions.

15

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. Randomly-primed libraries are preferable, in that they will contain more sequences which contain the 5' regions of genes. Use of a randomly primed library may be especially preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries can be useful for extension of sequence into 5' non-transcribed regulatory regions.

20

25

Commercially available capillary electrophoresis systems can be used to analyze the size or confirm the nucleotide sequence of PCR or sequencing products. For example, capillary sequencing can employ flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) that are laser activated, and detection of the emitted wavelengths by a charge coupled device camera. Output/light intensity can be converted to electrical signal using appropriate

30

software (e.g. GENOTYPER and Sequence NAVIGATOR, Perkin Elmer), and the entire process from loading of samples to computer analysis and electronic data display can be computer controlled. Capillary electrophoresis is especially preferable for the sequencing of small pieces of DNA that might be present in limited amounts in a particular sample.

Obtaining Polypeptides

Human protein phosphatase 2C-like enzyme polypeptides can be obtained, for example, by purification from human cells, by expression of protein phosphatase 2C-like enzyme polynucleotides, or by direct chemical synthesis.

Protein Purification

Human protein phosphatase 2C-like enzyme polypeptides can be purified from any cell that expresses the polypeptide, including host cells that have been transfected with protein phosphatase 2C-like enzyme expression constructs. A purified protein phosphatase 2C-like enzyme polypeptide is separated from other compounds that normally associate with the protein phosphatase 2C-like enzyme polypeptide in the cell, such as certain proteins, carbohydrates, or lipids, using methods well-known in the art. Such methods include, but are not limited to, size exclusion chromatography, ammonium sulfate fractionation, ion exchange chromatography, affinity chromatography, and preparative gel electrophoresis. A preparation of purified protein phosphatase 2C-like enzyme polypeptides is at least 80% pure; preferably, the preparations are 90%, 95%, or 99% pure. Purity of the preparations can be assessed by any means known in the art, such as SDS-polyacrylamide gel electrophoresis.

Expression of Polynucleotides

To express a protein phosphatase 2C-like enzyme polynucleotide, the polynucleotide can be inserted into an expression vector that contains the necessary elements for the

- transcription and translation of the inserted coding sequence. Methods that are well known to those skilled in the art can be used to construct expression vectors containing sequences encoding protein phosphatase 2C-like enzyme polypeptides and appropriate transcriptional and translational control elements. These methods include *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo* genetic recombination. Such techniques are described, for example, in Sambrook *et al.* (1989) and in Ausubel *et al.*, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, N.Y., 1989.
- 10 A variety of expression vector/host systems can be utilized to contain and express sequences encoding a protein phosphatase 2C-like enzyme polypeptide. These include, but are not limited to, microorganisms, such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors, insect cell systems infected with virus expression vectors (*e.g.*, baculovirus), plant cell systems transformed with virus expression vectors (*e.g.*, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (*e.g.*, Ti or pBR322 plasmids), or animal cell systems.
- 20 The control elements or regulatory sequences are those non-translated regions of the vector -- enhancers, promoters, 5' and 3' untranslated regions -- which interact with host cellular proteins to carry out transcription and translation. Such elements can vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, can be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the BLUESCRIPT phagemid (Stratagene, LaJolla, Calif.) or pSPORT1 plasmid (Life Technologies) and the like can be used. The baculovirus polyhedrin promoter can be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (*e.g.*, heat shock, RUBISCO, and storage protein genes) or from plant viruses (*e.g.*, viral promoters or leader sequences) can be cloned into the vector. In mammalian
- 30

cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of a nucleotide sequence encoding a protein phosphatase 2C-like enzyme polypeptide, vectors based on SV40 or EBV can be used with an appropriate selectable marker.

5

Bacterial and Yeast Expression Systems

In bacterial systems, a number of expression vectors can be selected depending upon the use intended for the protein phosphatase 2C-like enzyme polypeptide. For example, when a large quantity of a protein phosphatase 2C-like enzyme polypeptide is needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified can be used. Such vectors include, but are not limited to, multifunctional *E. coli* cloning and expression vectors such as BLUESCRIPT (Stratagene). In a BLUESCRIPT vector, a sequence encoding the protein phosphatase 2C-like enzyme polypeptide can be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of β -galactosidase so that a hybrid protein is produced. pIN vectors (Van Heeke & Schuster, *J. Biol. Chem.* 264, 5503-5509, 1989) or pGEX vectors (Promega, Madison, Wis.) also can be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems can be designed to include heparin, thrombin, or factor Xa protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

25

In the yeast *Saccharomyces cerevisiae*, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH can be used. For reviews, see Ausubel *et al.* (1989) and Grant *et al.*, *Methods Enzymol.* 153, 516-544, 1987.

30

Plant and Insect Expression Systems

If plant expression vectors are used, the expression of sequences encoding protein phosphatase 2C-like enzyme polypeptides can be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV can be used alone or in combination with the omega leader sequence from TMV (Takamatsu, *EMBO J.* 6, 307-311, 1987). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters can be used (Coruzzi *et al.*, *EMBO J.* 3, 1671-1680, 1984; Broglie *et al.*, *Science* 224, 838-843, 1984; Winter *et al.*, *Results Probl. Cell Differ.* 17, 85-105, 1991). These constructs can be introduced into plant cells by direct DNA transformation or by pathogen-mediated transfection. Such techniques are described in a number of generally available reviews (*e.g.*, Hobbs or Murray, in MCGRAW HILL YEARBOOK OF SCIENCE AND TECHNOLOGY, McGraw Hill, New York, N.Y., pp. 191-196, 1992).

An insect system also can be used to express a protein phosphatase 2C-like enzyme polypeptide. For example, in one such system *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in *Spodoptera frugiperda* cells or in *Trichoplusia* larvae. Sequences encoding protein phosphatase 2C-like enzyme polypeptides can be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of protein phosphatase 2C-like enzyme polypeptides will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses can then be used to infect *S. frugiperda* cells or *Trichoplusia* larvae in which protein phosphatase 2C-like enzyme polypeptides can be expressed (Engelhard *et al.*, *Proc. Nat. Acad. Sci.* 91, 3224-3227, 1994).

Mammalian Expression Systems

A number of viral-based expression systems can be used to express protein phosphatase 2C-like enzyme polypeptides in mammalian host cells. For example, if

an adenovirus is used as an expression vector, sequences encoding protein phosphatase 2C-like enzyme polypeptides can be ligated into an adenovirus transcription/translation complex comprising the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome can be used to obtain a viable virus that is capable of expressing a protein phosphatase 2C-like enzyme polypeptide in infected host cells (Logan & Shenk, *Proc. Natl. Acad. Sci.* 81, 3655-3659, 1984). If desired, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, can be used to increase expression in mammalian host cells.

Human artificial chromosomes (HACs) also can be used to deliver larger fragments of DNA than can be contained and expressed in a plasmid. HACs of 6M to 10M are constructed and delivered to cells via conventional delivery methods (*e.g.*, liposomes, polycationic amino polymers, or vesicles).

Specific initiation signals also can be used to achieve more efficient translation of sequences encoding protein phosphatase 2C-like enzyme polypeptides. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding a protein phosphatase 2C-like enzyme polypeptide, its initiation codon, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals (including the ATG initiation codon) should be provided. The initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons can be of various origins, both natural and synthetic. The efficiency of expression can be enhanced by the inclusion of enhancers which are appropriate for the particular cell system which is used (see Scharf *et al.*, *Results Probl. Cell Differ.* 20, 125-162, 1994).

Host Cells

A host cell strain can be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein phosphatase 2C-like enzyme polypeptide in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the polypeptide also can be used to facilitate correct insertion, folding and/or function. Different host cells that have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38), are available from the American Type Culture Collection (ATCC; 10801 University Boulevard, Manassas, VA 20110-2209) and can be chosen to ensure the correct modification and processing of the foreign protein.

Stable expression is preferred for long-term, high-yield production of recombinant proteins. For example, cell lines which stably express protein phosphatase 2C-like enzyme polypeptides can be transformed using expression vectors which can contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells can be allowed to grow for 1-2 days in an enriched medium before they are switched to a selective medium. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced protein phosphatase 2C-like enzyme sequences. Resistant clones of stably transformed cells can be proliferated using tissue culture techniques appropriate to the cell type. See, for example, ANIMAL CELL CULTURE, R.I. Freshney, ed., 1986.

Any number of selection systems can be used to recover transformed cell lines.

These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler *et al.*, *Cell* 11, 223-32, 1977) and adenine phosphoribosyltransferase (Lowy

et al., *Cell* 22, 817-23, 1980) genes which can be employed in *tk⁻* or *aprt⁻* cells, respectively. Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate (Wigler *et al.*, *Proc. Natl. Acad. Sci.* 77, 3567-70, 1980), *npt* confers resistance to the aminoglycosides, neomycin and G-418 (Colbere-Garapin *et al.*, *J. Mol. Biol.* 150, 1-14, 1981), and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murray, 1992, *supra*). Additional selectable genes have been described. For example, *trpB* allows cells to utilize indole in place of tryptophan, or *hisD*, which allows cells to utilize histinol in place of histidine (Hartman & Mulligan, *Proc. Natl. Acad. Sci.* 85, 8047-51, 1988). Visible markers such as anthocyanins, β -glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, can be used to identify transformants and to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes *et al.*, *Methods Mol. Biol.* 55, 121-131, 1995).

Detecting Expression

Although the presence of marker gene expression suggests that the protein phosphatase 2C-like enzyme polynucleotide is also present, its presence and expression may need to be confirmed. For example, if a sequence encoding a protein phosphatase 2C-like enzyme polypeptide is inserted within a marker gene sequence, transformed cells containing sequences that encode a protein phosphatase 2C-like enzyme polypeptide can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding a protein phosphatase 2C-like enzyme polypeptide under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the protein phosphatase 2C-like enzyme polynucleotide.

Alternatively, host cells which contain a protein phosphatase 2C-like enzyme polynucleotide and which express a protein phosphatase 2C-like enzyme polypeptide

can be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques that include membrane, solution, or chip-based technologies for the detection and/or quantification of nucleic acid or protein. For example, the presence of a polynucleotide sequence encoding a protein phosphatase 2C-like enzyme polypeptide can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes or fragments or fragments of polynucleotides encoding a protein phosphatase 2C-like enzyme polypeptide. Nucleic acid amplification-based assays involve the use of oligonucleotides selected from sequences encoding a protein phosphatase 2C-like enzyme polypeptide to detect transformants that contain a protein phosphatase 2C-like enzyme polynucleotide.

A variety of protocols for detecting and measuring the expression of a protein phosphatase 2C-like enzyme polypeptide, using either polyclonal or monoclonal antibodies specific for the polypeptide, are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay using monoclonal antibodies reactive to two non-interfering epitopes on a protein phosphatase 2C-like enzyme polypeptide can be used, or a competitive binding assay can be employed. These and other assays are described in Hampton *et al.*, SEROLOGICAL METHODS: A LABORATORY MANUAL, APS Press, St. Paul, Minn., 1990) and Maddox *et al.*, *J. Exp. Med.* 158, 1211-1216, 1983).

A wide variety of labels and conjugation techniques are known by those skilled in the art and can be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding protein phosphatase 2C-like enzyme polypeptides include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, sequences encoding a protein phosphatase 2C-like enzyme polypeptide can be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and can be used to

synthesize RNA probes *in vitro* by addition of labeled nucleotides and an appropriate RNA polymerase such as T7, T3, or SP6. These procedures can be conducted using a variety of commercially available kits (Amersham Pharmacia Biotech, Promega, and US Biochemical). Suitable reporter molecules or labels which can be used for ease of detection include radionuclides, enzymes, and fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Expression and Purification of Polypeptides

Host cells transformed with nucleotide sequences encoding a protein phosphatase 2C-like enzyme polypeptide can be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The polypeptide produced by a transformed cell can be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode protein phosphatase 2C-like enzyme polypeptides can be designed to contain signal sequences which direct secretion of soluble protein phosphatase 2C-like enzyme polypeptides through a prokaryotic or eukaryotic cell membrane or which direct the membrane insertion of membrane-bound protein phosphatase 2C-like enzyme polypeptide.

As discussed above, other constructions can be used to join a sequence encoding a protein phosphatase 2C-like enzyme polypeptide to a nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, Wash.). Inclusion of cleavable linker sequences such as those specific for Factor Xa or enterokinase (Invitrogen, San Diego, CA) between the purification domain and the protein phosphatase 2C-like enzyme polypeptide also

can be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing a protein phosphatase 2C-like enzyme polypeptide and 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification by IMAC (immobilized metal ion affinity chromatography, as described in Porath *et al.*, *Prot. Exp. Purif.* 3, 263-281, 1992), while the enterokinase cleavage site provides a means for purifying the protein phosphatase 2C-like enzyme polypeptide from the fusion protein. Vectors that contain fusion proteins are disclosed in Kroll *et al.*, *DNA Cell Biol.* 12, 441-453, 1993.

Chemical Synthesis

Sequences encoding a protein phosphatase 2C-like enzyme polypeptide can be synthesized, in whole or in part, using chemical methods well known in the art (see Caruthers *et al.*, *Nucl. Acids Res. Symp. Ser.* 215-223, 1980; Horn *et al.* *Nucl. Acids Res. Symp. Ser.* 225-232, 1980). Alternatively, a protein phosphatase 2C-like enzyme polypeptide itself can be produced using chemical methods to synthesize its amino acid sequence, such as by direct peptide synthesis using solid-phase techniques (Merrifield, *J. Am. Chem. Soc.* 85, 2149-2154, 1963; Roberge *et al.*, *Science* 269, 202-204, 1995). Protein synthesis can be performed using manual techniques or by automation. Automated synthesis can be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer). Optionally, fragments of protein phosphatase 2C-like enzyme polypeptides can be separately synthesized and combined using chemical methods to produce a full-length molecule.

The newly synthesized peptide can be substantially purified by preparative high performance liquid chromatography (*e.g.*, Creighton, *PROTEINS: STRUCTURES AND MOLECULAR PRINCIPLES*, WH Freeman and Co., New York, N.Y., 1983). The composition of a synthetic protein phosphatase 2C-like enzyme polypeptide can be confirmed by amino acid analysis or sequencing (*e.g.*, the Edman degradation procedure; *see* Creighton, *supra*). Additionally, any portion of the amino acid

sequence of the protein phosphatase 2C-like enzyme polypeptide can be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins to produce a variant polypeptide or a fusion protein.

5 Production of Altered Polypeptides

As will be understood by those of skill in the art, it may be advantageous to produce protein phosphatase 2C-like enzyme polypeptide-encoding nucleotide sequences possessing non-naturally occurring codons. For example, codons preferred by a
10 particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce an RNA transcript having desirable properties, such as a half-life that is longer than that of a transcript generated from the naturally occurring sequence.

15 The nucleotide sequences disclosed herein can be engineered using methods generally known in the art to alter protein phosphatase 2C-like enzyme polypeptide-encoding sequences for a variety of reasons, including but not limited to, alterations which modify the cloning, processing, and/or expression of the polypeptide or mRNA product. DNA shuffling by random fragmentation and PCR reassembly of
20 gene fragments and synthetic oligonucleotides can be used to engineer the nucleotide sequences. For example, site-directed mutagenesis can be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, introduce mutations, and so forth.

25 Antibodies

Any type of antibody known in the art can be generated to bind specifically to an epitope of a protein phosphatase 2C-like enzyme polypeptide. "Antibody" as used herein includes intact immunoglobulin molecules, as well as fragments thereof, such
30 as Fab, F(ab')₂, and Fv, which are capable of binding an epitope of a protein phosphatase 2C-like enzyme polypeptide. Typically, at least 6, 8, 10, or 12

contiguous amino acids are required to form an epitope. However, epitopes which involve non-contiguous amino acids may require more, *e.g.*, at least 15, 25, or 50 amino acids.

5 An antibody which specifically binds to an epitope of a protein phosphatase 2C-like enzyme polypeptide can be used therapeutically, as well as in immunochemical assays, such as Western blots, ELISAs, radioimmunoassays, immunohistochemical assays, immunoprecipitations, or other immunochemical assays known in the art. Various immunoassays can be used to identify antibodies having the desired
10 specificity. Numerous protocols for competitive binding or immunoradiometric assays are well known in the art. Such immunoassays typically involve the measurement of complex formation between an immunogen and an antibody that specifically binds to the immunogen.

15 Typically, an antibody which specifically binds to a protein phosphatase 2C-like enzyme polypeptide provides a detection signal at least 5-, 10-, or 20-fold higher than a detection signal provided with other proteins when used in an immunochemical assay. Preferably, antibodies which specifically bind to protein phosphatase 2C-like enzyme polypeptides do not detect other proteins in immunochemical assays and can
20 immunoprecipitate a protein phosphatase 2C-like enzyme polypeptide from solution.

Human protein phosphatase 2C-like enzyme polypeptides can be used to immunize a mammal, such as a mouse, rat, rabbit, guinea pig, monkey, or human, to produce polyclonal antibodies. If desired, a protein phosphatase 2C-like enzyme polypeptide
25 can be conjugated to a carrier protein, such as bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin. Depending on the host species, various adjuvants can be used to increase the immunological response. Such adjuvants include, but are not limited to, Freund's adjuvant, mineral gels (*e.g.*, aluminum hydroxide), and surface active substances (*e.g.* lysolecithin, pluronic polyols, polyanions, peptides, oil
30 emulsions, keyhole limpet hemocyanin, and dinitrophenol). Among adjuvants used

in humans, BCG (*bacilli Calmette-Guerin*) and *Corynebacterium parvum* are especially useful.

5 Monoclonal antibodies that specifically bind to a protein phosphatase 2C-like enzyme polypeptide can be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These techniques include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique (Kohler *et al.*, *Nature* 256, 495-497, 1985; Kozbor *et al.*, *J. Immunol. Methods* 81, 31-42, 1985; Cote *et al.*, 10 *Proc. Natl. Acad. Sci.* 80, 2026-2030, 1983; Cole *et al.*, *Mol. Cell Biol.* 62, 109-120, 1984).

In addition, techniques developed for the production of "chimeric antibodies," the splicing of mouse antibody genes to human antibody genes to obtain a molecule with 15 appropriate antigen specificity and biological activity, can be used (Morrison *et al.*, *Proc. Natl. Acad. Sci.* 81, 6851-6855, 1984; Neuberger *et al.*, *Nature* 312, 604-608, 1984; Takeda *et al.*, *Nature* 314, 452-454, 1985). Monoclonal and other antibodies also can be "humanized" to prevent a patient from mounting an immune response against the antibody when it is used therapeutically. Such antibodies may be 20 sufficiently similar in sequence to human antibodies to be used directly in therapy or may require alteration of a few key residues. Sequence differences between rodent antibodies and human sequences can be minimized by replacing residues which differ from those in the human sequences by site directed mutagenesis of individual residues or by grating of entire complementarity determining regions. Alternatively, 25 humanized antibodies can be produced using recombinant methods, as described in GB2188638B. Antibodies that specifically bind to a protein phosphatase 2C-like enzyme polypeptide can contain antigen binding sites which are either partially or fully humanized, as disclosed in U.S. 5,565,332.

30 Alternatively, techniques described for the production of single chain antibodies can be adapted using methods known in the art to produce single chain antibodies that

specifically bind to protein phosphatase 2C-like enzyme polypeptides. Antibodies with related specificity, but of distinct idiotypic composition, can be generated by chain shuffling from random combinatorial immunoglobulin libraries (Burton, *Proc. Natl. Acad. Sci.* 88, 11120-23, 1991).

5

Single-chain antibodies also can be constructed using a DNA amplification method, such as PCR, using hybridoma cDNA as a template (Thirion *et al.*, 1996, *Eur. J. Cancer Prev.* 5, 507-11). Single-chain antibodies can be mono- or bispecific, and can be bivalent or tetravalent. Construction of tetravalent, bispecific single-chain antibodies is taught, for example, in Coloma & Morrison, 1997, *Nat. Biotechnol.* 15, 159-63. Construction of bivalent, bispecific single-chain antibodies is taught in Mallender & Voss, 1994, *J. Biol. Chem.* 269, 199-206.

10

15

A nucleotide sequence encoding a single-chain antibody can be constructed using manual or automated nucleotide synthesis, cloned into an expression construct using standard recombinant DNA methods, and introduced into a cell to express the coding sequence, as described below. Alternatively, single-chain antibodies can be produced directly using, for example, filamentous phage technology (Verhaar *et al.*, 1995, *Int. J. Cancer* 61, 497-501; Nicholls *et al.*, 1993, *J. Immunol. Meth.* 165, 81-91).

20

25

Antibodies which specifically bind to protein phosphatase 2C-like enzyme polypeptides also can be produced by inducing *in vivo* production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature (Orlandi *et al.*, *Proc. Natl. Acad. Sci.* 86, 3833-3837, 1989; Winter *et al.*, *Nature* 349, 293-299, 1991).

30

Other types of antibodies can be constructed and used therapeutically in methods of the invention. For example, chimeric antibodies can be constructed as disclosed in WO 93/03151. Binding proteins which are derived from immunoglobulins and which are multivalent and multispecific, such as the "diabodies" described in WO 94/13804, also can be prepared.

Antibodies according to the invention can be purified by methods well known in the art. For example, antibodies can be affinity purified by passage over a column to which a protein phosphatase 2C-like enzyme polypeptide is bound. The bound
5 antibodies can then be eluted from the column using a buffer with a high salt concentration.

Antisense Oligonucleotides

10 Antisense oligonucleotides are nucleotide sequences that are complementary to a specific DNA or RNA sequence. Once introduced into a cell, the complementary nucleotides combine with natural sequences produced by the cell to form complexes and block either transcription or translation. Preferably, an antisense oligonucleotide is at least 11 nucleotides in length, but can be at least 12, 15, 20, 25, 30, 35, 40, 45,
15 or 50 or more nucleotides long. Longer sequences also can be used. Antisense oligonucleotide molecules can be provided in a DNA construct and introduced into a cell as described above to decrease the level of protein phosphatase 2C-like enzyme gene products in the cell.

20 Antisense oligonucleotides can be deoxyribonucleotides, ribonucleotides, or a combination of both. Oligonucleotides can be synthesized manually or by an automated synthesizer, by covalently linking the 5' end of one nucleotide with the 3' end of another nucleotide with non-phosphodiester internucleotide linkages such as alkylphosphonates, phosphorothioates, phosphorodithioates, alkylphosphonothioates,
25 alkylphosphonates, phosphoramidates, phosphate esters, carbamates, acetamidate, carboxymethyl esters, carbonates, and phosphate triesters. See Brown, *Meth. Mol. Biol.* 20, 1-8, 1994; Sonveaux, *Meth. Mol. Biol.* 26, 1-72, 1994; Uhlmann *et al.*, *Chem. Rev.* 90, 543-583, 1990.

30 Modifications of protein phosphatase 2C-like enzyme gene expression can be obtained by designing antisense oligonucleotides that will form duplexes to the

control, 5', or regulatory regions of the protein phosphatase 2C-like enzyme gene. Oligonucleotides derived from the transcription initiation site, *e.g.*, between positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or chaperons. Therapeutic advances using triplex DNA have been described in the literature (*e.g.*, Gee *et al.*, in Huber & Carr, MOLECULAR AND IMMUNOLOGIC APPROACHES, Futura Publishing Co., Mt. Kisco, N.Y., 1994). An antisense oligonucleotide also can be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Precise complementarity is not required for successful complex formation between an antisense oligonucleotide and the complementary sequence of a protein phosphatase 2C-like enzyme polynucleotide. Antisense oligonucleotides which comprise, for example, 2, 3, 4, or 5 or more stretches of contiguous nucleotides which are precisely complementary to a protein phosphatase 2C-like enzyme polynucleotide, each separated by a stretch of contiguous nucleotides which are not complementary to adjacent protein phosphatase 2C-like enzyme nucleotides, can provide sufficient targeting specificity for protein phosphatase 2C-like enzyme mRNA. Preferably, each stretch of complementary contiguous nucleotides is at least 4, 5, 6, 7, or 8 or more nucleotides in length. Non-complementary intervening sequences are preferably 1, 2, 3, or 4 nucleotides in length. One skilled in the art can easily use the calculated melting point of an antisense-sense pair to determine the degree of mismatching which will be tolerated between a particular antisense oligonucleotide and a particular protein phosphatase 2C-like enzyme polynucleotide sequence.

Antisense oligonucleotides can be modified without affecting their ability to hybridize to a protein phosphatase 2C-like enzyme polynucleotide. These modifications can be internal or at one or both ends of the antisense molecule. For example, internucleoside phosphate linkages can be modified by adding cholesteryl

or diamine moieties with varying numbers of carbon residues between the amino groups and terminal ribose. Modified bases and/or sugars, such as arabinose instead of ribose, or a 3', 5'-substituted oligonucleotide in which the 3' hydroxyl group or the 5' phosphate group are substituted, also can be employed in a modified antisense oligonucleotide. These modified oligonucleotides can be prepared by methods well known in the art. See, e.g., Agrawal *et al.*, *Trends Biotechnol.* 10, 152-158, 1992; Uhlmann *et al.*, *Chem. Rev.* 90, 543-584, 1990; Uhlmann *et al.*, *Tetrahedron. Lett.* 215, 3539-3542, 1987.

10 Ribozymes

Ribozymes are RNA molecules with catalytic activity. See, e.g., Cech, *Science* 236, 1532-1539; 1987; Cech, *Ann. Rev. Biochem.* 59, 543-568; 1990, Cech, *Curr. Opin. Struct. Biol.* 2, 605-609; 1992, Couture & Stinchcomb, *Trends Genet.* 12, 510-515, 1996. Ribozymes can be used to inhibit gene function by cleaving an RNA sequence, as is known in the art (e.g., Haseloff *et al.*, U.S. Patent 5,641,673). The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Examples include engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of specific nucleotide sequences.

The coding sequence of a protein phosphatase 2C-like enzyme polynucleotide can be used to generate ribozymes that will specifically bind to mRNA transcribed from the protein phosphatase 2C-like enzyme polynucleotide. Methods of designing and constructing ribozymes which can cleave other RNA molecules in trans in a highly sequence specific manner have been developed and described in the art (see Haseloff *et al. Nature* 334, 585-591, 1988). For example, the cleavage activity of ribozymes can be targeted to specific RNAs by engineering a discrete "hybridization" region into the ribozyme. The hybridization region contains a sequence complementary to

the target RNA and thus specifically hybridizes with the target (see, for example, Gerlach *et al.*, EP 321,201).

5 Specific ribozyme cleavage sites within a protein phosphatase 2C-like enzyme RNA target can be identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target RNA containing the cleavage site can be evaluated for secondary structural features which may render the target inoperable. Suitability of candidate
10 protein phosphatase 2C-like enzyme RNA targets also can be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays. Longer complementary sequences can be used to increase the affinity of the hybridization sequence for the target. The hybridizing and cleavage regions of the ribozyme can be integrally related such that upon hybridizing
15 to the target RNA through the complementary regions, the catalytic region of the ribozyme can cleave the target.

Ribozymes can be introduced into cells as part of a DNA construct. Mechanical methods, such as microinjection, liposome-mediated transfection, electroporation, or
20 calcium phosphate precipitation, can be used to introduce a ribozyme-containing DNA construct into cells in which it is desired to decrease protein phosphatase 2C-like enzyme expression. Alternatively, if it is desired that the cells stably retain the DNA construct, the construct can be supplied on a plasmid and maintained as a separate element or integrated into the genome of the cells, as is known in the art. A
25 ribozyme-encoding DNA construct can include transcriptional regulatory elements, such as a promoter element, an enhancer or UAS element, and a transcriptional terminator signal, for controlling transcription of ribozymes in the cells.

As taught in Haseloff *et al.*, U.S. Patent 5,641,673, ribozymes can be engineered so
30 that ribozyme expression will occur in response to factors that induce expression of a target gene. Ribozymes also can be engineered to provide an additional level of

regulation, so that destruction of mRNA occurs only when both a ribozyme and a target gene are induced in the cells.

Differentially Expressed Genes

5

Described herein are methods for the identification of genes whose products interact with human protein phosphatase 2C-like enzyme. Such genes may represent genes that are differentially expressed in disorders including, but not limited to, CNS disorders, COPD, obesity, and diabetes.

10

Further, such genes may represent genes that are differentially regulated in response to manipulations relevant to the progression or treatment of such diseases. Additionally, such genes may have a temporally modulated expression, increased or decreased at different stages of tissue or organism development. A differentially
15 expressed gene may also have its expression modulated under control versus experimental conditions. In addition, the human protein phosphatase 2C-like enzyme gene or gene product may itself be tested for differential expression.

20

The degree to which expression differs in a normal versus a diseased state need only be large enough to be visualized via standard characterization techniques such as differential display techniques. Other such standard characterization techniques by which expression differences may be visualized include but are not limited to, quantitative RT (reverse transcriptase), PCR, and Northern analysis.

25

Identification of Differentially Expressed Genes

To identify differentially expressed genes total RNA or, preferably, mRNA is isolated from tissues of interest. For example, RNA samples are obtained from tissues of experimental subjects and from corresponding tissues of control subjects.
30 Any RNA isolation technique that does not select against the isolation of mRNA may be utilized for the purification of such RNA samples. See, for example, Ausubel *et*

al., ed., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, Inc. New York, 1987-1993. Large numbers of tissue samples may readily be processed using techniques well known to those of skill in the art, such as, for example, the single-step RNA isolation process of Chomczynski, U.S. Patent 4,843,155.

5

Transcripts within the collected RNA samples that represent RNA produced by differentially expressed genes are identified by methods well known to those of skill in the art. They include, for example, differential screening (Tedder *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 85, 208-12, 1988), subtractive hybridization (Hedrick *et al.*,
10 *Nature* 308, 149-53; Lee *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 88, 2825, 1984), and, preferably, differential display (Liang & Pardee, *Science* 257, 967-71, 1992; U.S. Patent 5,262,311).

The differential expression information may itself suggest relevant methods for the
15 treatment of disorders involving the human protein phosphatase 2C-like enzyme. For example, treatment may include a modulation of expression of the differentially expressed genes and/or the gene encoding the human protein phosphatase 2C-like enzyme. The differential expression information may indicate whether the expression or activity of the differentially expressed gene or gene product or the
20 human protein phosphatase 2C-like enzyme gene or gene product are up-regulated or down-regulated.

Screening Methods

25 The invention provides assays for screening test compounds that bind to or modulate the activity of a protein phosphatase 2C-like enzyme polypeptide or a protein phosphatase 2C-like enzyme polynucleotide. A test compound preferably binds to a protein phosphatase 2C-like enzyme polypeptide or polynucleotide. More preferably, a test compound decreases or increases enzymatic activity by at least about 10,
30 preferably about 50, more preferably about 75, 90, or 100% relative to the absence of the test compound.

Test Compounds

Test compounds can be pharmacologic agents already known in the art or can be
5 compounds previously unknown to have any pharmacological activity. The
compounds can be naturally occurring or designed in the laboratory. They can be
isolated from microorganisms, animals, or plants, and can be produced
recombinantly, or synthesized by chemical methods known in the art. If desired, test
10 compounds can be obtained using any of the numerous combinatorial library methods
known in the art, including but not limited to, biological libraries, spatially
addressable parallel solid phase or solution phase libraries, synthetic library methods
requiring deconvolution, the "one-bead one-compound" library method, and
synthetic library methods using affinity chromatography selection. The biological
15 library approach is limited to polypeptide libraries, while the other four approaches
are applicable to polypeptide, non-peptide oligomer, or small molecule libraries of
compounds. See Lam, *Anticancer Drug Des.* 12, 145, 1997.

Methods for the synthesis of molecular libraries are well known in the art (see, for
example, DeWitt *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 90, 6909, 1993; Erb *et al.* *Proc.*
20 *Natl. Acad. Sci. U.S.A.* 91, 11422, 1994; Zuckermann *et al.*, *J. Med. Chem.* 37, 2678,
1994; Cho *et al.*, *Science* 261, 1303, 1993; Carell *et al.*, *Angew. Chem. Int. Ed. Engl.*
33, 2059, 1994; Carell *et al.*, *Angew. Chem. Int. Ed. Engl.* 33, 2061; Gallop *et al.*, *J.*
Med. Chem. 37, 1233, 1994). Libraries of compounds can be presented in solution
(see, e.g., Houghten, *BioTechniques* 13, 412-421, 1992), or on beads (Lam, *Nature*
25 354, 82-84, 1991), chips (Fodor, *Nature* 364, 555-556, 1993), bacteria or spores
(Ladner, U.S. Patent 5,223,409), plasmids (Cull *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*
89, 1865-1869, 1992), or phage (Scott & Smith, *Science* 249, 386-390, 1990; Devlin,
Science 249, 404-406, 1990); Cwirla *et al.*, *Proc. Natl. Acad. Sci.* 97, 6378-6382,
1990; Felici, *J. Mol. Biol.* 222, 301-310, 1991; and Ladner, U.S. Patent 5,223,409).

High Throughput Screening

Test compounds can be screened for the ability to bind to protein phosphatase 2C-like enzyme polypeptides or polynucleotides or to affect protein phosphatase 2C-like enzyme activity or protein phosphatase 2C-like enzyme gene expression using high throughput screening. Using high throughput screening, many discrete compounds can be tested in parallel so that large numbers of test compounds can be quickly screened. The most widely established techniques utilize 96-well microtiter plates. The wells of the microtiter plates typically require assay volumes that range from 50 to 500 μ l. In addition to the plates, many instruments, materials, pipettors, robotics, plate washers, and plate readers are commercially available to fit the 96-well format. Alternatively, "free format assays," or assays that have no physical barrier between samples, can be used. For example, an assay using pigment cells (melanocytes) in a simple homogeneous assay for combinatorial peptide libraries is described by Jayawickreme *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 19, 1614-18 (1994). The cells are placed under agarose in petri dishes, then beads that carry combinatorial compounds are placed on the surface of the agarose. The combinatorial compounds are partially released the compounds from the beads. Active compounds can be visualized as dark pigment areas because, as the compounds diffuse locally into the gel matrix, the active compounds cause the cells to change colors.

Another example of a free format assay is described by Chelsky, "Strategies for Screening Combinatorial Libraries: Novel and Traditional Approaches," reported at the First Annual Conference of The Society for Biomolecular Screening in Philadelphia, Pa. (Nov. 7-10, 1995). Chelsky placed a simple homogenous enzyme assay for carbonic anhydrase inside an agarose gel such that the enzyme in the gel would cause a color change throughout the gel. Thereafter, beads carrying combinatorial compounds via a photolinker were placed inside the gel and the compounds were partially released by UV-light. Compounds that inhibited the enzyme were observed as local zones of inhibition having less color change.

Yet another example is described by Salmon *et al.*, *Molecular Diversity* 2, 57-63 (1996). In this example, combinatorial libraries were screened for compounds that had cytotoxic effects on cancer cells growing in agar.

- 5 Another high throughput screening method is described in Beutel *et al.*, U.S. Patent 5,976,813. In this method, test samples are placed in a porous matrix. One or more assay components are then placed within, on top of, or at the bottom of a matrix such as a gel, a plastic sheet, a filter, or other form of easily manipulated solid support. When samples are introduced to the porous matrix they diffuse sufficiently slowly,
10 such that the assays can be performed without the test samples running together.

Binding Assays

- For binding assays, the test compound is preferably a small molecule that binds to
15 and occupies, for example, the active site of the protein phosphatase 2C-like enzyme polypeptide, such that normal biological activity is prevented. Examples of such small molecules include, but are not limited to, small peptides or peptide-like molecules.

- 20 In binding assays, either the test compound or the protein phosphatase 2C-like enzyme polypeptide can comprise a detectable label, such as a fluorescent, radioisotopic, chemiluminescent, or enzymatic label, such as horseradish peroxidase, alkaline phosphatase, or luciferase. Detection of a test compound that is bound to the protein phosphatase 2C-like enzyme polypeptide can then be accomplished, for
25 example, by direct counting of radioemmission, by scintillation counting, or by determining conversion of an appropriate substrate to a detectable product.

- Alternatively, binding of a test compound to a protein phosphatase 2C-like enzyme polypeptide can be determined without labeling either of the interactants. For
30 example, a microphysiometer can be used to detect binding of a test compound with a protein phosphatase 2C-like enzyme polypeptide. A microphysiometer (e.g.,

Cytosensor™) is an analytical instrument that measures the rate at which a cell acidifies its environment using a light-addressable potentiometric sensor (LAPS). Changes in this acidification rate can be used as an indicator of the interaction between a test compound and a protein phosphatase 2C-like enzyme polypeptide (McConnell *et al.*, *Science* 257, 1906-1912, 1992).

Determining the ability of a test compound to bind to a protein phosphatase 2C-like enzyme polypeptide also can be accomplished using a technology such as real-time Bimolecular Interaction Analysis (BIA) (Sjolander & Urbaniczky, *Anal. Chem.* 63, 2338-2345, 1991, and Szabo *et al.*, *Curr. Opin. Struct. Biol.* 5, 699-705, 1995). BIA is a technology for studying biospecific interactions in real time, without labeling any of the interactants (*e.g.*, BIAcore™). Changes in the optical phenomenon surface plasmon resonance (SPR) can be used as an indication of real-time reactions between biological molecules.

In yet another aspect of the invention, a protein phosphatase 2C-like enzyme polypeptide can be used as a "bait protein" in a two-hybrid assay or three-hybrid assay (see, *e.g.*, U.S. Patent 5,283,317; Zervos *et al.*, *Cell* 72, 223-232, 1993; Madura *et al.*, *J. Biol. Chem.* 268, 12046-12054, 1993; Bartel *et al.*, *BioTechniques* 14, 920-924, 1993; Iwabuchi *et al.*, *Oncogene* 8, 1693-1696, 1993; and Brent W094/10300), to identify other proteins which bind to or interact with the protein phosphatase 2C-like enzyme polypeptide and modulate its activity.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. For example, in one construct, polynucleotide encoding a protein phosphatase 2C-like enzyme polypeptide can be fused to a polynucleotide encoding the DNA binding domain of a known transcription factor (*e.g.*, GAL-4). In the other construct a DNA sequence that encodes an unidentified protein ("prey" or "sample") can be fused to a polynucleotide that codes for the activation domain of the known transcription factor. If the "bait" and the "prey"

proteins are able to interact *in vivo* to form an protein-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (*e.g.*, LacZ), which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected, and cell colonies containing the functional transcription factor can be isolated and used to obtain the DNA sequence encoding the protein that interacts with the protein phosphatase 2C-like enzyme polypeptide.

It may be desirable to immobilize either the protein phosphatase 2C-like enzyme polypeptide (or polynucleotide) or the test compound to facilitate separation of bound from unbound forms of one or both of the interactants, as well as to accommodate automation of the assay. Thus, either the protein phosphatase 2C-like enzyme polypeptide (or polynucleotide) or the test compound can be bound to a solid support. Suitable solid supports include, but are not limited to, glass or plastic slides, tissue culture plates, microtiter wells, tubes, silicon chips, or particles such as beads (including, but not limited to, latex, polystyrene, or glass beads). Any method known in the art can be used to attach the enzyme polypeptide (or polynucleotide) or test compound to a solid support, including use of covalent and non-covalent linkages, passive absorption, or pairs of binding moieties attached respectively to the polypeptide (or polynucleotide) or test compound and the solid support. Test compounds are preferably bound to the solid support in an array, so that the location of individual test compounds can be tracked. Binding of a test compound to a protein phosphatase 2C-like enzyme polypeptide (or polynucleotide) can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and microcentrifuge tubes.

In one embodiment, the protein phosphatase 2C-like enzyme polypeptide is a fusion protein comprising a domain that allows the protein phosphatase 2C-like enzyme polypeptide to be bound to a solid support. For example, glutathione-S-transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical,

St. Louis, Mo.) or glutathione derivatized microtiter plates, which are then combined with the test compound or the test compound and the non-adsorbed protein phosphatase 2C-like enzyme polypeptide; the mixture is then incubated under conditions conducive to complex formation (*e.g.*, at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components. Binding of the interactants can be determined either directly or indirectly, as described above. Alternatively, the complexes can be dissociated from the solid support before binding is determined.

Other techniques for immobilizing proteins or polynucleotides on a solid support also can be used in the screening assays of the invention. For example, either a protein phosphatase 2C-like enzyme polypeptide (or polynucleotide) or a test compound can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated protein phosphatase 2C-like enzyme polypeptides (or polynucleotides) or test compounds can be prepared from biotin-NHS(N-hydroxysuccinimide) using techniques well known in the art (*e.g.*, biotinylation kit, Pierce Chemicals, Rockford, Ill.) and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies which specifically bind to a protein phosphatase 2C-like enzyme polypeptide, polynucleotide, or a test compound, but which do not interfere with a desired binding site, such as the active site of the protein phosphatase 2C-like enzyme polypeptide, can be derivatized to the wells of the plate. Unbound target or protein can be trapped in the wells by antibody conjugation.

Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies which specifically bind to the protein phosphatase 2C-like enzyme polypeptide or test compound, enzyme-linked assays which rely on detecting an activity of the protein phosphatase 2C-like enzyme polypeptide, and SDS gel electrophoresis under non-reducing conditions.

Screening for test compounds which bind to a protein phosphatase 2C-like enzyme polypeptide or polynucleotide also can be carried out in an intact cell. Any cell which comprises a protein phosphatase 2C-like enzyme polypeptide or polynucleotide can be used in a cell-based assay system. A protein phosphatase 2C-like enzyme polynucleotide can be naturally occurring in the cell or can be introduced using techniques such as those described above. Binding of the test compound to a protein phosphatase 2C-like enzyme polypeptide or polynucleotide is determined as described above.

10 Enzyme Assays

Test compounds can be tested for the ability to increase or decrease the enzymatic activity of a human protein phosphatase 2C-like enzyme polypeptide. Enzymatic activity can be measured, for example, as described in U.S. Patent 5,853,997.

15 Enzyme assays can be carried out after contacting either a purified protein phosphatase 2C-like enzyme polypeptide, a cell membrane preparation, or an intact cell with a test compound. A test compound that decreases an enzymatic activity of a protein phosphatase 2C-like enzyme polypeptide by at least about 10, preferably about 50, more preferably about 75, 90, or 100% is identified as a potential therapeutic agent for decreasing protein phosphatase 2C-like enzyme activity. A test compound which increases an enzymatic activity of a human protein phosphatase 2C-like enzyme polypeptide by at least about 10, preferably about 50, more preferably about 75, 90, or 100% is identified as a potential therapeutic agent for increasing human protein phosphatase 2C-like enzyme activity.

25 Gene Expression

In another embodiment, test compounds that increase or decrease protein phosphatase 2C-like enzyme gene expression are identified. A protein phosphatase 2C-like enzyme polynucleotide is contacted with a test compound, and the expression

of an RNA or polypeptide product of the protein phosphatase 2C-like enzyme polynucleotide is determined. The level of expression of appropriate mRNA or polypeptide in the presence of the test compound is compared to the level of expression of mRNA or polypeptide in the absence of the test compound. The test
5 compound can then be identified as a modulator of expression based on this comparison. For example, when expression of mRNA or polypeptide is greater in the presence of the test compound than in its absence, the test compound is identified as a stimulator or enhancer of the mRNA or polypeptide expression. Alternatively, when expression of the mRNA or polypeptide is less in the presence of the test
10 compound than in its absence, the test compound is identified as an inhibitor of the mRNA or polypeptide expression.

The level of protein phosphatase 2C-like enzyme mRNA or polypeptide expression in the cells can be determined by methods well known in the art for detecting mRNA
15 or polypeptide. Either qualitative or quantitative methods can be used. The presence of polypeptide products of a protein phosphatase 2C-like enzyme polynucleotide can be determined, for example, using a variety of techniques known in the art, including immunochemical methods such as radioimmunoassay, Western blotting, and immunohistochemistry. Alternatively, polypeptide synthesis can be determined *in*
20 *vivo*, in a cell culture, or in an *in vitro* translation system by detecting incorporation of labeled amino acids into a protein phosphatase 2C-like enzyme polypeptide.

Such screening can be carried out either in a cell-free assay system or in an intact cell. Any cell that expresses a protein phosphatase 2C-like enzyme polynucleotide
25 can be used in a cell-based assay system. The protein phosphatase 2C-like enzyme polynucleotide can be naturally occurring in the cell or can be introduced using techniques such as those described above. Either a primary culture or an established cell line, such as CHO or human embryonic kidney 293 cells, can be used.

Pharmaceutical Compositions

The invention also provides pharmaceutical compositions that can be administered to a patient to achieve a therapeutic effect. Pharmaceutical compositions of the invention can comprise, for example, a protein phosphatase 2C-like enzyme polypeptide, protein phosphatase 2C-like enzyme polynucleotide, ribozymes or antisense oligonucleotides, antibodies which specifically bind to a protein phosphatase 2C-like enzyme polypeptide, or mimetics, activators, or inhibitors of a protein phosphatase 2C-like enzyme polypeptide activity. The compositions can be administered alone or in combination with at least one other agent, such as stabilizing compound, which can be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water. The compositions can be administered to a patient alone, or in combination with other agents, drugs or hormones.

In addition to the active ingredients, these pharmaceutical compositions can contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries that facilitate processing of the active compounds into preparations which can be used pharmaceutically. Pharmaceutical compositions of the invention can be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, parenteral, topical, sublingual, or rectal means. Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combination of active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to

obtain tablets or dragee cores. Suitable excipients are carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxy-propylmethyl-cellulose, or sodium carboxymethylcellulose; gums including arabic and tragacanth; and proteins such as gelatin and collagen. If desired, disintegrating
5 or solubilizing agents can be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.

Dragee cores can be used in conjunction with suitable coatings, such as concentrated
10 sugar solutions, which also can contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments can be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, *i.e.*, dosage.

15 Pharmaceutical preparations that can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds can be
20 dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration can be formulated
25 in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions can contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds can be prepared as appropriate oily injection suspensions.
30 Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.

Non-lipid polycationic amino polymers also can be used for delivery. Optionally, the suspension also can contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

The pharmaceutical compositions of the present invention can be manufactured in a manner that is known in the art, *e.g.*, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes. The pharmaceutical composition can be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred preparation can be a lyophilized powder which can contain any or all of the following: 1-50 mM histidine, 0.1%-2% sucrose, and 2-7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

Further details on techniques for formulation and administration can be found in the latest edition of REMINGTON'S PHARMACEUTICAL SCIENCES (Maack Publishing Co., Easton, Pa.). After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. Such labeling would include amount, frequency, and method of administration.

25

Therapeutic Indications and Methods

Human protein phosphatase 2C-like enzyme can be regulated to treat CNS disorders, COPD, obesity, and diabetes.

30

CNS disorders

Central and peripheral nervous system disorders also can be treated, such as primary and secondary disorders after brain injury, disorders of mood, anxiety disorders, disorders of thought and volition, disorders of sleep and wakefulness, diseases of the motor unit, such as neurogenic and myopathic disorders, neurodegenerative disorders such as Alzheimer's and Parkinson's disease, and processes of peripheral and chronic pain.

Pain that is associated with CNS disorders also can be treated by regulating the activity of human epoxide hydrolase-like protein. Pain which can be treated includes that associated with central nervous system disorders, such as multiple sclerosis, spinal cord injury, sciatica, failed back surgery syndrome, traumatic brain injury, epilepsy, Parkinson's disease, post-stroke, and vascular lesions in the brain and spinal cord (e.g., infarct, hemorrhage, vascular malformation). Non-central neuropathic pain includes that associated with post mastectomy pain, reflex sympathetic dystrophy (RSD), trigeminal neuralgias, post-surgical pain, HIV/AIDS related pain, cancer pain, metabolic neuropathies (e.g., diabetic neuropathy, vasculitic neuropathy secondary to connective tissue disease), paraneoplastic polyneuropathy associated, for example, with carcinoma of lung, or leukemia, or lymphoma, or carcinoma of prostate, colon or stomach, trigeminal neuralgia, cranial neuralgias, and post-herpetic neuralgia. Pain associated with cancer and cancer treatment also can be treated, as can headache pain (for example, migraine with aura, migraine without aura, and other migraine disorders), episodic and chronic tension-type headache, tension-type like headache, cluster headache, and chronic paroxysmal hemicrania.

COPD

Chronic obstructive pulmonary (or airways) disease (COPD) is a condition defined physiologically as airflow obstruction that generally results from a mixture of

emphysema and peripheral airway obstruction due to chronic bronchitis (Senior & Shapiro, *Pulmonary Diseases and Disorders*, 3d ed., New York, McGraw-Hill, 1998, pp. 659-681, 1998; Barnes, *Chest* 117, 10S-14S, 2000). Emphysema is characterized by destruction of alveolar walls leading to abnormal enlargement of the air spaces of the lung. Chronic bronchitis is defined clinically as the presence of chronic productive cough for three months in each of two successive years. In COPD, airflow obstruction is usually progressive and is only partially reversible. By far the most important risk factor for development of COPD is cigarette smoking, although the disease does occur in non-smokers.

Chronic inflammation of the airways is a key pathological feature of COPD (Senior & Shapiro, 1998). The inflammatory cell population comprises increased numbers of macrophages, neutrophils, and CD8⁺ lymphocytes. Inhaled irritants, such as cigarette smoke, activate macrophages which are resident in the respiratory tract, as well as epithelial cells leading to release of chemokines (e.g., interleukin-8) and other chemotactic factors. These chemotactic factors act to increase the neutrophil/monocyte trafficking from the blood into the lung tissue and airways. Neutrophils and monocytes recruited into the airways can release a variety of potentially damaging mediators such as proteolytic enzymes and reactive oxygen species. Matrix degradation and emphysema, along with airway wall thickening, surfactant dysfunction, and mucus hypersecretion, all are potential sequelae of this inflammatory response that lead to impaired airflow and gas exchange.

Diabetes

mellitus is a common metabolic disorder characterized by an abnormal elevation in blood glucose, alterations in lipids and abnormalities (complications) in the cardiovascular system, eye, kidney and nervous system. Diabetes is divided into two separate diseases: type 1 diabetes (juvenile onset), which results from a loss of cells which make and secrete insulin, and type 2 diabetes (adult onset), which is caused by a defect in insulin secretion and a defect in insulin action.

Type 1 diabetes is initiated by an autoimmune reaction that attacks the insulin secreting cells (beta cells) in the pancreatic islets. Agents that prevent this reaction from occurring or that stop the reaction before destruction of the beta cells has been accomplished are potential therapies for this disease. Other agents that induce beta cell proliferation and regeneration also are potential therapies.

Type II diabetes is the most common of the two diabetic conditions (6% of the population). The defect in insulin secretion is an important cause of the diabetic condition and results from an inability of the beta cell to properly detect and respond to rises in blood glucose levels with insulin release. Therapies that increase the response by the beta cell to glucose would offer an important new treatment for this disease.

The defect in insulin action in Type II diabetic subjects is another target for therapeutic intervention. Agents that increase the activity of the insulin receptor in muscle, liver, and fat will cause a decrease in blood glucose and a normalization of plasma lipids. The receptor activity can be increased by agents that directly stimulate the receptor or that increase the intracellular signals from the receptor. Other therapies can directly activate the cellular end process, *i.e.* glucose transport or various enzyme systems, to generate an insulin-like effect and therefore a produce beneficial outcome. Because overweight subjects have a greater susceptibility to Type II diabetes, any agent that reduces body weight is a possible therapy.

Both Type I and Type diabetes can be treated with agents that mimic insulin action or that treat diabetic complications by reducing blood glucose levels. Likewise, agents that reduces new blood vessel growth can be used to treat the eye complications that develop in both diseases.

Obesity.

Obesity and overweight are defined as an excess of body fat relative to lean body mass. An increase in caloric intake or a decrease in energy expenditure or both can bring about this imbalance leading to surplus energy being stored as fat. Obesity is associated with important medical morbidities and an increase in mortality. The causes of obesity are poorly understood and may be due to genetic factors, environmental factors or a combination of the two to cause a positive energy balance. In contrast, anorexia and cachexia are characterized by an imbalance in energy intake versus energy expenditure leading to a negative energy balance and weight loss. Agents that either increase energy expenditure and/or decrease energy intake, absorption or storage would be useful for treating obesity, overweight, and associated comorbidities. Agents that either increase energy intake and/or decrease energy expenditure or increase the amount of lean tissue would be useful for treating cachexia, anorexia and wasting disorders.

This gene, translated proteins and agents which modulate this gene or portions of the gene or its products are useful for treating obesity, overweight, anorexia, cachexia, wasting disorders, appetite suppression, appetite enhancement, increases or decreases in satiety, modulation of body weight, and/or other eating disorders such as bulimia. Also this gene, translated proteins and agents which modulate this gene or portions of the gene or its products are useful for treating obesity/overweight-associated comorbidities including hypertension, type 2 diabetes, coronary artery disease, hyperlipidemia, stroke, gallbladder disease, gout, osteoarthritis, sleep apnea and respiratory problems, some types of cancer including endometrial, breast, prostate, and colon cancer, thrombotic disease, polycystic ovarian syndrome, reduced fertility, complications of pregnancy, menstrual irregularities, hirsutism, stress incontinence, and depression.

This invention further pertains to the use of novel agents identified by the screening assays described above. Accordingly, it is within the scope of this invention to use a

test compound identified as described herein in an appropriate animal model. For example, an agent identified as described herein (*e.g.*, a modulating agent, an antisense nucleic acid molecule, a specific antibody, ribozyme, or a protein phosphatase 2C-like enzyme polypeptide binding molecule) can be used in an animal model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described herein can be used in an animal model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein.

10

A reagent which affects protein phosphatase 2C-like enzyme activity can be administered to a human cell, either *in vitro* or *in vivo*, to reduce protein phosphatase 2C-like enzyme activity. The reagent preferably binds to an expression product of a human protein phosphatase 2C-like enzyme gene. If the expression product is a protein, the reagent is preferably an antibody. For treatment of human cells *ex vivo*, an antibody can be added to a preparation of stem cells that have been removed from the body. The cells can then be replaced in the same or another human body, with or without clonal propagation, as is known in the art.

15

20

In one embodiment, the reagent is delivered using a liposome. Preferably, the liposome is stable in the animal into which it has been administered for at least about 30 minutes, more preferably for at least about 1 hour, and even more preferably for at least about 24 hours. A liposome comprises a lipid composition that is capable of targeting a reagent, particularly a polynucleotide, to a particular site in an animal, such as a human. Preferably, the lipid composition of the liposome is capable of targeting to a specific organ of an animal, such as the lung, liver, spleen, heart brain, lymph nodes, and skin.

25

30

A liposome useful in the present invention comprises a lipid composition that is capable of fusing with the plasma membrane of the targeted cell to deliver its contents to the cell. Preferably, the transfection efficiency of a liposome is about 0.5

µg of DNA per 16 nmole of liposome delivered to about 10^6 cells, more preferably about 1.0 µg of DNA per 16 nmole of liposome delivered to about 10^6 cells, and even more preferably about 2.0 µg of DNA per 16 nmol of liposome delivered to about 10^6 cells. Preferably, a liposome is between about 100 and 500 nm, more preferably
5 between about 150 and 450 nm, and even more preferably between about 200 and 400 nm in diameter.

Suitable liposomes for use in the present invention include those liposomes standardly used in, for example, gene delivery methods known to those of skill in the
10 art. More preferred liposomes include liposomes having a polycationic lipid composition and/or liposomes having a cholesterol backbone conjugated to polyethylene glycol. Optionally, a liposome comprises a compound capable of targeting the liposome to a particular cell type, such as a cell-specific ligand exposed on the outer surface of the liposome.

15 Complexing a liposome with a reagent such as an antisense oligonucleotide or ribozyme can be achieved using methods that are standard in the art (see, for example, U.S. Patent 5,705,151). Preferably, from about 0.1 µg to about 10 µg of polynucleotide is combined with about 8 nmol of liposomes, more preferably from
20 about 0.5 µg to about 5 µg of polynucleotides are combined with about 8 nmol liposomes, and even more preferably about 1.0 µg of polynucleotides is combined with about 8 nmol liposomes.

In another embodiment, antibodies can be delivered to specific tissues *in vivo* using
25 receptor-mediated targeted delivery. Receptor-mediated DNA delivery techniques are taught in, for example, Findeis *et al.* *Trends in Biotechnol.* 11, 202-05 (1993); Chiou *et al.*, GENE THERAPEUTICS: METHODS AND APPLICATIONS OF DIRECT GENE TRANSFER (J.A. Wolff, ed.) (1994); Wu & Wu, *J. Biol. Chem.* 263, 621-24 (1988); Wu *et al.*, *J. Biol. Chem.* 269, 542-46 (1994); Zenke *et al.*, *Proc. Natl. Acad. Sci.*
30 *U.S.A.* 87, 3655-59 (1990); Wu *et al.*, *J. Biol. Chem.* 266, 338-42 (1991).

Determination of a Therapeutically Effective Dose

5 The determination of a therapeutically effective dose is well within the capability of those skilled in the art. A therapeutically effective dose refers to that amount of active ingredient which increases or decreases protein phosphatase 2C-like enzyme activity relative to the protein phosphatase 2C-like enzyme activity which occurs in the absence of the therapeutically effective dose.

10 For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays or in animal models, usually mice, rabbits, dogs, or pigs. The animal model also can be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

15 Therapeutic efficacy and toxicity, e.g., ED_{50} (the dose therapeutically effective in 50% of the population) and LD_{50} (the dose lethal to 50% of the population), can be determined by standard pharmaceutical procedures in cell cultures or experimental animals. The dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD_{50}/ED_{50} .

20 Pharmaceutical compositions that exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that include the ED_{50} with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.

25 The exact dosage will be determined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to provide sufficient levels of the active ingredient or to maintain the desired effect. Factors that can be taken into account include the severity of the disease state,

general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions can be administered every 3 to 4 days, every week, or once every two weeks depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts can vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

If the reagent is a single-chain antibody, polynucleotides encoding the antibody can be constructed and introduced into a cell either *ex vivo* or *in vivo* using well-established techniques including, but not limited to, transferrin-polycation-mediated DNA transfer, transfection with naked or encapsulated nucleic acids, liposome-mediated cellular fusion, intracellular transportation of DNA-coated latex beads, protoplast fusion, viral infection, electroporation, "gene gun," and DEAE- or calcium phosphate-mediated transfection.

Effective *in vivo* dosages of an antibody are in the range of about 5 µg to about 50 µg/kg, about 50 µg to about 5 mg/kg, about 100 µg to about 500 µg/kg of patient body weight, and about 200 to about 250 µg/kg of patient body weight. For administration of polynucleotides encoding single-chain antibodies, effective *in vivo* dosages are in the range of about 100 ng to about 200 ng, 500 ng to about 50 mg, about 1 µg to about 2 mg, about 5 µg to about 500 µg, and about 20 µg to about 100 µg of DNA.

If the expression product is mRNA, the reagent is preferably an antisense oligonucleotide or a ribozyme. Polynucleotides that express antisense oligonucleotides or ribozymes can be introduced into cells by a variety of methods, as described above.

5

Preferably, a reagent reduces expression of a protein phosphatase 2C-like enzyme gene or the activity of a protein phosphatase 2C-like enzyme polypeptide by at least about 10, preferably about 50, more preferably about 75, 90, or 100% relative to the absence of the reagent. The effectiveness of the mechanism chosen to decrease the level of expression of a protein phosphatase 2C-like enzyme gene or the activity of a protein phosphatase 2C-like enzyme polypeptide can be assessed using methods well known in the art, such as hybridization of nucleotide probes to protein phosphatase 2C-like enzyme-specific mRNA, quantitative RT-PCR, immunologic detection of a protein phosphatase 2C-like enzyme polypeptide, or measurement of protein phosphatase 2C-like enzyme activity.

10

15

In any of the embodiments described above, any of the pharmaceutical compositions of the invention can be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy can be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents can act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

20

25

Any of the therapeutic methods described above can be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

Diagnostic Methods

Human protein phosphatase 2C-like enzyme also can be used in diagnostic assays for detecting diseases and abnormalities or susceptibility to diseases and abnormalities related to the presence of mutations in the nucleic acid sequences that encode the enzyme. For example, differences can be determined between the cDNA or genomic sequence encoding protein phosphatase 2C-like enzyme in individuals afflicted with a disease and in normal individuals. If a mutation is observed in some or all of the afflicted individuals but not in normal individuals, then the mutation is likely to be the causative agent of the disease.

Sequence differences between a reference gene and a gene having mutations can be revealed by the direct DNA sequencing method. In addition, cloned DNA segments can be employed as probes to detect specific DNA segments. The sensitivity of this method is greatly enhanced when combined with PCR. For example, a sequencing primer can be used with a double-stranded PCR product or a single-stranded template molecule generated by a modified PCR. The sequence determination is performed by conventional procedures using radiolabeled nucleotides or by automatic sequencing procedures using fluorescent tags.

Genetic testing based on DNA sequence differences can be carried out by detection of alteration in electrophoretic mobility of DNA fragments in gels with or without denaturing agents. Small sequence deletions and insertions can be visualized, for example, by high resolution gel electrophoresis. DNA fragments of different sequences can be distinguished on denaturing formamide gradient gels in which the mobilities of different DNA fragments are retarded in the gel at different positions according to their specific melting or partial melting temperatures (*see, e.g., Myers et al., Science 230, 1242, 1985*). Sequence changes at specific locations can also be revealed by nuclease protection assays, such as RNase and S 1 protection or the chemical cleavage method (*e.g., Cotton et al., Proc. Natl. Acad. Sci. USA 85, 4397-4401, 1985*). Thus, the detection of a specific DNA sequence can be performed

by methods such as hybridization, RNase protection, chemical cleavage, direct DNA sequencing or the use of restriction enzymes and Southern blotting of genomic DNA. In addition to direct methods such as gel-electrophoresis and DNA sequencing, mutations can also be detected by *in situ* analysis.

5

Altered levels of protein phosphatase 2C-like enzyme also can be detected in various tissues. Assays used to detect levels of the receptor polypeptides in a body sample, such as blood or a tissue biopsy, derived from a host are well known to those of skill in the art and include radioimmunoassays, competitive binding assays, Western blot analysis, and ELISA assays.

10

All patents and patent applications cited in this disclosure are expressly incorporated herein by reference. The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific examples, which are provided for purposes of illustration only and are not intended to limit the scope of the invention.

15

EXAMPLE 1*Detection of protein phosphatase 2C-like enzyme activity*

The polynucleotide of SEQ ID NO: 1 is inserted into the expression vector pCEV4 and the expression vector pCEV4-protein phosphatase 2C-like enzyme polypeptide obtained is transfected into human embryonic kidney 293 cells. From these cells extracts are obtained and protein phosphatase activity is assayed by using phosphorylated casein as a substrate. The radiolabeled casein is precipitated with 15 % trichloroacetic acid (TCA), washed three times with cold 20% TCA and twice with cold acetone, air-dried, dissolved in 0.2 M Tris HCl (pH 8.0), and stored at 4°C. The cell extract is assayed for phosphatase activity in a time-course experiment in 50 µl of incubation mixture consisting of 50 mM Tris HCl (pH 7.0), 0.1 mM EGTA, 0.1% 2-mercaptoethanol, 20 mM magnesium acetate, 1 µM okadic acid, around 0.2 µg of the fusion protein, and 2 x 10⁴ cpm (Cerenkov counts) of 32P-labeled casein at 30°C. All reactions are terminated by the addition of 50µl cold 30% TCA. After 5 min of incubation on ice, the samples are centrifuged for 10 min at 14,000 x g, and the radioactivity in the supernatant and pellet is measured by Cerenkov counting. It is shown that the polypeptide of SEQ ID NO: 2 has a protein phosphatase 2C-like enzyme activity.

20

EXAMPLE 2*Expression of recombinant human protein phosphatase 2C-like enzyme*

The *Pichia pastoris* expression vector pPICZB (Invitrogen, San Diego, CA) is used to produce large quantities of recombinant human protein phosphatase 2C-like enzyme polypeptides in yeast. The protein phosphatase 2C-like enzyme-encoding DNA sequence is derived from SEQ ID NO: 1. Before insertion into vector pPICZB, the DNA sequence is modified by well known methods in such a way that it contains at its 5'-end an initiation codon and at its 3'-end an enterokinase cleavage site, a His6 reporter tag and a termination codon. Moreover, at both termini recognition sequences for restriction endonucleases are added and after digestion of the multiple

25

30

cloning site of pPICZ B with the corresponding restriction enzymes the modified DNA sequence is ligated into pPICZB. This expression vector is designed for inducible expression in *Pichia pastoris*, driven by a yeast promoter. The resulting pPICZ/md-His6 vector is used to transform the yeast.

5

The yeast is cultivated under usual conditions in 5 liter shake flasks and the recombinantly produced protein isolated from the culture by affinity chromatography (Ni-NTA-Resin) in the presence of 8 M urea. The bound polypeptide is eluted with buffer, pH 3.5, and neutralized. Separation of the polypeptide from the His6 reporter tag is accomplished by site-specific proteolysis using enterokinase (Invitrogen, San Diego, CA) according to manufacturer's instructions. Purified human protein phosphatase 2C-like enzyme polypeptide is obtained.

10

EXAMPLE 3

Identification of test compounds that bind to protein phosphatase 2C-like enzyme polypeptides

15

Purified protein phosphatase 2C-like enzyme polypeptides comprising a glutathione-S-transferase protein and absorbed onto glutathione-derivatized wells of 96-well microtiter plates are contacted with test compounds from a small molecule library at pH 7.0 in a physiological buffer solution. Human protein phosphatase 2C-like enzyme polypeptides comprise the amino acid sequence shown in SEQ ID NO: 2. The test compounds comprise a fluorescent tag. The samples are incubated for 5 minutes to one hour. Control samples are incubated in the absence of a test compound.

20

25

The buffer solution containing the test compounds is washed from the wells. Binding of a test compound to a protein phosphatase 2C-like enzyme polypeptide is detected by fluorescence measurements of the contents of the wells. A test compound that increases the fluorescence in a well by at least 15% relative to

30

fluorescence of a well in which a test compound is not incubated is identified as a compound which binds to a protein phosphatase 2C-like enzyme polypeptide.

EXAMPLE 4

5 *Identification of a test compound which decreases protein phosphatase 2C-like enzyme gene expression*

A test compound is administered to a culture of human cells transfected with a protein phosphatase 2C-like enzyme expression construct and incubated at 37 °C for
10 10 to 45 minutes. A culture of the same type of cells that have not been transfected is incubated for the same time without the test compound to provide a negative control.

RNA is isolated from the two cultures as described in Chirgwin *et al.*, *Biochem. 18*,
5294-99, 1979). Northern blots are prepared using 20 to 30 µg total RNA and
15 hybridized with a ³²P-labeled protein phosphatase 2C-like enzyme-specific probe at 65 °C in Express-hyb (CLONTECH). The probe comprises at least 11 contiguous nucleotides selected from the complement of SEQ ID NO: 1. A test compound that decreases the protein phosphatase 2C-like enzyme-specific signal relative to the signal obtained in the absence of the test compound is identified as an inhibitor of
20 protein phosphatase 2C-like enzyme gene expression.

EXAMPLE 5

25 *Identification of a test compound which decreases protein phosphatase 2C-like enzyme activity*

A test compound is administered to a culture of human cells transfected with a protein phosphatase 2C-like enzyme expression construct and incubated at 37 °C for
10 to 45 minutes. A culture of the same type of cells that have not been transfected is incubated for the same time without the test compound to provide a negative control.
30 Enzymatic activity is measured using the method of U.S. Patent 5,853,997.

A test compound which decreases the protein phosphatase 2C-like enzyme activity of the protein phosphatase 2C-like enzyme relative to the protein phosphatase 2C-like enzyme activity in the absence of the test compound is identified as an inhibitor of protein phosphatase 2C-like enzyme activity.

5

EXAMPLE 6

Tissue-specific expression of protein phosphatase 2C-like enzyme

The qualitative expression pattern of protein phosphatase 2C-like enzyme in various
10 tissues is determined by Reverse Transcription-Polymerase Chain Reaction (RT-PCR).

To demonstrate that protein phosphatase 2C-like enzyme is involved in the disease
process of COPD, the initial expression panel consists of RNA samples from
15 respiratory tissues and inflammatory cells relevant to COPD: lung (adult and fetal),
trachea, freshly isolated alveolar type II cells, cultured human bronchial epithelial
cells, cultured small airway epithelial cells, cultured bronchial smooth muscle cells,
cultured H441 cells (Clara-like), freshly isolated neutrophils and monocytes, and
cultured monocytes (macrophage-like). Body map profiling also is carried out, using
20 total RNA panels purchased from Clontech. The tissues are adrenal gland, bone
marrow, brain, colon, heart, kidney, liver, lung, mammary gland, pancreas, prostate,
salivary gland, skeletal muscle, small intestine, spleen, stomach, testis, thymus,
trachea, thyroid, and uterus.

To demonstrate that protein phosphatase 2C-like enzyme is involved in the disease
process of obesity, expression is determined in the following tissues: subcutaneous
adipose tissue, mesenteric adipose tissue, adrenal gland, bone marrow, brain
(cerebellum, spinal cord, cerebral cortex, caudate, medulla, substantia nigra, and
putamen), colon, fetal brain, heart, kidney, liver, lung, mammary gland, pancreas,
25 placenta, prostate, salivary gland, skeletal muscle, small intestine, spleen, stomach,
30 testes, thymus, thyroid, trachea, and uterus. Neuroblastoma cell lines SK-Nr-Be (2),

Hr, Sk-N-As, HTB-10, IMR-32, SNSY-5Y, T3, SK-N-D2, D283, DAOY, CHP-2, U87MG, BE(2)C, T986, KANTS, MO59K, CHP234, C6 (rat), SK-N-F1, SK-PU-DW, PFSK-1, BE(2)M17, and MCIXC also are tested for protein phosphatase 2C-like enzyme expression. As a final step, the expression of protein phosphatase 2C-like enzyme in cells derived from normal individuals with the expression of cells
5 derived from obese individuals is compared.

To demonstrate that protein phosphatase 2C-like enzyme is involved in the disease process of diabetes, the following whole body panel is screened to show predominant
10 or relatively high expression: subcutaneous and mesenteric adipose tissue, adrenal gland, bone marrow, brain, colon, fetal brain, heart, hypothalamus, kidney, liver, lung, mammary gland, pancreas, placenta, prostate, salivary gland, skeletal muscle, small intestine, spleen, stomach, testis, thymus, thyroid, trachea, and uterus. Human islet cells and an islet cell library also are tested. As a final step, the expression of
15 protein phosphatase 2C-like enzyme in cells derived from normal individuals with the expression of cells derived from diabetic individuals is compared.

To demonstrate that protein phosphatase 2C-like enzyme is involved in CNS disorders, the following tissues are screened: fetal and adult brain, muscle, heart,
20 lung, kidney, liver, thymus, testis, colon, placenta, trachea, pancreas, kidney, gastric mucosa, colon, liver, cerebellum, skin, cortex (Alzheimer's and normal), hypothalamus, cortex, amygdala, cerebellum, hippocampus, choroid, plexus, thalamus, and spinal cord.

25 *Quantitative expression profiling.* Quantitative expression profiling is performed by the form of quantitative PCR analysis called "kinetic analysis" firstly described in Higuchi *et al.*, *BioTechnology* 10, 413-17, 1992, and Higuchi *et al.*, *BioTechnology* 11, 1026-30, 1993. The principle is that at any given cycle within the exponential phase of PCR, the amount of product is proportional to the initial number of template
30 copies.

If the amplification is performed in the presence of an internally quenched fluorescent oligonucleotide (TaqMan probe) complementary to the target sequence, the probe is cleaved by the 5'-3' endonuclease activity of Taq DNA polymerase and a fluorescent dye released in the medium (Holland *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 88, 7276-80, 1991). Because the fluorescence emission will increase in direct proportion to the amount of the specific amplified product, the exponential growth phase of PCR product can be detected and used to determine the initial template concentration (Heid *et al.*, *Genome Res.* 6, 986-94, 1996, and Gibson *et al.*, *Genome Res.* 6, 995-1001, 1996).

The amplification of an endogenous control can be performed to standardize the amount of sample RNA added to a reaction. In this kind of experiment, the control of choice is the 18S ribosomal RNA. Because reporter dyes with differing emission spectra are available, the target and the endogenous control can be independently quantified in the same tube if probes labeled with different dyes are used.

All "real time PCR" measurements of fluorescence are made in the ABI Prism 7700. *RNA extraction and cDNA preparation.* Total RNA from the tissues listed above are used for expression quantification. RNAs labeled "from autopsy" were extracted from autaptic tissues with the TRIzol reagent (Life Technologies, MD) according to the manufacturer's protocol.

Fifty µg of each RNA were treated with DNase I for 1 hour at 37 °C in the following reaction mix: 0.2 U/µl RNase-free DNase I (Roche Diagnostics, Germany); 0.4 U/µl RNase inhibitor (PE Applied Biosystems, CA); 10 mM Tris-HCl pH 7.9; 10mM MgCl₂; 50 mM NaCl; and 1 mM DTT.

After incubation, RNA is extracted once with 1 volume of phenol:chloroform:isoamyl alcohol (24:24:1) and once with chloroform, and precipitated with 1/10 volume of 3 M NaAcetate, pH5.2, and 2 volumes of ethanol.

- 66 -

Fifty μg of each RNA from the autaptic tissues are DNase treated with the DNA-free kit purchased from Ambion (Ambion, TX). After resuspension and spectrophotometric quantification, each sample is reverse transcribed with the TaqMan Reverse Transcription Reagents (PE Applied Biosystems, CA) according to the
5 manufacturer's protocol. The final concentration of RNA in the reaction mix is 200ng/ μL . Reverse transcription is carried out with 2.5 μM of random hexamer primers.

TaqMan quantitative analysis. Specific primers and probe are designed according to
10 the recommendations of PE Applied Biosystems; the probe can be labeled at the 5' end FAM (6-carboxy-fluorescein) and at the 3' end with TAMRA (6-carboxy-tetramethyl-rhodamine). Quantification experiments are performed on 10 ng of reverse transcribed RNA from each sample. Each determination is done in triplicate.

15 Total cDNA content is normalized with the simultaneous quantification (multiplex PCR) of the 18S ribosomal RNA using the Pre-Developed TaqMan Assay Reagents (PDAR) Control Kit (PE Applied Biosystems, CA).

The assay reaction mix is as follows: 1X final TaqMan Universal PCR Master Mix
20 (from 2X stock) (PE Applied Biosystems, CA); 1X PDAR control – 18S RNA (from 20X stock); 300 nM forward primer; 900 nM reverse primer; 200 nM probe; 10 ng cDNA; and water to 25 μl .

Each of the following steps are carried out once: pre PCR, 2 minutes at 50 $^{\circ}\text{C}$, and
25 10 minutes at 95 $^{\circ}\text{C}$. The following steps are carried out 40 times: denaturation, 15 seconds at 95 $^{\circ}\text{C}$, annealing/extension, 1 minute at 60 $^{\circ}\text{C}$.

The experiment is performed on an ABI Prism 7700 Sequence Detector (PE Applied Biosystems, CA). At the end of the run, fluorescence data acquired during PCR are
30 processed as described in the ABI Prism 7700 user's manual in order to achieve

better background subtraction as well as signal linearity with the starting target quantity.

EXAMPLE 7

5 *In vivo testing of compounds/target validation*

1. Pain:

Acute Pain

Acute pain is measured on a hot plate mainly in rats. Two variants of hot plate testing
10 are used: In the classical variant animals are put on a hot surface (52 to 56 °C) and
the latency time is measured until the animals show nocifensive behavior, such as
stepping or foot licking. The other variant is an increasing temperature hot plate
where the experimental animals are put on a surface of neutral temperature. Sub-
sequently this surface is slowly but constantly heated until the animals begin to lick a
15 hind paw. The temperature which is reached when hind paw licking begins is a
measure for pain threshold.

Compounds are tested against a vehicle treated control group. Substance application
is performed at different time points via different application routes (i.v., i.p., p.o.,
20 i.t., i.c.v., s.c., intradermal, transdermal) prior to pain testing.

Persistent Pain

Persistent pain is measured with the formalin or capsaicin test, mainly in rats. A
25 solution of 1 to 5% formalin or 10 to 100 µg capsaicin is injected into one hind paw
of the experimental animal. After formalin or capsaicin application the animals show
nocifensive reactions like flinching, licking and biting of the affected paw. The
number of nocifensive reactions within a time frame of up to 90 minutes is a measure
for intensity of pain.

Compounds are tested against a vehicle treated control group. Substance application is performed at different time points via different application routes (i.v., i.p., p.o., i.t., i.c.v., s.c., intradermal, transdermal) prior to formalin or capsaicin administration.

5 *Neuropathic Pain*

Neuropathic pain is induced by different variants of unilateral sciatic nerve injury mainly in rats. The operation is performed under anesthesia. The first variant of sciatic nerve injury is produced by placing loosely constrictive ligatures around the common sciatic nerve. The second variant is the tight ligation of about the half of the diameter of the common sciatic nerve. In the next variant, a group of models is used in which tight ligations or transections are made of either the L5 and L6 spinal nerves, or the L₅ spinal nerve only. The fourth variant involves an axotomy of two of the three terminal branches of the sciatic nerve (tibial and common peroneal nerves) leaving the remaining sural nerve intact whereas the last variant comprises the axotomy of only the tibial branch leaving the sural and common nerves uninjured. Control animals are treated with a sham operation.

Postoperatively, the nerve injured animals develop a chronic mechanical allodynia, cold allodynia, as well as a thermal hyperalgesia. Mechanical allodynia is measured by means of a pressure transducer (electronic von Frey Anesthesiometer, IITC Inc.-Life Science Instruments, Woodland Hills, SA, USA; Electronic von Frey System, Somedic Sales AB, Hörby, Sweden). Thermal hyperalgesia is measured by means of a radiant heat source (Plantar Test, Ugo Basile, Comerio, Italy), or by means of a cold plate of 5 to 10 °C where the nocifensive reactions of the affected hind paw are counted as a measure of pain intensity. A further test for cold induced pain is the counting of nocifensive reactions, or duration of nocifensive responses after plantar administration of acetone to the affected hind limb. Chronic pain in general is assessed by registering the circadian rhythms in activity (Surjo and Arndt, Universität zu Köln, Cologne, Germany), and by scoring differences in gait

(foot print patterns; FOOTPRINTS program, Klapdor et al., 1997. A low cost method to analyze footprint patterns. J. Neurosci. Methods 75, 49-54).

Compounds are tested against sham operated and vehicle treated control groups.
5 Substance application is performed at different time points via different application routes (i.v., i.p., p.o., i.t., i.c.v., s.c., intradermal, transdermal) prior to pain testing.

Inflammatory Pain

10 Inflammatory pain is induced mainly in rats by injection of 0.75 mg carrageenan or complete Freund's adjuvant into one hind paw. The animals develop an edema with mechanical allodynia as well as thermal hyperalgesia. Mechanical allodynia is measured by means of a pressure transducer (electronic von Frey Anesthesiometer, IITC Inc.-Life Science Instruments, Woodland Hills, SA, USA). Thermal
15 hyperalgesia is measured by means of a radiant heat source (Plantar Test, Ugo Basile, Comerio, Italy, Paw thermal stimulator, G. Ozaki, University of California, USA). For edema measurement two methods are being used. In the first method, the animals are sacrificed and the affected hindpaws sectioned and weighed. The second method comprises differences in paw volume by measuring water displacement in a
20 plethysmometer (Ugo Basile, Comerio, Italy).

Compounds are tested against uninflamed as well as vehicle treated control groups. Substance application is performed at different time points via different application routes (i.v., i.p., p.o., i.t., i.c.v., s.c., intradermal, transdermal) prior to pain testing.

25

Diabetic Neuropathic Pain

Rats treated with a single intraperitoneal injection of 50 to 80 mg/kg streptozotocin develop a profound hyperglycemia and mechanical allodynia within 1 to 3 weeks.
30 Mechanical allodynia is measured by means of a pressure transducer (electronic von

Frey Anesthesiometer, IITC Inc.-Life Science Instruments, Woodland Hills, SA, USA).

5 Compounds are tested against diabetic and non-diabetic vehicle treated control groups. Substance application is performed at different time points via different application routes (i.v., i.p., p.o., i.t., i.c.v., s.c., intradermal, transdermal) prior to pain testing.

2. Parkinson's disease

10 *6-Hydroxydopamine (6-OH-DA) Lesion*

Degeneration of the dopaminergic nigrostriatal and striatopallidal pathways is the central pathological event in Parkinson's disease. This disorder has been mimicked experimentally in rats using single/sequential unilateral stereotaxic injections of
15 6-OH-DA into the medium forebrain bundle (MFB).

Male Wistar rats (Harlan Winkelmann, Germany), weighing 200±250 g at the beginning of the experiment, are used. The rats are maintained in a temperature- and humidity-controlled environment under a 12 h light/dark cycle with free access to
20 food and water when not in experimental sessions. The following in vivo protocols are approved by the governmental authorities. All efforts are made to minimize animal suffering, to reduce the number of animals used, and to utilize alternatives to in vivo techniques.

25 Animals are administered pargyline on the day of surgery (Sigma, St. Louis, MO, USA; 50 mg/kg i.p.) in order to inhibit metabolism of 6-OHDA by monoamine oxidase and desmethylinipramine HCl (Sigma; 25 mg/kg i.p.) in order to prevent uptake of 6-OHDA by noradrenergic terminals. Thirty minutes later the rats are anesthetized with sodium pentobarbital (50 mg/kg) and placed in a stereotaxic frame.
30 In order to lesion the DA nigrostriatal pathway 4 µl of 0.01% ascorbic acid-saline containing 8 µg of 6-OHDA HBr (Sigma) are injected into the left medial fore-brain

bundle at a rate of 1 μ l/min (2.4 mm anterior, 1.49 mm lateral, -2.7 mm ventral to Bregma and the skull surface). The needle is left in place an additional 5 min to allow diffusion to occur.

5 Stepping Test

Forelimb akinesia is assessed three weeks following lesion placement using a modified stepping test protocol. In brief, the animals are held by the experimenter with one hand fixing the hindlimbs and slightly raising the hind part above the surface. One paw is touching the table, and is then moved slowly sideways (5 s for 1 m), first in the forehand and then in the backhand direction. The number of adjusting steps is counted for both paws in the backhand and forehand direction of movement. The sequence of testing is right paw forehand and backhand adjusting stepping, followed by left paw forehand and backhand directions. The test is repeated three times on three consecutive days, after an initial training period of three days prior to the first testing. Forehand adjusted stepping reveals no consistent differences between lesioned and healthy control animals. Analysis is therefore restricted to backhand adjusted stepping.

20 Balance Test

Balance adjustments following postural challenge are also measured during the stepping test sessions. The rats are held in the same position as described in the stepping test and, instead of being moved sideways, tilted by the experimenter towards the side of the paw touching the table. This maneuver results in loss of balance and the ability of the rats to regain balance by forelimb movements is scored on a scale ranging from 0 to 3. Score 0 is given for a normal forelimb placement. When the forelimb movement is delayed but recovery of postural balance detected, score 1 is given. Score 2 represents a clear, yet insufficient, forelimb reaction, as evidenced by muscle contraction, but lack of success in recovering balance, and score 3 is given for no reaction of movement. The test is repeated three times a day on each

side for three consecutive days after an initial training period of three days prior to the first testing.

Staircase Test (Paw Reaching)

5

A modified version of the staircase test is used for evaluation of paw reaching behavior three weeks following primary and secondary lesion placement. Plexiglass test boxes with a central platform and a removable staircase on each side are used. The apparatus is designed such that only the paw on the same side at each staircase can be used, thus providing a measure of independent forelimb use. For each test the animals are left in the test boxes for 15 min. The double staircase is filled with 7 x 3 chow pellets (Precision food pellets, formula: P, purified rodent diet, size 45 mg; Sandown Scientific) on each side. After each test the number of pellets eaten (successfully retrieved pellets) and the number of pellets taken (touched but dropped) for each paw and the success rate (pellets eaten/pellets taken) are counted separately. After three days of food deprivation (12 g per animal per day) the animals are tested for 11 days. Full analysis is conducted only for the last five days.

MPTP treatment

20

The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine (MPTP) causes degeneration of mesencephalic dopaminergic (DAergic) neurons in rodents, non-human primates, and humans and, in so doing, reproduces many of the symptoms of Parkinson's disease. MPTP leads to a marked decrease in the levels of dopamine and its metabolites, and in the number of dopaminergic terminals in the striatum as well as severe loss of the tyrosine hydroxylase (TH)-immunoreactive cell bodies in the substantia nigra, pars compacta.

In order to obtain severe and long-lasting lesions, and to reduce mortality, animals receive single injections of MPTP, and are then tested for severity of lesion 7–10 days later. Successive MPTP injections are administered on days 1, 2 and 3. Animals

30

receive application of 4 mg/kg MPTP hydrochloride (Sigma) in saline once daily. All injections are intraperitoneal (i.p.) and the MPTP stock solution is frozen between injections. Animals are decapitated on day 11.

5 Immunohistology

At the completion of behavioral experiments, all animals are anaesthetized with 3 ml thiopental (1 g/40 ml i.p., Tyrol Pharma). The mice are perfused transcardially with 0.01 M PBS (pH 7.4) for 2 min, followed by 4% paraformaldehyde (Merck) in PBS
10 for 15 min. The brains are removed and placed in 4% paraformaldehyde for 24 h at 4 °C. For dehydration they are then transferred to a 20% sucrose (Merck) solution in 0.1 M PBS at 4 °C until they sink. The brains are frozen in methylbutan at -20 °C for 2 min and stored at -70 °C. Using a sledge microtome (mod. 3800-Frigocut, Leica), 25 µm sections are taken from the genu of the corpus callosum (AP 1.7 mm) to the
15 hippocampus (AP 21.8 mm) and from AP 24.16 to AP 26.72. Forty-six sections are cut and stored in assorters in 0.25 M Tris buffer (pH 7.4) for immunohistochemistry.

A series of sections is processed for free-floating tyrosine hydroxylase (TH) immunohistochemistry. Following three rinses in 0.1 M PBS, endogenous peroxidase activity is quenched for 10 min in 0.3% H₂O₂ ±PBS. After rinsing in PBS,
20 sections are preincubated in 10% normal bovine serum (Sigma) for 5 min as blocking agent and transferred to either primary anti-rat TH rabbit antiserum (dilution 1:2000).

Following overnight incubation at room temperature, sections for TH immunoreactivity are rinsed in PBS (2 x10 min) and incubated in biotinylated anti-rabbit immunoglobulin G raised in goat (dilution 1:200) (Vector) for 90 min, rinsed repeatedly and transferred to Vectastain ABC (Vector) solution for 1 h. 3,3'-Diaminobenzidine tetrahydrochloride (DAB; Sigma) in 0.1 M PBS, supplemented with 0.005% H₂O₂, serves as chromogen in the subsequent visualization reaction. Sections
25 are mounted on to gelatin-coated slides, left to dry overnight, counter-stained with
30

hematoxylin dehydrated in ascending alcohol concentrations and cleared in butyl-acetate. Coverslips are mounted on entellan.

Rotarod Test

5

We use a modification of the procedure described by Rozas and Labandeira-Garcia (1997), with a CR-1 Rotamex system (Columbus Instruments, Columbus, OH) comprising an IBM-compatible personal computer, a CIO-24 data acquisition card, a control unit, and a four-lane rotarod unit. The rotarod unit consists of a rotating spindle (diameter 7.3 cm) and individual compartments for each mouse. The system software allows preprogramming of session protocols with varying rotational speeds (0–80 rpm). Infrared beams are used to detect when a mouse has fallen onto the base grid beneath the rotarod. The system logs the fall as the end of the experiment for that mouse, and the total time on the rotarod, as well as the time of the fall and all the set-up parameters, are recorded. The system also allows a weak current to be passed through the base grid, to aid training.

15

3. Dementia

The object recognition task

20

The object recognition task has been designed to assess the effects of experimental manipulations on the cognitive performance of rodents. A rat is placed in an open field, in which two identical objects are present. The rats inspects both objects during the first trial of the object recognition task. In a second trial, after a retention interval of for example 24 hours, one of the two objects used in the first trial, the ‘familiar’ object, and a novel object are placed in the open field. The inspection time at each of the objects is registered. The basic measures in the OR task is the time spent by a rat exploring the two object the second trial. Good retention is reflected by higher exploration times towards the novel than the ‘familiar’ object.

25

30

- 75 -

Administration of the putative cognition enhancer prior to the first trial predominantly allows assessment of the effects on acquisition, and eventually on consolidation processes. Administration of the testing compound after the first trial allows to assess the effects on consolidation processes, whereas administration before the second trial allows to measure effects on retrieval processes.

The passive avoidance task

The passive avoidance task assesses memory performance in rats and mice. The inhibitory avoidance apparatus consists of a two-compartment box with a light compartment and a dark compartment. The two compartments are separated by a guillotine door that can be operated by the experimenter. A threshold of 2 cm separates the two compartments when the guillotine door is raised. When the door is open, the illumination in the dark compartment is about 2 lux. The light intensity is about 500 lux at the center of the floor of the light compartment.

Two habituation sessions, one shock session, and a retention session are given, separated by inter-session intervals of 24 hours. In the habituation sessions and the retention session the rat is allowed to explore the apparatus for 300 sec. The rat is placed in the light compartment, facing the wall opposite to the guillotine door. After an accommodation period of 15 sec. the guillotine door is opened so that all parts of the apparatus can be visited freely. Rats normally avoid brightly lit areas and will enter the dark compartment within a few seconds.

In the shock session the guillotine door between the compartments is lowered as soon as the rat has entered the dark compartment with its four paws, and a scrambled 1 mA footshock is administered for 2 sec. The rat is removed from the apparatus and put back into its home cage. The procedure during the retention session is identical to that of the habituation sessions.

The step-through latency, that is the first latency of entering the dark compartment (in sec.) during the retention session is an index of the memory performance of the animal; the longer the latency to enter the dark compartment, the better the retention is. A testing compound in given half an hour before the shock session, together with
5 1 mg*kg⁻¹ scopolamine. Scopolamine impairs the memory performance during the retention session 24 hours later. If the test compound increases the enter latency compared with the scopolamine-treated controls, is likely to possess cognition enhancing potential.

10 *The Morris water escape task*

The Morris water escape task measures spatial orientation learning in rodents. It is a test system that has extensively been used to investigate the effects of putative
15 therapeutic on the cognitive functions of rats and mice. The performance of an animal is assessed in a circular water tank with an escape platform that is submerged about 1 cm below the surface of the water. The escape platform is not visible for an animal swimming in the water tank. Abundant extra-maze cues are provided by the furniture in the room, including desks, computer equipment, a second water tank, the presence of the experimenter, and by a radio on a shelf that is playing softly.

20

The animals receive four trials during five daily acquisition sessions. A trial is started by placing an animal into the pool, facing the wall of the tank. Each of four starting positions in the quadrants north, east, south, and west is used once in a series of four trials; their order is randomized. The escape platform is always in the same position.

25

A trial is terminated as soon as the animal had climbs onto the escape platform or when 90 seconds have elapsed, whichever event occurs first. The animal is allowed to stay on the platform for 30 seconds. Then it is taken from the platform and the next trial is started. If an animal did not find the platform within 90 seconds it is put on the platform by the experimenter and is allowed to stay there for 30 seconds. After
30 the fourth trial of the fifth daily session, an additional trial is given as a probe trial: the platform is removed, and the time the animal spends in the four quadrants is

measured for 30 or 60 seconds. In the probe trial, all animals start from the same start position, opposite to the quadrant where the escape platform had been positioned during acquisition.

5 Four different measures are taken to evaluate the performance of an animal during acquisition training: escape latency, traveled distance, distance to platform, and swimming speed. The following measures are evaluated for the probe trial: time (s) in quadrants and traveled distance (cm) in the four quadrants. The probe trial provides additional information about how well an animal learned the position of the
10 escape platform. If an animal spends more time and swims a longer distance in the quadrant where the platform had been positioned during the acquisition sessions than in any other quadrant, one concludes that the platform position has been learned well.

In order to assess the effects of putative cognition enhancing compounds, rats or mice
15 with specific brain lesions which impair cognitive functions, or animals treated with compounds such as scopolamine or MK-801, which interfere with normal learning, or aged animals which suffer from cognitive deficits, are used.

The T-maze spontaneous alternation task

20 The T-maze spontaneous alternation task (TeMCAT) assesses the spatial memory performance in mice. The start arm and the two goal arms of the T-maze are provided with guillotine doors which can be operated manually by the experimenter. A mouse is put into the start arm at the beginning of training. The guillotine door is
25 closed. In the first trial, the 'forced trial', either the left or right goal arm is blocked by lowering the guillotine door. After the mouse has been released from the start arm, it will negotiate the maze, eventually enter the open goal arm, and return to the start position, where it will be confined for 5 seconds, by lowering the guillotine door. Then, the animal can choose freely between the left and right goal arm (all
30 guillotine-doors opened) during 14 'free choice' trials. As soon as the mouse has entered one goal arm, the other one is closed. The mouse eventually returns to the

start arm and is free to visit whichever go alarm it wants after having been confined to the start arm for 5 seconds. After completion of 14 free choice trials in one session, the animal is removed from the maze. During training, the animal is never handled.

5

The percent alternations out of 14 trials is calculated. This percentage and the total time needed to complete the first forced trial and the subsequent 14 free choice trials (in s) is analyzed. Cognitive deficits are usually induced by an injection of scopolamine, 30 min before the start of the training session. Scopolamine reduced the per-cent alternations to chance level, or below. A cognition enhancer, which is always administered before the training session, will at least partially, antagonize the scopolamine-induced reduction in the spontaneous alternation rate.

10

EXAMPLE 8

15 *Diabetes: In vivo testing of compounds/target validation*

1. Glucose Production:

20

25

Over-production of glucose by the liver, due to an enhanced rate of gluconeogenesis, is the major cause of fasting hyperglycemia in diabetes. Overnight fasted normal rats or mice have elevated rates of gluconeogenesis as do streptozotocin-induced diabetic rats or mice fed ad libitum. Rats are made diabetic with a single intravenous injection of 40 mg/kg of streptozotocin while C57BL/KsJ mice are given 40-60 mg/kg i.p. for 5 consecutive days. Blood glucose is measured from tail-tip blood and then compounds are administered via different routes (p.o., i.p., i.v., s.c.). Blood is collected at various times thereafter and glucose measured. Alternatively, compounds are administered for several days, then the animals are fasted overnight, blood is collected and plasma glucose measured. Compounds that inhibit glucose production will decrease plasma glucose levels compared to the vehicle-treated control group.

2. Insulin Sensitivity:

Both ob/ob and db/db mice as well as diabetic Zucker rats are hyperglycemic, hyperinsulinemic and insulin resistant. The animals are pre-bled, their glucose levels measured, and then they are grouped so that the mean glucose level is the same for each group. Compounds are administered daily either q.d. or b.i.d. by different routes (p.o., i.p., s.c.) for 7-28 days. Blood is collected at various times and plasma glucose and insulin levels determined. Compounds that improve insulin sensitivity in these models will decrease both plasma glucose and insulin levels when compared to the vehicle-treated control group.

3. Insulin Secretion:

Compounds that enhance insulin secretion from the pancreas will increase plasma insulin levels and improve the disappearance of plasma glucose following the administration of a glucose load. When measuring insulin levels, compounds are administered by different routes (p.o., i.p., s.c. or i.v.) to overnight fasted normal rats or mice. At the appropriate time an intravenous glucose load (0.4g/kg) is given, blood is collected one minute later. Plasma insulin levels are determined. Compounds that enhance insulin secretion will increase plasma insulin levels compared to animals given only glucose. When measuring glucose disappearance, animals are bled at the appropriate time after compound administration, then given either an oral or intraperitoneal glucose load (1g/kg), bled again after 15, 30, 60 and 90 minutes and plasma glucose levels determined. Compounds that increase insulin levels will decrease glucose levels and the area-under-the glucose curve when compared to the vehicle-treated group given only glucose.

Compounds that enhance insulin secretion from the pancreas will increase plasma insulin levels and improve the disappearance of plasma glucose following the administration of a glucose load. When measuring insulin levels, test compounds

which regulate phosphatidic acid phosphatase type 2c-like protein are administered by different routes (p.o., i.p., s.c., or i.v.) to overnight fasted normal rats or mice. At the appropriate time an intravenous glucose load (0.4g/kg) is given, blood is collected one minute later. Plasma insulin levels are determined. Test compounds that enhance
5 insulin secretion will increase plasma insulin levels compared to animals given only glucose. When measuring glucose disappearance, animals are bled at the appropriate time after compound administration, then given either an oral or intraperitoneal glucose load (1g/kg), bled again after 15, 30, 60, and 90 minutes and plasma glucose levels determined. Test compounds that increase insulin levels will decrease glucose
10 levels and the area-under-the glucose curve when compared to the vehicle-treated group given only glucose.

4. Glucose Production:

15 Over-production of glucose by the liver, due to an enhanced rate of gluconeogenesis, is the major cause of fasting hyperglycemia in diabetes. Overnight fasted normal rats or mice have elevated rates of gluconeogenesis as do streptozotocin-induced diabetic rats or mice fed ad libitum. Rats are made diabetic with a single intravenous injection of 40 mg/kg of streptozotocin while C57BL/KsJ mice are given 40-60
20 mg/kg i.p. for 5 consecutive days. Blood glucose is measured from tail-tip blood and then compounds are administered via different routes (p.o., i.p., i.v., s.c.). Blood is collected at various times thereafter and glucose measured. Alternatively, compounds are administered for several days, then the animals are fasted overnight, blood is collected and plasma glucose measured. Compounds that inhibit glucose
25 production will decrease plasma glucose levels compared to the vehicle-treated control group.

5. Insulin Sensitivity:

30 Both ob/ob and db/db mice as well as diabetic Zucker rats are hyperglycemic, hyperinsulinemic and insulin resistant. The animals are pre-bled, their glucose levels

measured, and then they are grouped so that the mean glucose level is the same for each group. Compounds are administered daily either q.d. or b.i.d. by different routes (p.o., i.p., s.c.) for 7-28 days. Blood is collected at various times and plasma glucose and insulin levels determined. Compounds that improve insulin sensitivity in these models will decrease both plasma glucose and insulin levels when compared to the vehicle-treated control group.

6. Insulin Secretion:

Compounds that enhance insulin secretion from the pancreas will increase plasma insulin levels and improve the disappearance of plasma glucose following the administration of a glucose load. When measuring insulin levels, compounds are administered by different routes (p.o., i.p., s.c. or i.v.) to overnight fasted normal rats or mice. At the appropriate time an intravenous glucose load (0.4g/kg) is given, blood is collected one minute later. Plasma insulin levels are determined. Compounds that enhance insulin secretion will increase plasma insulin levels compared to animals given only glucose. When measuring glucose disappearance, animals are bled at the appropriate time after compound administration, then given either an oral or intraperitoneal glucose load (1g/kg), bled again after 15, 30, 60 and 90 minutes and plasma glucose levels determined. Compounds that increase insulin levels will decrease glucose levels and the area-under-the glucose curve when compared to the vehicle-treated group given only glucose.

EXAMPLE 9

Identification of test compound efficacy in a COPD animal model

Guinea pigs are exposed on a single occasion to tobacco smoke for 50 minutes. Animals are sacrificed between 10 minutes and 24 hour following the end of the exposure and their lungs placed in RNeasyTM. The lung tissue is homogenized, and total RNA is extracted using a Qiagen RNeasyTM Maxi kit. Molecular Probes

RiboGreen™ RNA quantitation method is used to quantify the amount of RNA in each sample.

5 Total RNA is reverse transcribed, and the resultant cDNA is used in a real-time polymerase chain reaction (PCR). The cDNA is added to a solution containing the sense and anti-sense primers and the 6-carboxy-tetramethyl-rhodamine labeled probe of the protein phosphatase 2C-like enzyme gene. Cyclophilin is used as the house-keeping gene. The expression of the protein phosphatase 2C-like enzyme gene is measured using the TaqMan real-time PCR system that generates an amplification
10 curve for each sample. From this curve a threshold cycle value is calculated: the fractional cycle number at which the amount of amplified target reaches a fixed threshold. A sample containing many copies of the protein phosphatase 2C-like enzyme gene will reach this threshold earlier than a sample containing fewer copies. The threshold is set at 0.2, and the threshold cycle C_T is calculated from the
15 amplification curve. The C_T value for the protein phosphatase 2C-like enzyme gene is normalized using the C_T value for the housekeeping gene.

Expression of the protein phosphatase 2C-like enzyme gene is increased by at least 3-fold between 10 minutes and 3 hours post tobacco smoke exposure compared to air
20 exposed control animals.

Test compounds are evaluated as follows. Animals are pre-treated with a test compound between 5 minutes and 1 hour prior to the tobacco smoke exposure and they are then sacrificed up to 3 hours after the tobacco smoke exposure has been
25 completed. Control animals are pre-treated with the vehicle of the test compound via the route of administration chosen for the test compound. A test compound that reduces the tobacco smoke induced upregulation of protein phosphatase 2C-like enzyme gene relative to the expression seen in vehicle treated tobacco smoke exposed animals is identified as an inhibitor of protein phosphatase 2C-like enzyme
30 gene expression.

EXAMPLE 10*Expression of human protein phosphatase 2C-like enzyme*

5 Total RNA used for Taqman quantitative analysis were either purchased (Clontech,CA) or extracted from tissues using TRIzol reagent (Life Technologies, MD) according to a modified vendor protocol which utilizes the Rneasy protocol (Qiagen, CA)

10 One hundred µg of each RNA were treated with DNase I using RNase free- DNase (Qiagen, CA) for use with RNeasy or QiaAmp columns.

After elution and quantitation with Ribogreen (Molecular Probes Inc., OR), each sample was reverse transcribed using the GibcoBRL Superscript II First Strand Synthesis System for RT-PCR according to vendor protocol (Life Technologies, 15 MD). The final concentration of RNA in the reaction mix was 50ng/µL. Reverse transcription was performed with 50 ng of random hexamers.

Specific forward and reverse primers, and probe were designed according to PE Applied Biosystems' recommendations. The primers and probe used were as 20 follows:

Forward primer: 5'- CCACTGGCTACGCAGAGGTTA -3'

Reverse primer: 5'- CACAGCTGGCTTGGTCTTCA -3'

Probe: 5'-(FAM)- CAATGCCGGAAGAGCACACACAA-3'

25 where FAM = 6-carboxy-fluorescein.

Quantitation experiments were performed on 25 ng of reverse transcribed RNA from each sample. 18S ribosomal RNA was measured as a control using the Pre-Developed TaqMan Assay Reagents (PDAR)(PE Applied Biosystems, CA). The 30 assay reaction mix was as follows:

- 84 -

		final
	TaqMan SYBR Green PCR Master Mix (2x)	1x
	(PE Applied Biosystems, CA)	
5	Forward primer	300nM
	Reverse primer	300nM
	cDNA	25ng
	Water	to 25uL
	PCR conditions:	
10	Once: 2' minutes at 50° C	
	10 minutes at 95°C	
	40cycles: 15 sec. at 95°C	
	1 minute at 60°C	
15	The experiment was performed on an ABI Prism 7700 Sequence Detector (PE Applied Biosystems, CA). At the end of the run, fluorescence data acquired during PCR were processed as described in the ABI Prism 7700 user's manual. Fold change was calculated using the delta-delta CT method with normalization to the 18S values. Relative expression was calculated by normalizing to 18s (D Ct), then making the	
20	highest expressing tissue 100 and everything else relative to it. Copy number conversion was performed without normalization using the formula $C_n = 10^{(C_t - 40.007)/-3.623}$.	

The results are shown in FIGS. 16 and 17.

25

Expression of human protein phosphatase 2C-like enzyme in skeletal muscle could be regulated to increase insulin sensitivity.

SEQUENCE LISTING

<110> Bayer AG

<120> REGULATION OF HUMAN PROTEIN PHOSPHATASE 2C-LIKE ENZYME

<130> Lio357

<150> USSN 60/294,006

<151> 2001-05-30

<150> USSN 60/354,928

<151> 2002-02-11

<160> 4

<170> PatentIn version 3.1

<210> 1

<211> 1542

<212> DNA

<213> Homo sapiens

<400> 1

```

atgetcactc gagtgaaatc tgccgtggcc aatttcattg gcggcatcat ggctggcagc      60
tcaggctccg agcacggcgg cggcagctgc ggaggctcgg acctgcccct gcgtttcccc      120
tacggggcggc cagagtctct ggggctgtct caggacgagg tggagtgcag cgccgaccac      180
atcgcccgcc ccatcctcat cctcaaggag actcggcggc tgccctgggc cactggctac      240
gcagaggtta tcaatgccgg gaagagcaca cacaatgaag accaagccag ctgtgaggtg      300
ctcactgtga agaagaaggc agggggccgtg acctcaacct caaacaggaa ctcattccaag      360
agacggtcct cccttcccaa tggggaaggg ctgcagctga aggagaactc ggaatccgag      420
ggtgtttcct gccactattg gtcgctgttt gacgggcacg cggggtccgg ggccgcgggtg      480
gtggcgctac gcctgctgca gcaccacatc acggagcagc tgcaggacat cgtggacatc      540
ctgaagaact ccgccgtcct gcccctacc tgccctggggg aggagcctga gaacacgccc      600
gccaacagcc ggactctgac ccgggcagcc tccctgcgcg gaggggtggg ggccccgggc      660
tccccagca cgccccccac acgcttcttt accgagaaga agattcccca tgagtgcctg      720
gtcatcggag cgcttgaaag tgcattcaag gaaatggacc tacagataga acgagagagg      780
agttcatata atatatctgg tggctgcacg gccctcattg tgatttgcct tttggggaag      840
ctgtatgttg caaatgctgg ggatagcagg gccataatca tcagaaatgg agaaattatc      900
cccatgtctt cagaatttac ccccgagacg gagcgccagc gacttcagta cctggcattc      960
atgcagcctc acttgctggg aaatgagttc acacatttgg agtttccaag gagagtacag     1020

```

- 86 -

```

agaaaggagc ttggaagaa gatgctctac agggacttta atatgacagg ctgggcatac 1080
aaaaccattg aggatgagga cttgaagttc ccccttatat atggagaagg caagaaggcc 1140
cgggtaatgg caactattgg agtgaccagg ggacttgggg accatgacct gaaggtgcat 1200
gactccaaca tctacattaa accattcctg tottcagctc cagaggtaag aatctacgat 1260
ctttcaaaat atgatcatgg atcagatgat gtgctgatct tggccactga tggactctgg 1320
gacgttttat caaatgaaga agtagcagaa gcaatcactc agtttcttcc taactgtgat 1380
ccagatgatc ctcacaggta cacactggca gctcaggacc tggatgatgcg tgcccggggc 1440
gtgctgaagg acagaggatg gcggatatct aatgaccgac tgggctcagg agacgacatt 1500
totgtatatg tcattccttt aatacatgga aacaagctgt ca 1542

```

```

<210> 2
<211> 514
<212> PRT
<213> Homo sapiens

```

```

<400> 2

```

```

Met Leu Thr Arg Val Lys Ser Ala Val Ala Asn Phe Met Gly Gly Ile
1           5           10          15

```

```

Met Ala Gly Ser Ser Gly Ser Glu His Gly Gly Gly Ser Cys Gly Gly
          20           25           30

```

```

Ser Asp Leu Pro Leu Arg Phe Pro Tyr Gly Arg Pro Glu Phe Leu Gly
          35           40           45

```

```

Leu Ser Gln Asp Glu Val Glu Cys Ser Ala Asp His Ile Ala Arg Pro
          50           55           60

```

```

Ile Leu Ile Leu Lys Glu Thr Arg Arg Leu Pro Trp Ala Thr Gly Tyr
65           70           75           80

```

```

Ala Glu Val Ile Asn Ala Gly Lys Ser Thr His Asn Glu Asp Gln Ala
          85           90           95

```

```

Ser Cys Glu Val Leu Thr Val Lys Lys Lys Ala Gly Ala Val Thr Ser
          100          105          110

```

```

Thr Pro Asn Arg Asn Ser Ser Lys Arg Arg Ser Ser Leu Pro Asn Gly
          115          120          125

```

- 87 -

Glu Gly Leu Gln Leu Lys Glu Asn Ser Glu Ser Glu Gly Val Ser Cys
 130 135 140

His Tyr Trp Ser Leu Phe Asp Gly His Ala Gly Ser Gly Ala Ala Val
 145 150 155 160

Val Ala Ser Arg Leu Leu Gln His His Ile Thr Glu Gln Leu Gln Asp
 165 170 175

Ile Val Asp Ile Leu Lys Asn Ser Ala Val Leu Pro Pro Thr Cys Leu
 180 185 190

Gly Glu Glu Pro Glu Asn Thr Pro Ala Asn Ser Arg Thr Leu Thr Arg
 195 200 205

Ala Ala Ser Leu Arg Gly Gly Val Gly Ala Pro Gly Ser Pro Ser Thr
 210 215 220

Pro Pro Thr Arg Phe Phe Thr Glu Lys Lys Ile Pro His Glu Cys Leu
 225 230 235 240

Val Ile Gly Ala Leu Glu Ser Ala Phe Lys Glu Met Asp Leu Gln Ile
 245 250 255

Glu Arg Glu Arg Ser Ser Tyr Asn Ile Ser Gly Gly Cys Thr Ala Leu
 260 265 270

Ile Val Ile Cys Leu Leu Gly Lys Leu Tyr Val Ala Asn Ala Gly Asp
 275 280 285

Ser Arg Ala Ile Ile Ile Arg Asn Gly Glu Ile Ile Pro Met Ser Ser
 290 295 300

Glu Phe Thr Pro Glu Thr Glu Arg Gln Arg Leu Gln Tyr Leu Ala Phe
 305 310 315 320

Met Gln Pro His Leu Leu Gly Asn Glu Phe Thr His Leu Glu Phe Pro
 325 330 335

Arg Arg Val Gln Arg Lys Glu Leu Gly Lys Lys Met Leu Tyr Arg Asp
 340 345 350

Phe Asn Met Thr Gly Trp Ala Tyr Lys Thr Ile Glu Asp Glu Asp Leu
 355 360 365

- 88 -

Lys Phe Pro Leu Ile Tyr Gly Glu Gly Lys Lys Ala Arg Val Met Ala
370 375 380

Thr Ile Gly Val Thr Arg Gly Leu Gly Asp His Asp Leu Lys Val His
385 390 395 400

Asp Ser Asn Ile Tyr Ile Lys Pro Phe Leu Ser Ser Ala Pro Glu Val
405 410 415

Arg Ile Tyr Asp Leu Ser Lys Tyr Asp His Gly Ser Asp Asp Val Leu
420 425 430

Ile Leu Ala Thr Asp Gly Leu Trp Asp Val Leu Ser Asn Glu Glu Val
435 440 445

Ala Glu Ala Ile Thr Gln Phe Leu Pro Asn Cys Asp Pro Asp Asp Pro
450 455 460

His Arg Tyr Thr Leu Ala Ala Gln Asp Leu Val Met Arg Ala Arg Gly
465 470 475 480

Val Leu Lys Asp Arg Gly Trp Arg Ile Ser Asn Asp Arg Leu Gly Ser
485 490 495

Gly Asp Asp Ile Ser Val Tyr Val Ile Pro Leu Ile His Gly Asn Lys
500 505 510

Leu Ser

<210> 3
<211> 399
<212> PRT
<213> Homo sapiens

<400> 3

Met Ala Gly Ile Cys Cys Gly Val Val Gly Glu Thr Glu Pro Ala Ala
1 5 10 15

Pro Val Asp Ser Thr Ser Arg Ala Ser Leu Arg Arg Arg Leu Asp Leu
20 25 30

Leu Pro Ser Ile Lys Ile Val Ala Asp Ser Ala Val Ala Pro Pro Leu
35 40 45

- 89 -

Glu Asn Cys Arg Lys Arg Gln Lys Arg Glu Thr Val Val Leu Ser Thr
 50 55 60

Leu Pro Gly Asn Leu Asp Leu Asp Ser Asn Val Arg Ser Glu Asn Lys
 65 70 75 80

Lys Ala Arg Ser Ala Val Thr Asn Ser Asn Ser Val Thr Glu Ala Glu
 85 90 95

Ser Phe Phe Ser Asp Val Pro Lys Ile Gly Thr Thr Ser Val Cys Gly
 100 105 110

Arg Arg Arg Asp Met Glu Asp Ala Val Ser Ile His Pro Ser Phe Leu
 115 120 125

Gln Arg Asn Ser Glu Asn His His Phe Tyr Gly Val Phe Asp Gly His
 130 135 140

Gly Cys Ser His Val Ala Glu Lys Cys Arg Glu Arg Leu His Asp Ile
 145 150 155 160

Val Lys Lys Glu Val Glu Val Met Ala Ser Asp Glu Trp Thr Glu Thr
 165 170 175

Met Val Lys Ser Phe Gln Lys Met Asp Lys Glu Val Ser Gln Arg Glu
 180 185 190

Cys Asn Leu Val Val Asn Gly Ala Thr Arg Ser Met Lys Asn Ser Cys
 195 200 205

Arg Cys Glu Leu Gln Ser Pro Gln Cys Asp Ala Val Gly Ser Thr Ala
 210 215 220

Val Val Ser Val Val Thr Pro Glu Lys Ile Ile Val Ser Asn Cys Gly
 225 230 235 240

Asp Ser Arg Ala Val Leu Cys Arg Asn Gly Val Ala Ile Pro Leu Ser
 245 250 255

Val Asp His Lys Pro Asp Arg Pro Asp Glu Leu Ile Arg Ile Gln Gln
 260 265 270

Ala Gly Gly Arg Val Ile Tyr Trp Asp Gly Ala Arg Val Leu Gly Val
 275 280 285

- 90 -

Leu Ala Met Ser Arg Ala Ile Gly Asp Asn Tyr Leu Lys Pro Tyr Val
 290 295 300

Ile Pro Asp Pro Glu Val Thr Val Thr Asp Arg Thr Asp Glu Asp Glu
 305 310 315 320

Cys Leu Ile Leu Ala Ser Asp Gly Leu Trp Asp Val Val Pro Asn Glu
 325 330 335

Thr Ala Cys Gly Val Ala Arg Met Cys Leu Arg Gly Ala Gly Ala Gly
 340 345 350

Asp Asp Ser Asp Ala Ala His Asn Ala Cys Ser Asp Ala Ala Leu Leu
 355 360 365

Leu Thr Lys Leu Ala Leu Ala Arg Gln Ser Ser Asp Asn Val Ser Val
 370 375 380

Val Val Val Asp Leu Arg Lys Arg Arg Asn Asn Gln Ala Ser Ser
 385 390 395

<210> 4
 <211> 6463
 <212> DNA
 <213> Homo sapiens

<400> 4
 acatgacccg gcggcagtag ccgtggcagc agccgcggcg gctccgcgag ctcgccgggt 60
 gggctcagtt cagcgcacgc cggagccgag cgcagggggc ggggaaggga cctgctgcag 120
 ctgcagccgc ctgggcgctc ctggagcgcg cgggtgactcc cccggtcggc ccgctccatg 180
 cagctccgtt gcggaagtgt agcgggggga ggcggcggcc accgcggcac taagcacgag 240
 aggccggggc tcggccccct gcagcactag gctctgggag ccgcgcgcgg cgcgtcccag 300
 tggccccgact cgccgtgcgc ccggcgccca ccgcagcctg catgccccgc gctgcgcctt 360
 gcccgcccc cgccgcctcc tgctcgcacc gctgcagccg ggcgccggag taatatgctc 420
 actcgagtga aatctgccgt ggccaatttc atgggcggca tcatggctgg cagctcaggc 480
 tccgagcacg gcggcggcag ctgcggaggc tcggacctgc ccctgcgttt cccctacggg 540
 cggccagagt tcctggggct gtctcaggac gaggtggagt gcagcgccga ccacatcgcc 600
 cgccccatcc tcatcctcaa ggagactcgg cggctgccct gggccactgg ctacgcagag 660
 gttatcaatg ccgggaagag cacacacaat gaagaccaag ccagctgtga ggtgctcact 720

- 91 -

gtgaagaaga aggcaggggc cgtgacctca accccaaaca ggaactcatc caagagacgg	780
tcctcccttc ccaatgggga agggctgcag ctgaaggaga actcggaatc cgagggtggt	840
tcctgccact attggtcgct gtttgacggg cagcgggggt ccggggccgc ggtggtggcg	900
tcacgcctgc tgcagcacca catcacggag cagctgcagg acatcgtgga catcctgaag	960
aactccgccc tcctgcccc tacctgcctg ggggaggagc ctgagaacac gcccgccaac	1020
agccggactc tgaccgggc agcctccctg cgcggagggg tgggggcccc gggctcccc	1080
agcacgcccc ccacacgctt ctttaccgag aagaagattc cccatgagtg cctggtcatc	1140
ggagcgcttg aaagtgcatt caaggaaatg gacctacaga tagaacgaga gaggagtcca	1200
tataatatat ctggtggctg cagggccctc attgtgattt gccttttggg gaagctgtat	1260
gttgcaaatg ctggggatag cagggccata atcatcagaa atggagaaat tatcccatg	1320
tcttcagaat ttacccccga gacggagcgc cagcgacttc agtacctggc attcatgcag	1380
cctcacttgc tgggaaatga gttcacacat ttggagtttc caaggagagt acagagaaa	1440
gagcttgga agaagatgct ctacaggac ttaatatga caggctgggc atacaaaacc	1500
attgaggatg aggacttgaa gttccccctt atatatggag aaggcaagaa ggcccgggta	1560
atggcaacta ttggagtgc caggggactt ggggaccatg acctgaaggt gcatgactcc	1620
aacatctaca ttaaaccatt cctgtcttca gctccagagg taagaatcta cgatctttca	1680
aaatatgatc atggatcaga tgatgtgctg atcttggcca ctgatggact ctgggacgtt	1740
ttatcaaag aagaagtagc agaagcaatc actcagtttc ttcttaactg tgatccagat	1800
gatcctcaca ggtacacact ggcagctcag gacctggtga tgcgtgcccg ggtgtgctg	1860
aaggacagag gatggcggt atctaattgac cgactgggct caggagacga catttctgta	1920
tatgtcattc ctttaataca tggaaacaag ctgtcatgaa aatggcccag gggattggga	1980
ggacagaggg gaagaaagct gggatgcctc ttggcaggac ggaactggga agtgcccag	2040
ctgagttcca agtgatgcag tctcttccca gcccaagcgg ggagttcatg gccaaaagac	2100
tatgcttcaa gatgaccctt tggtttccat ttcttcttta gtaacaggtc aactcaacaa	2160
gagcaaaaca caaaggctgc taccaagtgt tgttgtattt cagttccttt cataggcctc	2220
cgagggtggc attgactatt tgggttatat atgtcatatt tattttatct agagtagctg	2280
gggcagccat tttcaggtgt aaatggcaga ggactcttca gcctgtcaag ctgccagctt	2340
atctacgggt taaaaagtgc tgcattggaa agtagggggt catgcctcaa aatgtaagta	2400
agtgcccacc ttctaggaag cctgaggttt atttcaggga ttgccgtctg cccccgcc	2460

ccctttctott	ttttttcttct	ctgtttctat	tcttttatgg	cagtgggtgga	gtgaggcagg	2520
gattttttttt	tttttttttt	cgtgtttttg	acatttcottg	aatctgtttt	ttattcccct	2580
tccacagaac	aggcctggga	ctttccaaca	ccctgctaag	gaagttctgt	gtccaagtcc	2640
caccagggct	gggttggtccc	cacctcctcc	agcccacaca	gccagggcag	catccggggc	2700
agtgccctgc	atgacagagg	gtctttgttg	tgtaatgttt	gttcccaagt	tgcattttct	2760
aaccgaatca	gtgtgttttc	atgaaactga	gtgtttctgt	ggaccagtag	ttcctctgtt	2820
gtcttcagtg	gtcttcctgt	gtggctcaag	ggttctctgt	gagagtctgg	attttcattt	2880
ctggaatggc	tggcccatc	ccacttttct	gtatcatggg	gacacatata	aagcagtgtt	2940
taatagagca	gtttaagaag	ttgcttgcac	ctgttggttc	accatggctc	atctggggac	3000
cattttggat	tcatgtttca	tggcttgtga	ctgtcccca	gccactcca	aacaaagtgt	3060
aaggatcaga	gttctgtcaa	ggagcagcag	ttctgctctc	cccatcatct	ttgtgcaagg	3120
cccctcgggg	ggcacttta	taaaagaatt	tgaaatgggt	tgactggcca	ttctcatgct	3180
gtgctccctg	tctcttctct	tctctaaaga	atcatgtccc	agctcctcaa	ggtccctcta	3240
tggttccaca	tctgagtgtt	cgccacaaga	gcagcagcag	caggcacagt	gcatgccata	3300
tctacctgct	gcttctctgc	tgggaggaat	ggccaagtag	attataaaaac	tcacttctgt	3360
ctcttaggca	gacttgtag	gccacaaaat	tacctagtct	tcttctctgct	gagctactga	3420
ggtattgcc	ccattttgac	aactttgagt	aattaaaaca	ctcttctgac	ccaaaaagga	3480
aaaaagggtca	ctgacgtgac	ccccccagca	tgctagagag	ctaattccag	ttctcatatt	3540
tgtttgaatt	tcttcccaga	ggagaggata	ggaacctctc	ctccagggca	gtaaatcacc	3600
tgcatttctg	gagttgtcgg	tattgtattc	gaaaaggcct	ggagcccctc	ctgctcagga	3660
aagaactcat	tccaggggtgt	ggagacagtg	ccgtctggca	ggtgaaatac	tgtgggaatt	3720
cacgccacca	ggtgtttgtg	caagtgttgg	cctgggaaga	atgggacttc	ggccttgtca	3780
ggagttgtct	tcatctgcag	cacgtttctt	cctcctgcag	tagatcttag	ctaccccaga	3840
tatctctatg	gagagaagtt	tgtggaaaat	gctttgcttc	gtggcagagt	ctgatgctgt	3900
agggaaaacct	tcgggcatgt	gacagcagtg	tgggtccactc	cctgttctgc	cctggcgctc	3960
agagtcatgt	gtaagtagga	aacctgagca	agtcttccgt	ggaggaccct	gagctgccgt	4020
ctttgggatc	cttcctgtgt	ccccaccgtc	tttcatttat	ttgctttcct	gggcctctat	4080
ctggggcccta	ccttgagctt	ctccagtttt	attcaagcca	ccagagtaag	aatttggtg	4140
tagatgtcac	aactaccttc	tactcaattc	accaattcat	ttactgctat	ggcacgtctc	4200
aggaataact	ctagaaacct	ctaaatcgaa	atattataaa	atcttgagca	cttagtcctg	4260

ctggtttttag ttagaaaggc atccaggaat tgtttttcta cgcccccttg agtggaaga	4320
tcttagtttag aagataaagt caagtttgtg ttcaggggat gggaggaaga ctataataa	4380
gatgaagaaa tcaaaagtag gaaacatgat gtaaacgaag catggcagat ctgtccagca	4440
ctgatattgc tctataaatt gagcttactc agttttggcc ttattttttt acccaggccc	4500
catgtcacc cagtaaccgt gtctacataa cgggttgccc cctggtgcat	4560
ccctggaaaa gtcaaaggac gcacacttcg aaattctgca gaacgtattt atacatggtt	4620
cagaaatctt gcgtatctga cttatagcca aatctgcttg ctogaatagc ctcagaggaa	4680
gtcttgttta ataaaaacct tttgatttcc tagtcaagtc tttatggttg tctcgagggg	4740
tgtgtggcta ctttaatgaa aggttttctt gctctaaatc tctttgctgg gctgggcctc	4800
tccagactat ctggtgaaac tcttttctt agaacaaact cagtcctgctc atgctctgtg	4860
gcattttgct agatgataac caaagcctta ttctgtagc cagtgtcagc agtcagagag	4920
gtggaggggtg tgttctgctg tggttatgca tacctatctg ctgttcttga ggtgtaaaag	4980
gaaaggtgaa aatcgggcca ggccaagtac tcagctgtct taataggatg aagccttaag	5040
cagtggaaat ttcagttatt ttccacagta ttccattttg gaggatttgg ggtgtttact	5100
ttttaaatc ttgaacaact taacctccat gaggtttgt gaagtcagct gtgaccacc	5160
tctcttact gtgttctcag tattcattca cttccaggga agaattgacag ccacagggag	5220
atggtggtgg gcaagaatga gagtcccagg atccagattt agcctcagat cttccccatt	5280
caggaaggggt tttccattta acaagagcac tagtatgaaa acattaggga caaatctccc	5340
atgtctttga aattcggatt ctctcttga gatccccctc ctcacctgcc aatcaacttt	5400
ataaggccac aagtggtcac tggttttctt tccacagggt tgaggttctc agctttcctt	5460
aagcgaccca gcagctccgc tgttttcaga gtgaatatgt taagctttga tgagattcta	5520
ttttcagtaa gttagtgtt ctgggacact tggagaaagc tgtgagagtc attgtctacg	5580
caaagaacaa cgaagctgat cctaaaagt atccaatcta agaaaatggt aaaacgagct	5640
ctggccacag cacagaattt tatgtgagga actcagattt ttgaagactt aacaattgca	5700
gagaaagggt gcagcctgca caccatagcc cacctctctg agcagacttt ggttttgtgt	5760
ggtgacgtgg cacatgtttg tacactggga tttttcaaag gacgctacgc gagcagactg	5820
acttgctct tctgtgagca ctgtggcttt tgtcagatgg agtgccggtc tgcagaggac	5880
tgtcttttgc aatccacagt gttatctgtg taaatagctt taatttttct tctgtgtctt	5940
aggtgaagtt ttgttcattg agcaaccagg tagacagtga ccaaataagg ctgtaaatgt	6000

- 94 -

gctgtagttt tctactgtga tgtacttgaa ggagaacctg tgcctctac tttctgac	6060
tcccacaagt attttgtgtt tgtttcctga gtcctgaggt tattatttta ctctgtttt	6120
gccccagtt ttctttgttt tttttctgga gaccagggga ggcccatggt ggagatcatt	6180
tgtaaggaat ggatcatggt ctgggtttcc aaaactaccc tagtacagt aatgagagaa	6240
atctgcctgg aaattgtttc agaaccatgt acctttatgc tttgtgattg tgaaacattg	6300
acttttttgt aacccccaaa tgaaaaactgt ttagtaaagg ggatctattt tgtgtgtttt	6360
gaaacttagg tgcaatgtcc cctggaaaaa gctaaagaaa tgtatatgtt caatgacatt	6420
ttaaaataaa atattatata tatgtatata cgacatatc agc	6463

CLAIMS

1. An isolated polynucleotide being selected from the group consisting of:
 - 5 a. a polynucleotide encoding a protein phosphatase 2C-like enzyme polypeptide comprising an amino acid sequence selected from the group consisting of:
 - 10 i. amino acid sequences which are at least about 97% identical to
 - ii. the amino acid sequence shown in SEQ ID NO: 2; and
 - iii. the amino acid sequence shown in SEQ ID NO: 2.
 - b. a polynucleotide comprising the sequence of SEQ ID NO: 1;
 - 15 c. a polynucleotide which hybridizes under stringent conditions to a polynucleotide specified in (a) and (b) and encodes a protein phosphatase 2C-like enzyme polypeptide;
 - 20 d. a polynucleotide the sequence of which deviates from the polynucleotide sequences specified in (a) to (c) due to the degeneration of the genetic code and encodes a protein phosphatase 2C-like enzyme polypeptide; and
 - 25 e. a polynucleotide which represents a fragment, derivative or allelic variation of a polynucleotide sequence specified in (a) to (d) and encodes a protein phosphatase 2C-like enzyme polypeptide.
2. An expression vector containing any polynucleotide of claim 1.
- 30 3. A host cell containing the expression vector of claim 2.

4. A substantially purified protein phosphatase 2C-like enzyme polypeptide encoded by a polynucleotide of claim 1.
5. A method for producing a protein phosphatase 2C-like enzyme polypeptide, wherein the method comprises the following steps:
 - a. culturing the host cell of claim 3 under conditions suitable for the expression of the protein phosphatase 2C-like enzyme polypeptide; and
 - b. recovering the protein phosphatase 2C-like enzyme polypeptide from the host cell culture.
6. A method for detection of a polynucleotide encoding a protein phosphatase 2C-like enzyme polypeptide in a biological sample comprising the following steps:
 - a. hybridizing any polynucleotide of claim 1 to a nucleic acid material of a biological sample, thereby forming a hybridization complex; and
 - b. detecting said hybridization complex.
7. The method of claim 6, wherein before hybridization, the nucleic acid material of the biological sample is amplified.
8. A method for the detection of a polynucleotide of claim 1 or a protein phosphatase 2C-like enzyme polypeptide of claim 4 comprising the steps of:
 - a. contacting a biological sample with a reagent which specifically interacts with the polynucleotide or the protein phosphatase 2C-like enzyme polypeptide and

- b. detecting the interaction.
9. A diagnostic kit for conducting the method of any one of claims 6 to 8.
- 5
10. A method of screening for agents which decrease the activity of a protein phosphatase 2C-like enzyme, comprising the steps of:
- a. contacting a test compound with any protein phosphatase 2C-like enzyme polypeptide encoded by any polynucleotide of claim 1;
 - 10 b. detecting binding of the test compound to the protein phosphatase 2C-like enzyme polypeptide, wherein a test compound which binds to the polypeptide is identified as a potential therapeutic agent for decreasing the activity of a protein phosphatase 2C-like enzyme.
- 15
11. A method of screening for agents which regulate the activity of a protein phosphatase 2C-like enzyme, comprising the steps of:
- 20 a. contacting a test compound with a protein phosphatase 2C-like enzyme polypeptide encoded by any polynucleotide of claim 1; and
 - b. detecting a protein phosphatase 2C-like enzyme activity of the polypeptide, wherein a test compound which increases the protein phosphatase 2C-like enzyme activity is identified as a potential therapeutic agent for increasing the activity of the protein phosphatase 2C-like enzyme, and wherein a test compound which decreases the protein phosphatase 2C-like enzyme activity of the polypeptide is identified as a potential therapeutic agent for decreasing the activity of the protein phosphatase 2C-like enzyme.
- 25
- 30

12. A method of screening for agents which decrease the activity of a protein phosphatase 2C-like enzyme, comprising the steps of:
- 5 a. contacting a test compound with any polynucleotide of claim 1 and detecting binding of the test compound to the polynucleotide, wherein a test compound which binds to the polynucleotide is identified as a potential therapeutic agent for decreasing the activity of protein phosphatase 2C-like enzyme.
- 10 13. A method of reducing the activity of protein phosphatase 2C-like enzyme, comprising the steps of:
- 15 a. contacting a cell with a reagent which specifically binds to any polynucleotide of claim 1 or any protein phosphatase 2C-like enzyme polypeptide of claim 4, whereby the activity of protein phosphatase 2C-like enzyme is reduced.
- 20 14. A reagent that modulates the activity of a protein phosphatase 2C-like enzyme polypeptide or a polynucleotide wherein said reagent is identified by the method of any of the claim 10 to 12.
- 25 15. A pharmaceutical composition, comprising:
- a. the expression vector of claim 2 or the reagent of claim 14 and a pharmaceutically acceptable carrier.
- 30 16. Use of the expression vector of claim 2 or the reagent of claim 14 in the preparation of a medicament for modulating the activity of a protein phosphatase 2C-like enzyme in a disease.

17. Use of claim 16 wherein the disease is CNS disorders, COPD, obesity, and diabetes.

- 1/21 -

Fig. 1

```

atgctcactc gagtgaaatc tgccgtggcc aatttcattg gcggcatcat ggctggcagc
tcaggctccg agcacggcgg cggcagctgc ggaggctcgg acctgcccct gcgtttcccc
tacgggcggc cagagttcct ggggctgtct caggacgagg tggagtgcag cgccgaccac
atcgcccgcc ccatacctcat cctcaaggag actcggcggc tgccctgggc cactggctac
gcagaggtta tcaatgccgg gaagagcaca cacaatgaag accaagccag ctgtgagggtg
ctcactgtga agaagaaggc aggggcccgtg acctcaacct caaacaggaa ctcatccaag
agacggtcct cccttcccaa tggggaaggg ctgcagctga aggagaactc ggaatccgag
gggtgtttcct gccactattg gtcgctgttt gacgggcacg cggggtcggg ggccgcggtg
gtggcgtcac gcctgctgca gcaccacatc acggagcagc tgcaggacat cgtggacatc
ctgaagaact ccgccgtcct gccccctacc tgccctggggg aggagcctga gaacacgccc
gccaacagcc ggactctgac ccgggcagcc tccctgcgcg gagggtggg ggcccggggc
tccccagca cgccccccac acgcttcttt accgagaaga agattcccca tgagtgcctg
gtcatcggag cgcttgaaag tgcattcaag gaaatggacc tacagataga acgagagagg
agttcatata atatatctgg tggctgcacg gccctcattg tgatttgcct tttggggaag
ctgtatgttg caaatgctgg ggatagcagg gccataatca tcagaaatgg agaaattatc
cccatgtctt cagaatttac ccccgagacg gagcgccagc gacttcagta cctggcattc
atgcagcctc acttgctggg aaatgagttc acacatttgg agtttccaag gagagtacag
agaaaggagc ttggaaagaa gatgctctac agggacttta atatgacagg ctgggcatac
aaaaccattg aggatgagga cttgaagttc ccccttatat atggagaagg caagaaggcc
cgggtaatgg caactattgg agtgaccagg ggacttgggg accatgacct gaaggtgcat
gactccaaca tctacattaa accattcctg tcttcagctc cagaggtaag aatctacgat
ctttcaaaat atgatcatgg atcagatgat gtgctgatct tggccactga tggactctgg
gacgttttat caaatgaaga agtagcagaa gcaatcactc agtttcttcc taactgtgat
ccagatgac ctcacaggta cacactggca gctcaggacc tggatgatgc tgcccggggg
gtgctgaagg acagaggatg gcggatatct aatgaccgac tgggctcagg agacgacatt
tctgtatatg tcattccttt aatacatgga aacaagctgt ca

```

Fig. 2

MLTRVKSAVA	NFMGGIMAGS	SGSEHGGGSC	GGSDLPLRFP	YGRPEFLGLS	QDEVECSADH
IARPILILKE	TRRLPWATGY	AEVINAGKST	HNEDQASCEV	LTVKKKAGAV	TSTPNRNSSK
RRSSLPNNEG	LQLKENSESE	GVSCHYWSLF	DGHAGSGAAV	VASRLQHHI	TEQLQDIVDI
LKNSAVLPPT	CLGEEPENTP	ANSRTLTRAA	SLRGGVGAPG	SPSTPPTRFF	TEKKIPHECL
VIGALESFAK	EMDLQIERER	SSYNISGGCT	ALIVICLLGK	LYVANAGDSR	AIIRNGEII
PMSSEFTPET	ERQRLQYLAF	MOPHLLGNEF	THLEFPRRVQ	RKELGKKMLY	RDFNMTGWAY
KTIEDEDLKF	PLIYGEGKKA	RVMATIGVTR	GLGDHDLKVH	DSNIYIKPFL	SSAPEVRIYD
LSKYDHGSDD	VLILATDGLW	DVLSNEEVAE	AITQFLPNCD	PDDPHRYTLA	AQDLVMRARG
VLKDRGWRI	NDRLGSGDDI	SVYVIPLIHG	NKLS		

Fig. 3

MAGICCGVVG	ETEPAAPVDS	TSRASLRRRL	DLLPSIKIVA	DSAVAPPLEN	CRKRQKRETV
VLSTLPGNLD	LDSNVRSENK	KARSAVTNSN	SVTEAESFFS	DVPKIGTTSV	CGRRRDMEDA
VSIHPSFLQR	NSENHHFYGV	FDGHGCSHVA	EKCRERLHDI	VKKEVEVMAS	DEWTETMVKS
FQKMDKEVSQ	RECNLVVNGA	TRSMKNSCRC	ELQSPQCDV	GSTAVVSVVT	PEKIIVSNCG
DSRAVLCRNG	VAIPLSVDHK	PDRPDELIRI	QQAGGRVIYW	DGARVLGVLA	MSRAIGDNYL
KPYVIPDPEV	TVTDRTDEDE	CLILASDGLW	DVVPNETACG	VARMCLRGAG	AGDDSDAAHN
ACSDAALLLT	KLALARQSSD	NVSVVVVDLR	KRRNNQASS		

Fig. 4

```

acatgacccg gcggcagtag ccgtggcagc agccgcggcg gctccgcgag ctccgcgggt
gggctcagtt cagcgcacgc cggagccgag cgcagggggc ggggaaggga cctgctgcag
ctgcagccgc ctgggcgctc ctggagcgcg cggtgactcc cccggtcggc ccgctccatg
cagctccgtt gcggaagtgt agcgggggga ggcggcggcc accgcggcac taagcacgag
aggccggggc tcggccccct gcagcactag gctctgggag ccgcgcgcgg cgcgtcccag
tgccccgact cgccgtgcgc ccggcgcccc cgcagcctg catgccccgc gctgcgcctt
gccccggccc cgccgcctcc tgctcgcaac gctgcagccg ggccgggag taatatgctc
actcgagtga aatctgccgt ggccaatttc atgggcggca tcatggctgg cagctcaggc
tccgagcacg gcggcggcag ctgcgagggc tcggacctgc ccctgcgttt cccctacggg
cggccagagt tcctggggct gtctcaggac gagggtggagt gcagcgccga ccacatcgcc
cgccccatcc tcatcctcaa ggagactcgg cggctgccct gggccactgg ctacgcagag
gttatcaatg ccgggaagag cacacacaat gaagaccaag ccagctgtga ggtgctcact
gtgaagaaga aggcaggggc cgtgacctca accccaaaca ggaactcatc caagagacgg
tcttcccttc ccaatgggga agggctgcag ctgaaggaga actcggaatc cgaggggtgt
tcttgcact attggtcgct gtttgacggg cagcggggt ccggggccgc ggtggtggcg
tcacgcctgc tgcagcaca catcacggag cagctgcagg acatcgaggga catcctgaag
aactccgccc tctgcccc tacctgctg ggggaggagc ctgagaacac gcccgccaac
agccggactc tgaccggggc agcctccctg cgcggagggg tgggggcccc gggctcccc
agcacgcccc ccacacgctt ctttaccgag aagaagattc cccatgagtg cctggtcac
ggagcgcttg aaagtgcatt caaggaaatg gacctacaga tagaacgaga gaggagtcca
tataatatat ctggtggctg cacggccctc attgtgattt gccttttggg gaagctgtat
gttgcaaatg ctggggatag cagggccata atcatcagaa atggagaaat tatccccatg
tcttcagaat ttacccccga gacggagcgc cagcgacttc agtacctggc attcatgcag
cctcacttgc tgggaaatga gttcacacat ttggagtttc caaggagagt acagagaaag
gagcttgga agaagatgct ctacagggac tttaatatga caggctgggc atacaaaacc
attgaggatg aggacttgaa gttccccctt atatatggag aaggcaagaa ggcccgggta
atggcaacta ttggagtgc caggggactt ggggacctg acctgaagg gcatgactcc
aacatctaca ttaaaccatt cctgtcttca gctccagagg taagaatcta cgatctttca
aaatatgatc atggatcaga tgatgtgctg atcttggcca ctgatggact ctgggacgtt
ttatcaaatg aagaagtagc agaagcaatc actcagtttc ttctaactg tgatccagat
gatcctcaca ggtacacact ggcagctcag gacctggtga tgcgtgccc ggggtgtgctg
aaggacagag gatggcggat atctaatac cgactgggct caggagacga catttctgta
tatgtcattc ctttaataca tggaaacaag ctgtcatgaa aatggcccag gggattggga
ggacagaggg gaagaaagct gggatgcctc ttggcaggac ggaactggga agtgccccag
ctgagttcca agtgatgcag tctcttccca gcccaagcgg ggagtccatg gccaaaagac
tatgcttcaa gatgaccctt tggtttccat ttcttcttta gtaacaggtc aactcaacaa
gagcaaaaaca caaaggctgc taccaagtgt tggttgattt cagttccttt cataggcctc
cgaggtggcc attgactatt tggggtatat atgtcatatt tattttatct agagttagctg
gggcagccat tttcaggtgt aaatggcaga ggaacttca gcctgtcaag ctgccagctt
atctacgggt taaaaagtgc tgcattggaa agtaggggt catgcctcaa aatgtaagta
agtgccacc tcttaggaag cctgagggtt atttcaggga ttgccgtctg cccccgcc
cccttctctt ttttctctct ctgtttctat tcttttatgg cagtggtgga gtgaggcagg
gatttttttt tttttttttt cgtgtttttg acattccttg aatctgtttt ttattccctt
tccacagaac aggcctggga ctttccaaca ccctgctaag gaagttctgt gtccaagtcc
caccaggtc gggttgtccc cacctcctcc agcccacaca gcccaggcag catccgggcc
agtgcctgc atgacagagg gtctttgttg tgtaatgttt gttcccaagt tgcattttct
aaccgaatca gtgtgttttc atgaaactga gtgtttctgt ggaccagtag ttctctgtt
gtcttcagt gtcttccctgt gtggctcaag ggttctctgt gagagtctgg attttcattt
ctggaatggc tggcccccac ccactttct gtatcatggg aagcatata aagcagtgtt
taatagagca gtttaagaag ttgcttgcac accatgggtc atctggggac
cattttggat tcatgtttca tggcttgtga ctgtcccaa gccactcca aacaaagtgt
aaggatcaga gttctgtcaa ggagcagcag ttctgtcttc cccatcatct ttgtgcaagg
cccctcgggg ggcactttaa taaaagaatt tgaaatgggt tgactggcca ttctcatgct
gtgctccctg tctcttctct tctctaaaga atcatgtccc agctcctcaa ggtcccteta
tggttccaca tctgagtgtt cgccacaaga gcagcagcag caggcacagt gcatgccata
tctacctgct gcttctctgc tgggaggaat ggccaagtag attataaaac tcacttctgt
ctcttaggca gactgttacg gccacaaaat tacctagtct tcttctgct gagctactga
ggtattgccca ccatttgagc aactttgagt aattaaaaca ctcttctgac caaaaaggga

```


- 5/21 -

aaaaagggtca	ctgacgtgac	ccccccagca	tgctagagag	ctaattccag	ttctcatatt
tgtttgaatt	tcttcccaga	ggagaggata	ggaacctctc	ctccagggca	gtaaatacacc
tgcattttctg	gagttgtcgg	tattgtattc	gaaaaggcct	ggagcccctc	ctgctcagga
aagaactcat	tccagggtgt	ggagacagtg	ccgtctggca	ggtgaaatac	tgtgggaatt
cacgccacca	ggtgtttgtg	caagtgttgg	cctgggaaga	atgggacttc	ggccttgtca
ggagttgtct	tcatctgcag	cacgtttctt	cctcctgcag	tagatcttag	ctaccccaga
tatctctatg	gagagaagtt	tgtggaaaat	gctttgcttc	gtggcagagt	ctgatgctgt
aggaaaacct	tcgggcatgt	gacagcagtg	tgggccactc	cctgttctgc	cctggcgctc
agagtcatgt	gtaagtagga	aacctgagca	agtcttccgt	ggaggaccct	gagctgccgt
ctttgggata	cttctgtgt	ccccaccgtc	tttcatttat	ttgctttcct	gggcctctat
ctggggcccta	ccttgagctt	ctccagtttt	attcaagcca	ccagagtaag	aatttgggtg
tagatgtcac	aactaccttc	tactcaattc	accaattcat	ttactgctat	ggcacgtctc
aggaataact	ctagaaacct	ctaaatcgaa	atattataaa	atcttgagca	cttagtcctg
ctggttttag	ttagaaaggc	atccaggaat	tgttttccta	cgcccccttg	agtggaaaga
tcttagtttag	aagataaagt	caagtttgtg	ttcaggggat	gggaggaaga	ctataaataa
gatgaagaaa	tcaaaagtag	gaaacatgat	gtaaacgaag	catggcagat	ctgtccagca
ctgatattgc	tctataaatt	gagcttactc	agttttggcc	ttattttttt	accocaggccc
catgtcaccc	agtcctaaaa	cagtaaccgt	gtctacataa	cgggttggcc	cctggtgcat
ccctggaaaa	gtcaaaggac	gcacacttcg	aaattctgca	gaacgtattt	atacatggtt
cagaaatctt	gcgtatctga	cttatagcca	aatctgcttg	ctcgaatagc	ctcagaggaa
gtcttgttta	ataaaaaacct	tttgatttcc	tagtcaagtc	tttatgggtg	tctcgagggg
tgtgtggcta	ctttaatgaa	aggttttcc	gctctaaatc	tctttgctgg	gctgggcctc
ttcagactat	ctggtgaaac	tcctttcctt	agaacaaact	cagtccgtcc	atgctctgtg
gcattttgct	agatgataac	caaagcctta	ttcctgtagc	cagtgtcagc	agtcagagag
gtggagggtg	tgttctgctg	tggttatgca	taoctatctg	ctgttcttga	ggtgtaaaag
gaaagggtgaa	aatcgggcca	ggccaagtac	tcagctgtct	taataggatg	aagccttaag
cagtggaaat	ttcagttatt	ttccacagta	ttccattttg	gaggatttgg	ggtgtttact
ttttaaattc	ttgaacaact	taacctccat	gaggctttgt	gaagtcagct	gtgaccaccc
tcctcttact	gtgttctcag	tattcattca	cttccaggga	agaatgacag	ccacagggag
atggtgggtg	gcaagaatga	gagtcaccag	atccagattt	agcctcagat	cttccccatt
caggaagggt	tttccattta	acaagagcac	tagtatgaaa	acattaggga	caaactctcc
atgtctttga	aattcggatt	ctcctcttga	gatccccctc	ctcacctgcc	aatcaacttt
ataaggccac	aagtggtcac	tggttttcct	tcacacaggt	tgaggttctc	agctttcctt
aagcgaccca	gcagctccgc	tgttttcaga	gtgaatatgt	taagctttga	tgagattcta
ttttcagtaa	gttagtgctt	ctgggacact	tggagaaagc	tgtgagagtc	attgtctacg
caaagaacaa	cgaagctgat	cctaaaagtg	atccaatcta	agaaaatggt	aaaacgagct
ctggccacag	cacagaattt	tatgtgagga	actcagattt	ttgaagactt	aacaattgca
gagaaagggt	gcagcctgca	caccatagcc	cacctctctg	agcagacttt	ggttttgtgt
ggtgacgtgg	cacatgtttg	tacactggga	tttttcaaag	gacgctacgc	gagcagactg
acttgccctc	tctgtgagca	ctgtggcttt	tgtcagatgg	agtgccggtc	tgcagaggac
tgctctttcg	aatccacagt	gttatctgtg	taaatagctt	taatttttct	tctgtgtctt
aggtgaagtt	ttgttcatgt	agcaaccagg	tagacagtga	ccaaataaag	ctgtaaatgt
gctgtagttt	tctactgtga	tgtacttgaa	ggagaacctg	tgtcctctac	ttttctgac
tcccacaagt	attttgtgtt	tgtttcctga	gtcctgaggt	tattatttta	ctcctgtttt
gccccagtt	ttctttgttt	tttttctgga	gacccaggga	ggcccatggt	ggagatcatt
tgtaaaggaat	ggatcatggt	ctgggtttcc	aaaactaccc	tagtacagtg	aatgagagaa
atctgcctgg	aaattgtttc	agaaccatgt	acctttatgc	tttgtgattg	tgaacattgt
acttttttgt	aaccccaaaa	tgaaaaactgt	ttagtaaagg	ggatctattt	tgtgtgtttt
gaaacttagg	tgcaatgtcc	cctggaaaaa	gctaagaaaa	tgtatatgtt	caatgacatt
ttaaaaataaa	atattatata	tatgtatata	cgacatatcc	agc	

- 6/21-

Fig. 5

BLASTP - alignment of 533_Protein against aageneseq|AAW04327|AAW04327

Rat petrin.

This hit is scoring at : 0.0 (expectation value)

Alignment length (overlap) : 514

Identities : 96 %

Scoring matrix : BLOSUM62 (used to infer consensus pattern)

Database searched : aageneseq

Q: 1 MLTRVKS AVANFMGGIMAGSSGSEHGGGSCGGS DLPLRFPYGRPEFLGLSQDEVECSADH
 MLTRVKS AVANFMGGIMAGSSGSEHGG. .CGGSDLPLRFPYGRPEFLGLSQDEVECSADH

H: 135 MLTRVKS AVANFMGGIMAGSSGSEHGGGSCGGS DLPLRFPYGRPEFLGLSQDEVECSADH

IARPILILKETRRLPWATGYAEVINAGKSTHNEDQASCEVLTVKKKAGAVTSTPNRNSSK
 IARPILILKETRRLPWATGYAEVINAGKSTHNEDQASCEVLTVKKK.G.:TSTPNRNS K
 IARPILILKETRRLPWATGYAEVINAGKSTHNEDQASCEVLTVKKKVGITITSTPNRNS-K

RRSSLPNGEGLQLKENSESEGV SCHYWSLFDGHAGSGAAVVASRLLQHHITEQLQDIVDI
 RRSSLPNGEGLQLKENSESEG: SCHYWSLFDGHAGSGAAVVASRLLQHHIT:QLQDIV:I
 RRSSLPNGEGLQLKENSESEGISCHYWSLFDGHAGSGAAVVASRLLQHHITQQLQDIVEI

LKNSAVLPPTCLGEEPENTPANSRTLTRAASLRGGVGAPGSPSTPPTRRFFTEKKIPHECL
 LKNSA:LPPTCLGEEPE:TPA:.RTLTRAASLRGGVGAPGSPSTPPTRRFFTEKKIPHECL
 LKNSAILPPTCLGEEPESTPAHGRTLTRAASLRGGVGAPGSPSTPPTRRFFTEKKIPHECL

VIGALESFAKEMDLQIERERSYNISGGCTALIVICLLGKLYVANAGDSRAIIIRNGEII
 VIGALESFAKEMDLQIERERS:YNISGGCTALIV:CLLGKLYVANAGDSRAIIIRNGEII
 VIGALESFAKEMDLQIERERSAYNISGGCTALIVVCLLGKLYVANAGDSRAIIIRNGEII

PMSSEFTPETERQRLQYLAFMQPHLLGNEFTHLEFPRRVQRKELGKKMLYRDFNMTGWAY
 PMSSEFTPETERQRLQYLAFMQPHLLGNEFTHLEFPRRVQRKELGKKMLYRDFNMTGWAY
 PMSSEFTPETERQRLQYLAFMQPHLLGNEFTHLEFPRRVQRKELGKKMLYRDFNMTGWAY

KTIEDDLKFPLIYGEGKKARVMATIGVTRGLGDHDLKVHDSNIYIKPFLSSAPEVRIYD
 KTIED:DLKFPLIYGEGKKARVMATIGVTRGLGDHDLKVHDSNIYIKPFLSSAPEVR:YD
 KTIEDDDLKFPLIYGEGKKARVMATIGVTRGLGDHDLKVHDSNIYIKPFLSSAPEVRVYD

LSKYDHGSDDVLILATDGLWDVLSNEEVAEAITQFLPNCDDPHRYTLAAQDLVMRARG
 LSKY:HG:DDVLILATDGLWDVLSNEEVAEAITQFLPNCDDPHRYTLAAQDLVMRARG
 LSKYEHGADDVLILATDGLWDVLSNEEVAEAITQFLPNCDDPHRYTLAAQDLVMRARG

VLKDRGWRI SNDRLGSGDDISVYVIPLIHGNKLS 514

VLKDRGWRI SNDRLGSGDDISVYVIPLIHGNKLS

VLKDRGWRI SNDRLGSGDDISVYVIPLIHGNKLS 647

- 7/21 -

Fig. 6

BLASTP - alignment of 533_Protein against trembl|AB032983|AB032983_1
 gene: "KIAA1157"; product: "KIAA1157 protein"; Homo sapiens mRNA for KIAA1157
 protein, partial cds. //:gp|AB032983|6330129 gene: "KIAA1157"; product:
 "KIAA1157 protein"; Homo sapiens mRNA for KIAA1157 protein, partial cds.

This hit is scoring at : 0.0 (expectation value)
 Alignment length (overlap) : 428
 Identities : 100 %
 Scoring matrix : BLOSUM62 (used to infer consensus pattern)
 Database searched : nrdb_1_;

```

Q:      87 GKSTHNEDQASCEVLTVKKKAGAVTSTPNRNSSKRRSSLPNGEGLQLKENSESEGVSCHY
          GKSTHNEDQASCEVLTVKKKAGAVTSTPNRNSSKRRSSLPNGEGLQLKENSESEGVSCHY
H:      1  GKSTHNEDQASCEVLTVKKKAGAVTSTPNRNSSKRRSSLPNGEGLQLKENSESEGVSCHY

WSLFDGHAGSGAAVASRLLQHHITEQLQDIVDILKNSAVLPPTCLGEEPENTPANSRTL
WSLFDGHAGSGAAVASRLLQHHITEQLQDIVDILKNSAVLPPTCLGEEPENTPANSRTL
WSLFDGHAGSGAAVASRLLQHHITEQLQDIVDILKNSAVLPPTCLGEEPENTPANSRTL

TRAASLRGGVGAPGSPSTPPTRFFTEKKIPHECLVIGALESFAFKEMDLQIERERSSYNIS
TRAASLRGGVGAPGSPSTPPTRFFTEKKIPHECLVIGALESFAFKEMDLQIERERSSYNIS
TRAASLRGGVGAPGSPSTPPTRFFTEKKIPHECLVIGALESFAFKEMDLQIERERSSYNIS

GGCTALIVICLLGKLYVANAGDSRAIIIRNGEIIIPMSSEFTPETERQRLQYLAFMQPHLL
GGCTALIVICLLGKLYVANAGDSRAIIIRNGEIIIPMSSEFTPETERQRLQYLAFMQPHLL
GGCTALIVICLLGKLYVANAGDSRAIIIRNGEIIIPMSSEFTPETERQRLQYLAFMQPHLL

GNEFTHLEFPRRVQRKELGKKMLYRDFNMTGWAYKTIEDEDLKFPFIYEGGKKARVMATI
GNEFTHLEFPRRVQRKELGKKMLYRDFNMTGWAYKTIEDEDLKFPFIYEGGKKARVMATI
GNEFTHLEFPRRVQRKELGKKMLYRDFNMTGWAYKTIEDEDLKFPFIYEGGKKARVMATI

GVTRGLGDHDLKVHDSNIYIKPFLSSAPEVRIYDLSKYDHGSDDVLILATDGLWDVLSNE
GVTRGLGDHDLKVHDSNIYIKPFLSSAPEVRIYDLSKYDHGSDDVLILATDGLWDVLSNE
GVTRGLGDHDLKVHDSNIYIKPFLSSAPEVRIYDLSKYDHGSDDVLILATDGLWDVLSNE

EVAEAITQFLPNCDDPHRYTLAAQDLVMRARGVLKDRGWRI SNDRLGSGDDISVYVIP
EVAEAITQFLPNCDDPHRYTLAAQDLVMRARGVLKDRGWRI SNDRLGSGDDISVYVIP
EVAEAITQFLPNCDDPHRYTLAAQDLVMRARGVLKDRGWRI SNDRLGSGDDISVYVIP

LIHGNKLS      514
LIHGNKLS
LIHGNKLS      428
  
```

- 8/21 -

Fig. 7

BLASTP - alignment of 533_Protein against aageneseq_alert|EP1074617.1
13-FEB-2001

This hit is scoring at : 5e-153 (expectation value)

Alignment length (overlap) : 263

Identities : 99 %

Scoring matrix : BLOSUM62 (used to infer consensus pattern)

Database searched : aageneseq_alert

```
Q:      252 MDLQIERERSSYNISGGCTALIVICLLGKLYVANAGDSRAIIIRNGEIIIPMSSEFTPETE
          MDLQIERERSSYNISGGCTALIVICLLGKLYVANAGDSRAIIIRNGEIIIPMSSEFTPETE
H:        1 MDLQIERERSSYNISGGCTALIVICLLGKLYVANAGDSRAIIIRNGEIIIPMSSEFTPETE

          RQRLQYLAFMQPHLLGNEFTHLEFPRRVQRKELGKKMLYRDFNMTGWAYKTIEDEDLKFP
          RQRLQYLAFMQPHLLGNEFTHLEFPRRVQRKELGKKMLYRDFNMTGWAYKTIEDEDLKFP
          RQRLQYLAFMQPHLLGNEFTHLEFPRRVQRKELGKKMLYRDFNMTGWAYKTIEDEDLKFP

          LIYGEGKKARVMATIGVTRGLGDHDLKVHDSNIYIKPFLSSAPEVRIYDLSKYDHGSDDV
          LIYGEGKKARVMATIGVTRGLGDHDLKVHDSNIYIKPFLSSAPEVRIYDLSKYDHGSDDV
          LIYGEGKKARVMATIGVTRGLGDHDLKVHDSNIYIKPFLSSAPEVRIYDLSKYDHGSDDV

          LILATDGLWDVLSNEEVAEAITQFLPNCDPDDPHRYTLAAQDLVLRARGVLKDRGWRISN
          LILATDGLWDVLSNEEVAEAITQFLPNCDPDDPHRYTLAAQDL.MRARGVLKDRGWRISN
          LILATDGLWDVLSNEEVAEAITQFLPNCDPDDPHRYTLAAQDLAMRARGVLKDRGWRISN

          DRLGSGDDISVYVIPLIHGNKLS      514
          DRLGSGDDISVYVIPLIHGNKLS
          DRLGSGDDISVYVIPLIHGNKLS      263
```

- 9/21 -

Fig. 8

BLASTP - alignment of 533 Protein against tremblnew|AJ277743|FSY277743_1
 gene: "pp2C1"; product: "protein phpsphatase 2C (PP2C)"; Fagus sylvatica mRNA
 for ABA induced protein phosphatase 2C (PP2C), (pp2C1 gene)
 //:trembl|AJ277743|FSY277743_1 gene: "pp2C1"; product: "protein phpsphatase 2C (PP2C)"; Fagus sylvatica mRNA for ABA induced protein phosphatase 2C (PP2C), (pp2C1 gene) //:gp|AJ277743|7768151 gene: "pp2C1"; product: "protein phpsphatase 2C (PP2C)"; Fagus sylvatica mRNA for ABA induced protein phosphatase 2C (PP2C), (pp2C1 gene). //:gpnew|AJ277743|7768151 gene: "pp2C1"; product: "protein phpsphatase 2C (PP2C)"; Fagus sylvatica mRNA for ABA induced protein phosphatase 2C (PP2C), (pp2C1 gene).

This hit is scoring at : 4e-13 (expectation value)

Alignment length (overlap) : 283

Identities : 25 %

Scoring matrix : BLOSUM62 (used to infer consensus pattern)

Database searched : nrdb_1_;

```

Q:   245 LESAFKEMDLQIERERSSYNISG-----GCTALIVICLLGKLYVANAGDSRA
      :E.:F..MD :... R .....      G.TA:..I.. K:.V:N.GDSRA
H:   190 MEKSFDRMDKEVQEWVPIKTTNCRCDVQTPQCDAVGSTAVVAIVTPEKIIVSNCGDSRA

      IIIRNGEIIIPMSSEFTPETERQRLQYLAFMQPHLLGNEFTHLEFPRRVQRKELGKKMLYR
      ::RNG ..P:SS::P:          :P. L          V: ::G :::Y
      VLCRNGVAFPLSSDHKPD-----RPDEL-----VRIQDAGGRVIYW

      DFNMTGWAYKTIEDLKFPLIYGEGKKARVMATIGVTRGLGDHDLKVHDSNIYIKPFLS
      D                      ARV:.....:R.:GD:          Y:KP::
      D-----GARVLGVLAMSRAIGDN-----YLPYVI

      SAPEVRIYDLSKYDHGSDDVLILATDGLWDVLSNEEVAEAITQFLPNCDDPDDPHRYTLAA
      S.PEV.I D :      ..D:..LILA:DGLWDV:SNE... .... L .P..P R ..
      SEPEVTITDRT----AEDECLILASDGLWDVVSNETACGVARMCLRAQKPSSPPR--SPG

      QDLVMRARGVLKDRGWRISNDRL-----GSGDDISVYVIPL          507
      .D:: A.. .D:.. .:: L          S D::SV.V::L
      NDMAVGAASESSDKACSDASILTKLALARHSTDNVSVVVVDL          407
  
```

- 10/21-

Fig. 9

BLASTP - alignment of 533_Protein against swissnew|P49598|P2C4_ARATH
 PROTEIN PHOSPHATASE 2C (EC 3.1.3.16) (PP2C).//:swiss|P49598|P2C4_ARATH
 PROTEIN
 PHOSPHATASE 2C (EC 3.1.3.16) (PP2C).//:trreml|AC008153|AC008153 7 gene:
 "F24K9.8"; product: "protein phosphatase 2C (PP2C); 28184-26716";
 Arabidopsis
 thaliana chromosome 3 BAC F24K9 genomic sequence, complete sequence.
 //:trreml|D38109|ATPP2CA_1 product: "protein phosphatase 2C"; Arabidopsis
 thaliana mRNA for protein phosphatase 2C. //:pironly|S55457|S55457
 phosphoprotein phosphatase (EC 3.1.3.16) 2C - Arabidopsis
 thaliana//:gp|AC008153|12322910 gene: "F24K9.8"; product: "protein
 phosphatase 2C (PP2C); 28184-26716"; Arabidopsis thaliana chromosome 3
 BAC F24K9 genomic sequence, complete sequence. //:gp|D38109|633028 product:
 "protein phosphatase 2C"; Arabidopsis thaliana mRNA for protein phosphatase
 2C.

This hit is scoring at : 5e-10 (expectation value)

Alignment length (overlap) : 317

Identities : 24 %

Scoring matrix : BLOSUM62 (used to infer consensus pattern)

Database searched : nrdb_1_;

```

Q:   133 LKENSESEGVSCHYWSLFDGHAGSGAAVVASRLLQHHITEQLQDIVDILKNSAVLPPTCL
      L:.NSE:.      H:::FDGH   G.:VA:.      .E:L.DIV.
H:   128 LQRNSENH----HFYGVFDGH---GCSHVAEKC-----RERLHDIVK-----

      GEEPENTPANSRTLTRAASLRGGVGAPGSPSTPPTRRFFTEKKIPH-EC--LVIGALESAP
      :E E ..... T T...S.:                      ..K:... EC :V GA..S.
      -KEVEVMASDEWTETMVKSFOK-----MDKEVSQRECNLVVNGATRSMK

      KEMDLQIERERSSYNISGGCTALIVICLLGKLYVANAGDSRAIIIRNGEIIIPMSSEFTPE
      ... :..... : G.TA:: ... K:.V:N.GDSRA::.RNG .IP:S ...P:
      NSRCCELQSPQCD---AVGSTAVVSVVTPEKIIVSNCGDSRAVLCRNGVAIPLSVDHKPD

      TERQRLQYLAFMQPHLLGNEFTHLEFPRRVQRKELGKKMLYRDFNMTGWAYKTIEDLDK
      .. : :                      R:Q ..G :::Y D
      RPDELI-----RIQ--QAGGRVIYWD-----

      FPLIYGEGKKARVMATIGVTRGLGDHDLKVHDSNIYIKPFLSSAPEVRIYDLSKYDHGSD
      ARV:.....R.:GD:          Y:KP:. . PEV.: D :. .D
      -----GARVLGVLAMSRAIGDN-----YLPYVIPDPEVTVTDRTD----ED

      DVLILATDGLWDVLSNE          446
      :.LILA:DGLWDV:.NE
      ECLILASDGLWDVVPNE          336
  
```

- 11/21 -

Fig. 10

**BLASTP - alignment of 533_Protein against pdb|1A6Q|1A6Q
phosphatase 2c**

This hit is scoring at : 5e-05 (expectation value)

Alignment length (overlap) : 80

Identities : 36 %

Scoring matrix : BLOSUM62 (used to infer consensus pattern)

Database searched : nrdb_1_;

```
Q:   381 RVMATIGVTRGLGDHDLKVHDSNIYIKPFLSSAPEVRIYDLSKYDHGSDDVLILATDGLW
      RV ...V:R.LGD.D.K. ... ..:S..PEV. .: S: D   D...ILA.DG:W
H:   185 RVNGSLAVSRALGDFDYKCVHGKGPTEQLVSPEPEVHDIERSEED---DQFIILACDGIW

      DVLSNEEVAEAITQFLPNCD      460
      DV:.NEE::: ... L. .D
      DVMGNEELCDFVRSRLEVTD      261
```

- 12/21 -

Fig. 11

HMMPFAM - alignment of 533_Protein against pfam|hmm|PP2C
Protein phosphatase 2C

This hit is scoring at : 40.8 E=1.3e-10

Scoring matrix : BLOSUM62 (used to infer consensus pattern)

```
Q: 240 LVIGALESFAKEMDLQIERER---SSYN-----ISGGCTALIVICLLGKLYVANAGDS
      : .AL::F E.D.. E .. S: N           :S.G.TA::... .KLYVAN.GDS
H: 80 dledalkesfleadtdeelrsaeasaankvltkedlssGsTAvvalirgnkLyVANvGDS

      RAIIRNGEII----PMS      303
      RA::RNG..I      :::
      RavLcrngnaikwvtLt      157
```


- 13/21 -

Fig. 12

HMMPFAM - alignment of 533_Protein against pfam|hmm|PP2C
Protein phosphatase 2C

This hit is scoring at : 33.0 E=2.2e-08

Scoring matrix : BLOSUM62 (used to infer consensus pattern)

```
Q:   388 VTRGLGDHDLKVHDSNIYIK-----PFLSSAPEVR-IYDLSKydhgS-DDVL
      V:R..GD.:LK  ..      :      .....P:V.  DL:.      D:.L
H:   192 vSRAfGDfelKpgsklgpeesleanyeyikspeqlVtaePdvtssstdltp....dkDeFl

      ILATDGLWDVLSNEEVAEAITQFL      456
      ILA.DGLWDV:S::EV..... L
      iLAcDGLWDvvsdqevvdivrsel      271
```

- 14/21 -

Fig. 13**BLOCK search result:**

AC#	Description	Strength	Score
BL01032H	Protein phosphatase 2C proteins.	1294	1280
AA#	428 DDvLILAtDGLWD		
BL01032C	Protein phosphatase 2C proteins.	1286	1252
AA#	145 YwSlFDGHAG		
BL01032G	Protein phosphatase 2C proteins.	1334	1129
AA#	380 RVmaTigVTRgLGD		

- 15/21-

Fig. 14

BLASTN - alignment of 533_DNA_extended against
 BAYER_LIB DNA|cb_379101045220171
 Library 101 Plates 1-55 except 10 and 30

This hit is scoring at : 0.0 (expectation value)
 Alignment length (overlap) : 588
 Identities : 98 %
 Scoring matrix : blastn (used to infer consensus pattern)
 Query reading frame : +1
 Hit reading frame : +1
 Database searched : bayerall_1_;

Q: 5195 cagggagaagaatgacagccacagggagatggtggtgggcaagaatgagagtgcccaggatcc
 CAGGGAAGAATGACAGCCACAGGGAGATGGTGGTGGGCAAGAATGAGAGTCCCAGGATCC
 H: 9 cagggagaagaatgacagccacagggagatggtggtgggcaagaatgagagtgcccaggatcc

agatttagcctcagatcttccccattcaggaagggttttccatttaacaagagcactagt
 AGATTTAGCCTCAGATCTTCCCCATT CAGGAAGGGTTTCCATTTAACAAGAGCACTAGT
 agatttagcctcagatcttccccattcaggaagggttttccatttaacaagagcactagt

atgaaaacattagggacaaatctcccatgtctttgaaattcggattctcctcttgagatc
 ATGAAAACATTAGGGACAAATCTCCCATGTCTTTGAAATTCGGATTCTCCTCTTGAGATC
 atgaaaacattagggacaaatctcccatgtctttgaaattcggattctcctcttgagatc

cccttctcacctgccaatcaactttataaggccacaagtgggtcactgggttttcccttcca
 CCCTTCTCACCTGCCAATCAACTTTATAAGGCCACAAGTGGTCACTGGTTCCTTCCA
 cccttctcacctgccaatcaactttataaggccacaagtgggtcactgggttttcccttcca

caggtttgaggttctcagctttccttaagcgacccagcagctccgctggtttcagagtga
 CAGGTTTGAGGTTCTCAGCTTTCCTTAAGCGACCCAGCAGCTCCGCTGTTTTCAGAGTGA
 caggtttgaggttctcagctttccttaagcgacccagcagctccgctggtttcagagtga

atatgttaagctttgatgagattctattttcagtaagttagtgtcttctgggacacttgga
 ATATGTTAAGCTTTGATGAGATTCTATTTTCAGTAA TTAGTGCTTCTGGGACACTTGGA
 atatgttaagctttgatgagattctattttcagtaatttagtgcttctgggacacttgga

gaaagctgtg-agagtcattgtctacgcaaagaacaacgaagctgatcctaaaagtgatc
 GAAAGCTGTG A AGTCATTGTCTACGCAAAGAACAACGAAGCTGATCCTAAAAGTGATC
 gaaagctgtgaaaagtcattgtctacgcaaagaacaacgaagctgatcctaaaagtgatc

caatctaagaaaaatggtaaaacgagctctggccacagcacagaattttatgtgaggaact
 CAATCTAAGAAAAATGGTAAAACGAGCTCTGGCC CAGCACA AATTTTATGTGAGGAACT
 caatctaagaaaaatggtaaaacgagctctggcc-cagcacaaaaattttatgtgaggaact

cagatTTTTgaagacttaacaattgcagagaaaagggttgacgctgcacaccatagcccac
 CA ATTTTGAAG ACTTAACAATTGCAGA AAAGGTTGCAGCCTGCACACCATAGCCCAC
 canatTTTTgaanacttaacaattgcagagaaaagggttgacgctgcacaccatagcccac

ctctctgagcagacttttggttttgtgtggtgacgtggcacatgtttgt 5781
 CT TCTGA CA ACTTTGGTTTTGTGTGGTGACGTGGCACATGTTTGT
 ctntctganca-acttttggttttgtgtggtgacgtggcacatgtttgt 594

- 16/21-

Fig. 15**genewise output:**

```

AAW04327      3  ggsvgsrsggsagspgglssahaetgrrgagkrpaaaaarqpfpglsls
      + + ++ ++++++ ++++++ ++++++ ++++++ ++++++
      GSSRGSSRGGSASSPGGLSSAHAGAERRGRGR!TCCSCSRLGAPGARGD
NT_009711.3 -1686005  gaacgaacggtgatcgccatgcggggcagcgalattataccggcggcgg
      gggggggggggcgccggtgccacgcagggggg cggggggtgccgcgga
      ctctcccccccgcggtgctagccacgcgggag ccccccgcttagctc

AAW04327      52  llsrplapcrpvaevslgevaasssgstggrgsapa---alssrsrasq
      ++ +++ +++++ ++++++ ++ ++++++ ++ ++++++
      SPGRP-APCSSVAEVXRGEAAATAALSTRGRGSAPCST!ALGAARGASQ
NT_009711.3 -1685860  tcgcc gctatggggtcggggaggcaaagcgtgctaa2gcgggcggtc
      ccggc ccggtcataggacccccctgcggggcccggc ctgccggcca
      cctgc taccctgagggggggccgaacgacgcgccct tgacgcgcgcg

AAW04327      98  rphrpcaprppqpacpalhlgrpp-pparsaaarrsrnmltrvksavan
      + +++ ++++++ ++++++ ++++++ ++++++ ++++++
      WPDSPCARRPPQPACPALRLARPPQPPARTAAAGRRSNMLTRVKSAVAN
NT_009711.3 -1685717  tcgtctgcccccgctgcggcgcccccgaggggccaacacgatggga
      gcaccgcggccaccgcctgtcgccaccgcgggggattcgctacctca
      gccggcgcgaggtaccgggtcgcggttctctacgcgttgctagatcgct

AAW04327      146 fmggimagssgsehggsgcggsdlplrpfpygrpeflglsgdevecsadh
      ++++++ ++++++ ++++++ ++++++ ++++++
      FMGGIMAGSSGSEHGGGSCGGSDDLPLRFPYGRPEFLGLSQDEVECSADH
NT_009711.3 -1685570  taggaaggatgtgcgggatggtgccccctctgccgtcgctcggggtaggc
      ttggttcggcgcaagggggggcatctgtcaggcattgtcaaataggcaa
      cgcccgctccaccgccccccacgcgcgtcccggagcggggtgcgggcccc

AAW04327      195 iarpililketrirlpwatgya vi
      ++++++ ++++++ ++++++ ++++++ ++++++
      IARPILILKETRRLPWATGYA e:E[gag] VI
NT_009711.3 -1685423  agccacacagaccctgagtgGAGTGAGTG Intron 1 CAGGga
      tcgcttttaacgggtcgccgac <2-----[1685358:1583-2> tt
      ccccccccggtgggcgctcca tc

AAW04327      219 nagksthnedqascevlvkkkvgtitstpnrns-krrsslpngeglql
      ++++++ ++++++ ++++++ ++++++ ++++++
      NAGKSTHNEDQASCEVLTVKKKAGAVTSTPNRNSSKRRSSLPNGEGLQL
NT_009711.3 -1583092  aggaaacaggcgatggcagaaaggggatacaaaattaacttccaggggccc
      acgagcaaaaacggattctaaacgctccccagaccaggcctcagagtat
      tcggcactacacctggctggggagcgcacacgcacgagcctctgagggg

AAW04327      267 kens esegischywsldghagsgaa
      ++++++ ++++++ ++++++ ++++++ ++++++
      KENS ESEGVSCHYWSLFDGHAGSGAA
NT_009711.3 -1582945  agatGTAAGAC Intron 2 CAGgtgggttctttctggcggtggg
      aaac<0-----[1582933:1552-0>acagtcgaagcttagacgcgcc
      ggcg acgttccctgggtcgcggcgcg

```

- 17/21 -

```

AAW04327      293 vvasrllqhhitqqlqdiveilknsailpptclgeepstpahgrtltr
                ++++++
                VVASRLLQHHITEQLQDIVDILKNSAVLPPTCLGEEPENTPANSRTLTR
NT_009711.3 -1552914 gggtccccccaagcccaggacaatggcccatcgggcgaacgaacacac
                ttccgttaaatacaataattattaaccttcccgatgaacaacccaggctcg
                gggacggggcccgggggcgccggccccgcgtccggggtgcgccccgtgcg

AAW04327      342 aaslrggvgagpgspstpptrfftekkipheclvigalesafkem
                ++++++
                AASLRGGVGAGPGSPSTPPTRFFTEKKIPHECLVIGALESFAKEM
NT_009711.3 -1552767 ggtccggggggcgtaaccacttagaaaccgtcgaggcgagtaga
                ccctgggtgcccgcgcggcggttcaaatacaagtttgctagctaata
                accgcaggggcgccccgcacctcggtctgcgccagtatacagag

AAW04327      386                dlqierersaynisggctalivvc1l
                ++++++
                DLQIERERSSYNISGGCTALIVICLL
NT_009711.3 -1552635 GTAGGTA Intron 3 CAGgccagcgaattaatggtagcagatct
                <0-----[1552635:1539-0]>atatagaggcaatcgggccttttgtt
                cagaaaggtattattccgcctgtctg

AAW04327      412 gklyvanagds                aiiirngeiipm
                ++++++                ++++++
                GKLYVANAGDS                r:R[agg]                AIIIRNGEIIPM
NT_009711.3 -1539080 gactggaggggaAGGTAAGCA Intron 4 CAGGgaaaaaggaaca
                gatatacacgag <2-----[1539045:1488-2]> ctttgagattct
                gggttattgtc                caccataatccg

AAW04327      436 sseftpeterqrlqyl                afmqphllgn
                ++++++                ++++++
                SSEFTPETERQRLQYL                AFMQPHLLGN
NT_009711.3 -1488369 ttgtacgagccccctcGTAAGAG Intron 5 TAGgtaccctcga
                ccatccacagagtaata<0-----[1488321:1471-0]>cttacattga
                taatccgggcatgag                acggtcgggat

AAW04327      462 efthlefprrvqrkelgkkmlyrdnmtg
                ++++++
                EFTHLEFPRRVQRKELGKKMLYRDNMTG
NT_009711.3 -1471079 gtactgtcaagcaagcgaaactagtaaag
                atcatatcggtagaatgaattagatatcg
                gcatggtagaagaggtagggccgcttgac

AAW04327      491                ayktiedddlkfpliygegkk
                ++++++                ++++++
                w:W[tgg]                AYKTIEDEDLKFPLIYGEKK
NT_009711.3 -1470992 TGGTAAGAA Intron 6 CAGGgtaaaggggtatccatgggaa
                <2-----[1470990:1444-2]> caactaaaatatcttagagaa
                aactgtgcggcctataacgg

AAW04327      513                arvmatigvtrglgdhdklvhdsniy
                ++++++                ++++++
                ARVMATIGVTRGLGDHDLKVHDSNIY
NT_009711.3 -1444755 GTAGGCA Intron 7 TAGgcgagaaggaagcggcgcagcgtaata
                <0-----[1444755:1440-0]>cgttcctgtcggtgaaatataacata
                cgagattagcgatgctcggtccccc

```

- 18/21 -

AAW04327 539 ikpflssape vrvydlskyehgaddv
+++++++
IKPFLSSAPE VRIYDLSKYDHGSDDV
NT_009711.3 -1440548 aactcttgcgGTACCGC Intron 8 CAGgaatgctatgcgtggg
tacttcccca<0-----[1440518:1418-0>tgtaatcaaaagcaat
taacgtatag aaccttaatttaattg

AAW04327 565 lilatdglwdvlsneevaeaitqflpncdpddph
+++++++
LILATDGLWDVLSNEEVAEAITQFLPNCDDPH
NT_009711.3 -1418101 catgaggctggttaggggggaactccatgcggcc
ttccagtgattcaaatcactcattcagacaaca
gcgcttacgctaataaaaaactgtttcttatttc

AAW04327 599 ytlaaqdlvmrargvdkdrwri
+++++++
YTLAAQDLVMRARGVLKDRGWRI
NT_009711.3 -1417999 AGGTTTGTG r:R[agg] TAGGtacggcgcgacgcggcagagtca
<2-----[1417997:1399-2> actccaatttgcggttaaggggg
cagatgcgggtcgtgggcaaggga

AAW04327 623 sndrlgsgddisvyviplihgnkls
+++++++
SNDRLGSGDDISVYVIPLIHGNKLS
NT_009711.3 -1399396 tagccgtgggatgtgactacgaact
caagtgcgaatctattcttagaatc
ttcagcaaccttatcttaatacggga

//

>NT_009711.3.[1686005:1685908].sp
GGCAGTAGCCGTGGCAGCAGCCGCGGCGGCTCCGCGAGCTCGCCGGGTGGGCTCAGTTCA
GCGCAGCCCGGAGCCGAGCGCAGGGGGCGGGGAAGG
>NT_009711.3.[1685908:1685748].sp
ACCTGTGCAGCTGCAGCCGCTGGGCGCTCCTGGAGCGCGGGTGAAGTCCCCCGGTGCGG
CCCGCTCCATGCAGCTCCGTTGCGGAAGTGTAGCGGGGGGAGGCGGGCGGCCACCGCGGCA
CTAAGCACGAGAGGCCGGGGCTCGGCCCTGCAGCACT
>NT_009711.3.[1685747:1399320].sp
GCTCTGGGAGCCGCGCGCGGCGCTCCAGTGGCCGACTCGCCGTGCGCCCGGCGCCCA
CCGCAGCCTGCATGCCCCGCGCTGCGCCTTGCCCCGCCCCCGCAGCCTCCTGCTCGCACC
GCTGCAGCCGGGCGCCGGAGTAATATGCTCACTCGAGTGAAATCTGCCGTGGCCAATTTT
ATGGGCGGCATCATGGCTGGCAGCTCAGGCTCCGAGCACGGCGGCGGCGAGCTGCGGAGGC
TCGGACCTGCCCTGCGTTTCCCTACGGGCGGCCAGAGTTCTTGGGGTGTCTCAGGAC
GAGGTGGAGTGCAGCGCCGACCACATCGCCCCCCCCATCCTCATCTCAAGGAGACTCGG
CGGCTGCCCTGGGCACTGGCTACGCAGAGGTTATCAATGCCGGGAAGAGCACACACAAT
GAAGACCAAGCCAGCTGTGAGGTGCTCACTGTGAAGAAGAAGGCAGGGGGCGGTGACCTCA
ACCCCAAACAGGAATCATCAAGAGACGGTCTCTCCCTTCCCAATGGGGAAGGGCTGCAG
CTGAAGGAGAACTCGGAATCCGAGGGTGTTCCTGCCACTATTGGTTCGCTGTTTGACGGG
CACGCGGGGTCCGGGGCCGCGGTGGTGGCGTCACGCCGTGCTGCAGCACCACATCACGGAG
CAGCTGCAGGACATCGTGGACATCCTGAAGAACTCCGCCGTCTGCCCTTACCTGCCCTG
GGGGAGGAGCTGAGAACACGCCGCCAACAGCCGGAAGTCTGACCCGGGCGAGCTCCCTG
CGCGGAGGGGTGGGGGGCCCGGGCTCCCCCAGCAGCCCCCACACGCTTCTTTACCGAG
AAGAAGATTCCCCATGAGTGCCTGGTCATCGGAGCGCTTGAAAGTGCATTCAAGGAAATG
GACCTACAGATAGAACGAGAGAGGAGTTCATATAATATATCTGGTGGCTGCACGGCCCTC
ATTGTGATTTGCCTTTTGGGGAAGCTGTATGTTGCAAATGCTGGGGATAGCAGGGCCATA
ATCATCAGAAATGGAGAAATTTATCCCCATGTCTTCAGAAATTTACCCCCGAGACGGAGCGC
CAGCGACTTCAGTACCTGGCATTTCATGCAGCTCACTTGCTGGGAAATGAGTTCACACAT


- 19/21 -

TTGGAGTTTCCAAGGAGAGTACAGAGAAAGGAGCTTGGAAAGAAGATGCTCTACAGGGAC
 TTTAATATGACAGGCTGGGCATACAAAACCATTGAGGATGAGGACTTGAAGTTCCCCCTT
 ATATATGGAGAAGGCAAGAAGGCCCGGGTAATGGCAACTATTGGAGTGACCAGGGGACTT
 GGGGACCATGACCTGAAGGTGCATGACTCCAACATCTACATTAAACCATTCTGTCTTCA
 GCTCCAGAGGTAAGAATCTACGATCTTTCAAATATGATCATGGATCAGATGATGTGCTG
 ATCTTGGCCACTGATGGACTCTGGGACGTTTTATCAAATGAAGAAGTAGCAGAAGCAATC
 ACTCAGTTTCTTCTTAAGTGTGATCCAGATGATCCTCACAGGTACACACTGGCAGCTCAG
 GACCTGGTGATGCGTGCCCGGGGTGTGCTGAAGGACAGAGGATGGCGGATATCTAATGAC
 CGACTGGGCTCAGGAGACGACATTTCTGTATATGTCATTCTTTAATACATGGAAACAAG
 CTGTCA


//

NT_009711.3	GeneWise	match	1685908	1686005	28.18	-	.
AAW04327							
NT_009711.3	GeneWise	cds	1686004	1685908	0.00	-	0
NT_009711.3	GeneWise	match	1685748	1685908	-6.01	-	.
AAW04327							
NT_009711.3	GeneWise	cds	1685907	1685748	0.00	-	0
NT_009711.3	GeneWise	match	1399320	1685747	1140.29	-	.
AAW04327							
NT_009711.3	GeneWise	cds	1685746	1685357	0.00	-	0
NT_009711.3	GeneWise	intron	1685358	1583100	0.00	-	.
AAW04327							
NT_009711.3	GeneWise	cds	1583098	1582932	0.00	-	1
NT_009711.3	GeneWise	intron	1582933	1552981	0.00	-	.
AAW04327							
NT_009711.3	GeneWise	cds	1552979	1552634	0.00	-	0
NT_009711.3	GeneWise	intron	1552635	1539159	0.00	-	.
AAW04327							
NT_009711.3	GeneWise	cds	1539157	1539044	0.00	-	0
NT_009711.3	GeneWise	intron	1539045	1488407	0.00	-	.
AAW04327							
NT_009711.3	GeneWise	cds	1488405	1488320	0.00	-	1
NT_009711.3	GeneWise	intron	1488321	1471110	0.00	-	.
AAW04327							
NT_009711.3	GeneWise	cds	1471108	1470989	0.00	-	0
NT_009711.3	GeneWise	intron	1470990	1444820	0.00	-	.
AAW04327							
NT_009711.3	GeneWise	cds	1444818	1444754	0.00	-	1
NT_009711.3	GeneWise	intron	1444755	1440627	0.00	-	.
AAW04327							
NT_009711.3	GeneWise	cds	1440625	1440517	0.00	-	0
NT_009711.3	GeneWise	intron	1440518	1418150	0.00	-	.
AAW04327							
NT_009711.3	GeneWise	cds	1418148	1417996	0.00	-	0
NT_009711.3	GeneWise	intron	1417997	1399467	0.00	-	.
AAW04327							
NT_009711.3	GeneWise	cds	1399465	1399320	0.00	-	1

- 20/21 -

**FIG. 16**

- 21/21 -

**FIG. 17**

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
5 December 2002 (05.12.2002)

PCT

(10) International Publication Number
WO 02/097074 A3(51) International Patent Classification⁷: C12N 9/16, 15/00, 5/10, G01N 33/50, C12Q 1/68

(21) International Application Number: PCT/EP02/05874

(22) International Filing Date: 29 May 2002 (29.05.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/294,006 30 May 2001 (30.05.2001) US
60/354,928 11 February 2002 (11.02.2002) US

(71) Applicant (for all designated States except US): BAYER AKTIENGESELLSCHAFT [DE/DE]; 51368 Leverkusen (DE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): ZHU, Zhimin [CN/US]; 45 Hinckley Road, Waban, MA 02468 (US).

(74) Common Representative: BAYER AKTIENGESELLSCHAFT; 51368 Leverkusen (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU,

[Continued on next page]

(54) Title: HUMAN PROTEIN PHOSPHATASE 2C-LIKE ENZYME



(57) Abstract: Reagents that regulate human protein phosphatase 2C-like enzyme and reagents which bind to human protein phosphatase 2C-like enzyme gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, CNS disorders, COPD, obesity, and diabetes.

WO 02/097074 A3



SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

Published:

— with international search report

(88) Date of publication of the international search report:

13 November 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N9/16 C12N15/00 C12N5/10 G01N33/50 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N G01N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data, EMBL, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 02 18565 A (BAYER AG ;XIAO YONGHONG (US)) 7 March 2002 (2002-03-07) the whole document ---	1-17
X	DATABASE EMBL 'Online! 16 January 1997 (1997-01-16) LABES ET AL.: "Rat petrin" Database accession no. AAW04327 XP002224908 cited in the application abstract ---	1-17
X	-& WO 96 32476 A (MOUNT SINAI HOSPITAL CORP; LOZANO ANDRES (CA); LABES MONIKA (CA)) 17 October 1996 (1996-10-17) the whole document ---	1-17
	-/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

13 December 2002

Date of mailing of the international search report

29/01/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Friedrich, C

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>TRAVIS S M ET AL: "PP2Cgamma: a human protein phosphatase with a unique acidic domain"</p> <p>FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 412, no. 3, 1 August 1997 (1997-08-01), pages 415-419, XP002085149</p> <p>ISSN: 0014-5793</p> <p>the whole document</p>	1-17
X	<p>PRICE N E ET AL: "Brain protein serine/threonine phosphatases"</p> <p>CURRENT OPINION IN NEUROBIOLOGY, LONDON, GB, vol. 9, 1999, pages 336-342, XP002207990</p> <p>ISSN: 0959-4388</p> <p>page 339 -page 340</p>	1-17
X	<p>CHING YICK PANG ET AL: "Specificity of different isoforms of protein phosphatase-2A and protein phosphatase-2C studied using site-directed mutagenesis of HMG-CoA reductase"</p> <p>FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 411, no. 2-3, 1997, pages 265-268, XP002160001</p> <p>ISSN: 0014-5793</p> <p>the whole document</p>	1-17
X	<p>MARLEY ANNA E ET AL: "Biochemical characterization and deletion analysis of recombinant human protein phosphatase 2C-alpha."</p> <p>BIOCHEMICAL JOURNAL, vol. 320, no. 3, 1996, pages 801-806, XP002224907</p> <p>ISSN: 0264-6021</p> <p>the whole document</p>	1-17
X	<p>BARFORD D: "Molecular mechanisms of the protein serine/threonine phosphatases"</p> <p>TIBS TRENDS IN BIOCHEMICAL SCIENCES, ELSEVIER PUBLICATION, CAMBRIDGE, EN, vol. 21, no. 11, 1 November 1996 (1996-11-01), pages 407-412, XP004071015</p> <p>ISSN: 0968-0004</p> <p>the whole document</p>	1-17

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 8, 13, 14, and 16 relate to an extremely large number of possible reagents. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the reagents claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to antisense polynucleotides, antibodies, or ribozymes.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 0218565	A	07-03-2002	AU WO	9378001 A 0218565 A2		13-03-2002 07-03-2002
WO 9632476	A	17-10-1996	AU CA CA WO EP JP	5264496 A 2174025 A1 2217731 A1 9632476 A1 0821731 A1 11503324 T		30-10-1996 14-10-1996 17-10-1997 17-10-1996 04-02-1998 26-03-1999